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ABSTRACT OF DISSERTATION 
 
 
 
THE ECONOMICS OF MILK QUALITY MANAGEMENT PRACTICES AND MILK 
PRICING IN SIMULATED UNITED STATES DAIRY HERDS 
 
 Mastitis is considered one of the most common and costly diseases in the dairy 
industry.  Intramammary infection status at a herd level is measured using somatic cell 
count (SCC).  Understanding the total cost of an elevated somatic cell count can help 
influence dairy farmers to lower SCC and select management practices to produce higher 
quality milk.  The first objective of our research was to determine if the cost of an 
elevated somatic cell count to farms can be decreased through the adoption of 
management practices with varying expenses.  Using stochastic simulation modeling, the 
adoption of three differently priced management practices were modeled in herds with 
varying somatic cell counts.  Results were highly dependent on whether a premium 
scheme for lower SCC milk was in place and how close a herd’s initial SCC was to a 
premium level.  When herd SCC reduced enough to receive a premium, the total cost of 
SCC to the farm was dramatically reduced. 
One management practice that has historically been used in the industry is treating 
every quarter of every cow with an intramammary antibiotic at the end of her lactation.  
However, future restrictions of antibiotic use in animal agriculture may pressure dairy 
farmers to treat only cows with an intramammary infection at the end of the lactation.  
The second objective of our research was to complete an economic analysis comparing 
the total cost of dry cow therapy in simulated dairy farms when every quarter of every 
cow was treated with intramammary antibiotics compared treating only cows with an 
intramammary infection at end of the lactation.  Results from the model indicate the 
treating every quarter of every cow at the end of lactation was most economically feasible 
in simulated farms.  However, as the cost of a case of mastitis and mastitis incidence 
decrease, treating only cows with an intramammary infection may become economically 
feasible. 
 Within recent years, the dairy industry in the Southeastern United States has 
shown interest in changing the way milk is priced.  Currently, dairy farmers in the 
Southeast are paid for total fluid volume and butterfat, while other areas are paid for milk 
fat, protein, and other solids yields.  The third objective of our research was to determine 
the differences in milk value using the conventional milk pricing system compared to a 
multiple component pricing system using cow production records.  After examining 
average milk values, multiple component pricing may result in Southeastern dairy 
farmers being paid more for their milk.   
  
 KEYWORDS: stochastic modeling, somatic cell count, dry cow therapy, multiple 
component pricing, dairy cattle  
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1) CHAPTER ONE 
REVIEW OF LITERATURE 
 
INTRODUCTION 
The dairy industry has experienced many changes within the past ten years.  
While the number of dairy farms in the United States (US) has decreased, the number of 
total cows has steadily increased (USDA National Agricultural Statistics Service, 2017).  
Cow numbers, along with more efficient milk production has resulted in more milk on 
the market.  Because of the large quantity of milk on the market, dairy processors and co-
ops have become more selective of milk quality requirements (Nickerson, 2012, Nolan, 
2018).  One measure processors use to determine milk quality at a herd level is somatic 
cell count (SCC).  Though some are still offered, premiums for SCC are becoming a 
rarity and quality is to be expected (Nickerson, 2012, Nolan, 2018).  The demand for 
quality milk adds pressure to farmers to make sure they have management practices in 
place to meet milk quality expectations. 
Dry cow therapy, or treatment of cows with intramammary antibiotics (IMMA) at 
the end of the lactation, is used by farmers to treat intramammary infections (IMI) at the 
end of lactation and prevent new infections in the dry period.  However, pressure is being 
put on policymakers to decrease the use of antibiotics in animal agriculture (Croney et al., 
2012).  The use of dry cow therapy as a preventative measure is no longer allowed in 
some countries (Lam et al., 2017, McDougall, 2018).   
As changes in the dairy industry continue, use of management practices to 
maintain the production of high-quality milk while maintaining efficiency is magnified.  
The objectives of this literature review are to discuss 1) the importance of somatic cell 
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count (SCC) as a milk quality indicator, 2) the economics of herd SCC, 3) the efficacy 
and economics of different dry cow therapy schemes, and 4) how milk pricing options 
may affect the profitability of dairy farmers. 
SOMATIC CELLS 
Role of Somatic Cells 
 A large variety of body cells exist in the mammary gland.  However, concern 
arises in the dairy industry when white blood cells are present at high amounts in milk.  
White blood cells are present at higher amounts in the mammary gland during an 
infection.  Somatic cells primarily consist of polymorphonuclear neutrophils leukocytes 
(PMN), macrophages, and lymphocytes (Harmon, 1994).  No matter the infection status 
of the mammary gland, each of these cells always exist in milk.  The type of cells that 
exists changes based on whether the gland is infected.  In a healthy mammary gland, 
most white blood cells present in the milk consist of macrophages (15% to 40%) and 
lymphocytes (54% to 80%) (Rivas et al., 2001, Alhussien and Dang, 2018).  
Macrophages and lymphocytes may eliminate some microorganisms that enter the gland 
at each milking (Kehrli and Shuster, 1994) because of an open teat end (Alhussien and 
Dang, 2018).  
Polymorphonuclear neutrophils range from 0 to 7% of the cells in milk when the 
mammary gland is healthy (Lee et al., 1980, Rivas et al., 2001), but when the gland 
becomes infected PMN make up 90 to 95% of the cells in the milk (Harmon, 1994, 
Kehrli and Shuster, 1994).  Once in the milk, microorganisms release products of 
metabolism that act as chemoattractants, which enroll the help of PMN (Kehrli and 
Shuster, 1994, Alhussien and Dang, 2018).  Once recruited by an immune response, the 
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rate at which PMN enter the mammary tissue and milk increases for 2 to 3 hours (Persson 
et al., 1992) and can stay elevated for greater than 150 hours (Kehrli and Shuster, 1994).  
Thus, an increase in the number of somatic cells in milk is associated with an IMI. 
Somatic Cell Count  
 Prescott and Breed (1910) conducted one of the first studies to examine the count 
of somatic cells in milk.  Previously, milk was centrifuged to separate the cream and only 
the non-cream (sediment) layer was tested.  Prescott and Breed (1910) developed a 
"direct" method in which they counted somatic cells after the milk was shaken 
(homogenized) to distribute the cream.  They concluded that by separating the cream and 
only testing the sediment layer, SCC was highly underestimated.  The average SCC of 
milk tested with the sediment method was 305,000 cells/mL, while the average of the 
direct method on the same samples was 1,690,000 cells/mL.   
 Throughout the late 1900s, the automation of counting cells was developed and 
tested.  Two common methods were the Coulter and flow cytometry methods.  With the 
Coulter method, particles are suspended in an electrolyte solution, and the dispersion of 
the electrolyte solution is measured and correlated to the size of the particle.  Flow 
cytometry works in four steps.  First cells are placed into a solution.  In the case of the 
dairy industry, cells do not have to be placed in a solution other than milk.  Second, the 
flow cytometer takes in the solution and funnels the solution through a nozzle small 
enough that cells have to enter in a singular order.  Then a laser is passed through each 
cell in the solution, and light is scattered both forward and to the side.  In the final step, a 
histogram of both the forward and side scatter is made.  By combining the histograms 
from the entire solution, different cell populations can be determined.   
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 Both the Coulter and flow cytometry methods have been correlated with the direct 
counting method (Madsen, 1975).  Other research concluded that the Coulter method 
might lead to over counting somatic cells because any object above a certain size is 
counted (Brooker, 1978, Hill et al., 1982, Hoare et al., 1982).  Heald et al. (1977) 
concluded that the use of a Fossomatic (Foss, Hillerod, Denmark), which uses flow 
cytometry, was acceptable for use in Dairy Herd Information Association lab test.  The 
Dairy Herd Improvement Association and other milk quality testing labs are still using 
the Fossomatic today.   
 Somatic cell counts can be influenced by many different variables (lactation and 
days in milk (DIM)) (Harmon, 1994, Alhussien and Dang, 2018), making cow and herd 
SCC data skewed with the mean being greater than the median (Ali and Shook, 1980).  
To analyze cow and herd SCC data from a research standpoint, a transformation of the 
data must be completed.  Before the 1980s a geometric mean transformation was often 
performed.  Ali and Shook (1980) concluded that a log transformation was sufficient, and 
adding a constant improved the transformation.  Wiggans and Shook (1987) developed 
the following equation to log transform SCC data. 
𝑆𝐶𝑆 = 𝑙𝑜𝑔2 (
𝑆𝐶𝐶
100
) + 3 
With this equation, the log transformation of SCC is known in the dairy industry 
today as somatic cell score (SCS).  Somatic cell data can be reported to the farmer as 
either SCC or SCS.  However, SCS is most commonly used in research analysis.  Each 
one-point increase in SCS is equated to a doubling in SCC. 
Somatic Cell Count and Intramammary Infection 
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Evidence proves that when a mammary gland is infected with a pathogen, SCC 
will increase (Schalm et al., 1964, Schalm et al., 1966, Schalm and Ziv-Silberman, 1968).  
The majority of the increase in cells when the mammary gland is infected are PMN 
(Kelly et al., 2000, Pillai et al., 2001).  Differences in SCC can be observed even when 
clinical signs of the IMI are not present.  When physical signs of the IMI are present, the 
IMI is considered clinical mastitis (CM), while subclinical mastitis (SCM) cannot be 
seen with the naked eye.  In both CM and SCM, an IMI is confirmed by taking a 
bacteriological culture of milk from a cow.  A cow is considered to have an IMI when 
duplicate bacteriological cultures have positive growth with the same bacteria type 
(Oliver et al., 2004).  Because of the increase in SCC that comes with an IMI, SCC is the 
most common way SCM is detected. 
Natzke et al. (1972) were one of the first to examine the differences in SCC 
between cows with a healthy mammary gland and those with an IMI based on identified 
bacterial pathogen.  When investigating SCC a three year period the average ± standard 
deviation (SD) of cows that did not have an IMI was 214,000 ± 23,800 cells/mL while 
cows with an IMI had an average ± SD of 507,000 ± 94,908, 701,000 ± 150,457, and 
1,470,000 ± 557,210 cells/mL if the cow had 1, 2, 3, or 4 infected quarters, respectively.  
While Natzke et al. (1972) were one of the first to determine the average SCC between a 
healthy mammary gland and one with an IMI, future research helped determine the 
threshold of SCC to predict whether a gland was infected. 
McDermott et al. (1982) were one of the first to use SCC data to determine if IMI 
could be predicted at different SCC thresholds.  To predict IMI status, sensitivity, 
specificity, and predictability were calculated using the following 5 equations: 
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(1)  𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
  
(2) 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑡𝑦 =
𝑇𝑁
𝑇𝑁 + 𝐹𝑃
 
(3) 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
 
(4) 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 =
𝑇𝑁
𝑇𝑁 + 𝐹𝑁
 
(5) 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑜𝑓 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 =
𝑇𝑃 + 𝐹𝑁
𝑇𝑃 + 𝐹𝑃 + 𝑇𝑁 + 𝐹𝑁
 
Where:  
TP = true positive (bacteriological culture positive with a SCC above threshold)  
FP = false positive (bacteriological culture negative with a SCC above threshold) 
TN = true negative (bacteriological culture negative with a SCC below threshold) 
FN = false negative (bacteriological culture positive with a SCC below threshold) 
Sensitivity and specificity are often used in epidemiology and in the medical 
profession to measure the success of disease testing.  Sensitivity is the ability of a test to 
correctly identify those with a disease, while specificity is the ability of the test to 
identify those who do not have the disease correctly.  
Using the 5 equations, McDermott et al. (1982) examined SCC thresholds and 
concluded that 400,000 cells/mL was the optimal SCC to determine IMI.  Though 
McDermott et al. (1982) set a threshold of 400,000 cells/mL, more recent research has 
repeatedly shown that a SCC of 200,000 cells/mL has been optimal to limit false 
positives and negatives in IMI diagnosis (Dohoo and Leslie, 1991, Schepers et al., 1997, 
Pantoja et al., 2009b, Shook et al., 2017, Jadhav et al., 2018).  Therefore, a SCC greater 
than 200,000 cells/mL is associated with a cow having SCM. 
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Relationships besides IMI status are associated with varying SCC (Dohoo and 
Leslie, 1991, Harmon, 1994, Shook et al., 2017).  Herd, cow, season, stage of lactation, 
and parity have been shown to have a relationship with SCC (McDermott et al., 1982, 
Kehrli and Shuster, 1994, Schepers et al., 1997, Shook et al., 2017).  Though DIM and 
parity are associated with SCC (Harmon, 1994, Alhussien and Dang, 2018), these effects 
do not hold a cause and effect relationship.  For example, evidence suggests that if a cow 
has never had an IMI, SCC does not differ from lactation to lactation (Natzke et al., 
1972).  For cows that never experienced an IMI, average somatic cell counts were 
136,000 cells/mL, 112,000 cells/mL, and 153,000 cells/mL in their first, second and 
third, and fourth and greater lactations, respectively.  Laevens et al. (1997) presented 
similar results where mean SCC were similar across lactations for cows that did not 
experience an IMI.  However, Laevens et al. (1997) concluded that cows in their 2nd and 
3rd lactations had an increase in SCC toward the end of lactation compared to 1st parity 
cows. 
When examining the relationship between SCC and DIM, Schepers et al. (1997) 
and Laevens et al. (1997) found that when graphing SCC across lactation, the SCC curve 
was the inverse of the milk production curve.  Somatic cell count tends to start high at the 
beginning of the lactation, decrease to the lowest point in the mid-lactation, and increase 
at the end of the lactation (Harmon, 1994, Alhussien and Dang, 2018).  To explain the 
increase in SCC that is commonly seen at the end of lactation, Green et al. (2006) suggest 
that this phenomenon may be due to lack of dilution.   
Season of testing date has also shown to be associated with SCC (Harmon, 1994, 
Pantoja et al., 2009a, Shook et al., 2017).  However, this should not be looked at as a 
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cause and effect relationship either because season cannot physically affect SCC.  de 
Haas et al. (2002) suggests that rather than the season of the year affecting SCC, cows 
might be more prone to IMI during certain times of the year.    
Management of Herd Somatic Cell Counts 
The National Mastitis Council developed a 5-point program to help farmers 
control mastitis (Dodd and Neave, 1970).  Those points include post-milking teat 
disinfection (PST), comprehensive dry cow therapy, therapy of clinical mastitis cases 
during lactation, proper milking machine maintenance, and culling cows with chronic 
CM or SCM.  According to USDA Animal and Plant Health Inspection Service (2016), 
96.8% of surveyed dairies used a PST, 89.4% use intramammary IMMA to treat mastitis, 
90.8% used IMMA at dry off, and 24.0% cull cows due to mastitis.  Unfortunately, little 
research has been conducted examining the direct effects of adoption of a particular 
management practice on bulk tank SCC (BTSCC).  However, extensive research has 
determined relationships between BTSCC of herds with varying BTSCC and the 
management practices the dairy producers have implemented through survey data 
(Pantoja et al., 2009b, Schewe et al., 2015, Emanuelson and Nielsen, 2017).  In a review 
of published surveys, Dufour et al. (2011) concluded that some management practices 
were more frequently adopted by farmers with a lower (< 250,000 cells/mL) SCC.  These 
included cow hygiene, the use of test disinfectants at milking, the use of coliform mastitis 
vaccines, and antibiotic therapy at dry off. 
Hygiene.  When examining the relationship between management practices and 
BTSCC, Barkema et al. (1998a) concluded producers with a low BTSCC (< 150,000 
cell/mL) paid extra attention to hygiene of both facilities and cows.  Schreiner and Ruegg 
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(2003) determined there was a positive linear relationship with udder hygiene and SCC.  
For udder hygiene scores of 1, 2, 3, and 4 (Schreiner and Ruegg, 2002), IMI rates were 
7.7%, 10.0%, 10.6%, and 13.5%, respectively.  When evaluating cleanliness scores, 
udder hygiene has a higher association with SCC compared to flank and leg hygiene 
scores (Sant’Anna and Paranhos da Costa, 2011).  The higher association with udder 
hygiene, compared to flank or leg hygiene, suggests keeping the udder clean was most 
important measure for milk quality.  Sant’Anna and Paranhos da Costa (2011) concluded 
that cows with a very clean or clean udder had a significantly lower (P < 0.05) SCC than 
those with a very dirty udder. 
Teat Disinfectant.  Barkema et al. (1998a) indicated that the use of a PST was 
one of the most important factors between herds with a low herd SCC (< 150,000 
cells/mL) and other herds (P = 0.0007).  Farms that used a PST were 1.14 more times as 
likely to have a herd SCC < 150,000 cells/mL versus a herd SCC between 150,000 and 
250,000 cells/mL.  When used correctly, PST can decrease new IMI by 50% (Pyorala, 
2002).  The use of a dip cup rather than a sprayer was also more frequently adopted by 
farmers with a lower (< 250,000 cells/mL) herd SCC (Jayarao et al., 2004). 
Coliform Bacteria Vaccinations.  Early efficacy trials of an Escherichia coli J5 
mastitis vaccination concluded that the use of a vaccine might not lower IMI rates but 
would decrease the severity, SCC, and signs of CM (Hogan et al., 1992a, Hogan et al., 
1992b, Hogan et al., 1995b).  Though efficacy trials have been completed to show the 
benefits of coliform mastitis vaccinations at a cow level (Hogan et al., 1992a, Hogan et 
al., 1992b, Hogan et al., 1995a), authors found little research that has been done 
examining the effect of vaccination adoption on herd SCC.  In a study using 2002 
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National Animal Health Monitoring System data, Wenz et al. (2007) concluded that only 
49.5% of farmers surveyed were utilizing a coliform vaccine and those farms that had not 
adopted the vaccination were 1.65 times as likely to have a high BTSCC (> 400,000 
cells/mL).  
Antibiotic Treatment at Dry Off.  Over 80% of farms that had a majority of their 
cows with a SCC < 200,000 cells/mL, treated every cow with intramammary antibiotics 
at dry off (Hutton et al., 1990).  Barkema et al. (1998a) found that 93.2% of surveyed 
farms with a low SCC (< 150,000 cells/mL) treated all cows at dry off.  Only 76.4% of 
surveyed farms with a high SCC (251,000 to 400,000 cells/mL) had used intramammary 
antibiotics on all cows at dry off (Barkema et al., 1998a).  Dufour et al. (2011) concluded 
that the use of intramammary antibiotics on all cows at dry off was one of the most 
important management practices to improve milk quality. 
Overall Management.  The review completed by Dufour et al. (2011) suggests 
that many studies have found that farms with low SCC have adopted many of the same 
management practices.  Those practices included milkers wearing gloves, post milk teat 
disinfection, blanket dry cow therapy, and cleanliness of lactating cow housing and cow 
hygiene.  However, their review also found the relationship between herd SCC and 
adoption of certain management practices were not repeatable from study to study.  The 
large variation in results suggests the relationship between management practice 
implementation and herd SCC is very complex.  More research is needed on how herd 
SCC changes before and after management practice adoption. 
Somatic Cell Count and Milk Yield 
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 The main cost of both CM and SCM is due to milk income loss (Shim et al., 2004, 
Bar et al., 2008b, Sadeghi-Sefidmazgi et al., 2011, Liang et al., 2017).  Many studies 
have shown the negative relationship between an increase in SCC and decrease milk 
yield (Raubertas and Shook, 1982, Jones et al., 1984, Hadrich et al., 2018).  Raubertas 
and Shook (1982) were one of the first to examine the effect of SCC on milk yield and 
concluded that the effect of SCC on milk yield was curvilinear with a 134, 286, 271, and 
223 kg per lactation decrease in milk yield for lactations 1, 2, 3, and 4, respectively, for a 
one-unit increase in SCS.  When comparing the lactation effect, primiparous cows had 
50% of the production loss of multiparous cows.  When examining losses on a per-day 
basis, Bartlett et al. (1990) concluded that a loss of 1.18 to 2.37 kg of milk was lost per 
day with a one-unit increase in SCS for second and higher parities, while parity one cows 
lost an average of 1.17 kg of milk per day.    
More recent research has provided insights into the relationship between SCC and 
milk production.  When comparing across cows with similar SCC, cows with higher milk 
production lost a greater percentage of total milk yield throughout their lactation (Hand et 
al., 2012).  The same relationship was seen for cows with a consistently high SCC.  
Though a SCC 200,000 cells/mL has been used to determine IMI status, milk yield loss 
may occur at SCC less than 200,000 cells/mL (Raubertas and Shook, 1982, Bartlett et al., 
1990, Nolan, 2017, Hadrich et al., 2018).  Milk yield losses were greater in cows that had 
consecutive test day SCC greater than 100,000 cells/mL.  The more test days in which 
SCC was greater than 100,000 cells/mL, the greater the milk loss throughout the lactation 
(Hadrich et al., 2018).   
Management Costs 
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Cost of Poor Milk Quality.  Estimates for the cost of mastitis have been modeled 
extensively (Shim et al., 2004, Huijps et al., 2008, Steeneveld et al., 2011, Rollin et al., 
2015, Liang et al., 2017).  Average costs per case of mastitis have ranged from (all in 
2019 US$) $213.84 (Bar et al., 2008b) to $481.82 (Rollin et al., 2015).  When compared 
against multiple cost variables, milk loss contributes the most toward the total costs of 
mastitis (41 to 66%) (Shim et al., 2004, Huijps et al., 2008, Sadeghi-Sefidmazgi et al., 
2011, Liang et al., 2017).  Treatment decisions (extended or label therapies) (Steeneveld 
et al., 2011) and cow characteristics (Bar et al., 2008b) have effects on the variation of 
the cost.  Costs per CM case ranged from $244.17 to $298.43 when treated with the label 
and extra-label (extended therapy) treatment strategies, respectively (Steeneveld et al., 
2011).  Depending on cow traits, such as parity, DIM, and milk production, costs of 
mastitis could be as high as $481.44 per case (Bar et al., 2008b).  However, when cows 
are expected to be culled for reasons other than mastitis, costs of mastitis cases could be 
as low as $3.58/mastitis case (Bar et al., 2008b).  For example, for a cow with CM that is 
in late lactation that is expected to be culled for lameness reasons and low milk 
production, the cost of culling is split among the different reasons for culling.  
Cost of Culling.  The estimation of culling costs in animal health economics has 
been done using retention payoff value (RPO) (Dijkhuizen and Morris, 1997).  Often the 
cost of culling is oversimplified by taking the slaughter value of the cull cow minus the 
cost of her replacement (Bewley et al., 2010).  However, RPO takes into account the 
future value of the cull cow compared to the future value of her replacement.  The 
optimal time to cull the cow from the herd is when her RPO reaches 0 (Dijkhuizen and 
Morris, 1997).  Any value of above 0 should be considered an opportunity cost for her, 
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and when the RPO is below 0, money is being lost by not replacing the animal with a 
more profitable one (Dijkhuizen and Morris, 1997).  T 
 Troendle et al. (2017) also concluded that the cost of culling associated with SCC 
is oversimplified.  Culling benefit estimation for SCC is simplified to the benefit gained 
from culling a top contributor to a herd’s BTSCC to reach a SCC in which the processor 
will either pay a premium or remove a penalty minus the cost of culling the cow.  
However, Troendle et al. (2017) stated that the value of the replacements needs to be 
taken into account as well.  When taking into account the value of the cull cow’s 
replacement, producers could increase their annual profit from $786.00 to $8,301 
(Troendle et al., 2017). 
Cost of Disease 
 The cost of a case of mastitis has been extensively researched using stochastic 
simulation modeling (Bennett, 1992, Swinkels et al., 2005, Bewley et al., 2010, Halasa et 
al., 2010, van den Borne et al., 2010, Steeneveld et al., 2011, Liang, 2013, Rollin et al., 
2015, Liang et al., 2017, Nolan, 2017).  McInerney et al. (1992) stated that economic 
studies of disease have mainly focused on the costs due to particular diseases, and by 
determining the total cost of the disease, more information is provided for the farmer to 
make a decision.  McInerney et al. (1992) further explained that the cost of disease is 
made up of two parts: the output losses from the disease and expenditures for disease 
prevention and treatment. 
 The cost of disease can be broken down into a simple equation (McInerney et al., 
1992): 
𝐶 = 𝐿 + 𝐸 
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Where: 
C = the total cost of the disease 
L = losses or benefits taken away, (i.e., losses in milk production or losses in premiums) 
E = expenses used to manage the disease (i.e., veterinarian costs, drugs for treatment, 
preventative management costs) 
 Though Hogeveen and Van Der Voort (2017) agree with the equation and theory 
explained by McInerney et al. (1992), they consider the losses to be failure costs.  These 
failure costs should not only consider milk production losses but any losses in income 
from the disease such as veterinary costs and costs for treatment of the disease.  
McInerney et al. (1992) consider these to be losses.  Hogeveen and Van Der Voort (2017) 
consider expenses to be preventative costs, which are associated with measures to prevent 
disease (increased labor, vaccinations, or disinfectants).   
The equation above can also be explained in a graphical form known as a Loss-
Expenditure Frontier, as depicted in Figure 1.1 (McInerney et al., 1992).  The axes of the 
graph portray annual financial sums for losses (x-axis) and expenditures (y-axis).  If no 
actions are taken to control a disease, maximum losses, L in Figure 1.1, are experienced.  
Below the point of L, as more management practices are added, and the expenditures 
increase, losses from the disease decrease.  The curve of the total cost (Figure 1.1) slopes 
downward at a diminishing rate, meaning for each additional dollar spent on disease 
management, the financial value of reduced losses becomes smaller (McInerney et al., 
1992). 
 The point where LA intersects with EA in Figure 1.1 represents the technical 
optimum for the cost of disease.  Because most diseases cannot be eradicated, there 
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comes the point in which the losses from a disease cannot get any lower (LA in Figure 
1.1).  For this reason, any expenses past EA is not necessary.   
  Because both axes are scaled in monetary value, the point where losses + 
expenditures are at a minimum occurs at point M in Figure 1.1.  The point where LM and 
EM meet represents the economic optimum or the point where $1 invested in the 
management of a disease will return a $1 in reduced losses (McInerney et al., 1992). 
 With over 200 citations, the theory presented by McInerney et al. (1992) has been 
used frequently to calculate the cost of disease in livestock.  However, as argued by 
Hogeveen and Van Der Voort (2017), most of the research being completed with a focus 
in milk quality are only calculating the failure costs (losses and the costs of treatment).  
Little research has been conducted examining optimal management schemes. 
 McInerney et al. (1992) used the theory presented above to determine the 
economic benefit of investing in three different management practices to control mastitis.  
Management practices examined were the use of a teat disinfectant, DCT, and testing 
milking machines for proper function.  McInerney et al. (1992) concluded that mastitis 
had the least economic impact ($7,071.78/ farm per year in 2019 US$) on farms that 
adopted and used these procedures on all cows or year-round.  Benefits from adoption 
included increased milk production and increased premiums for higher quality milk.  
DRY COW MANAGEMENT 
The Dry Period 
 The dry period is the time in the lactation cycle in which the cow is no longer 
producing milk.  Three stages define the dry period (Hurley, 1989).  The first is 
involution, which is the time in which the mammary gland switches from lactating to 
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non-lactating.  During the involution period, the mammary epithelial cells regress.  The 
second stage is considered a steady state in which the mammary tissue is not producing 
milk.  Finally, the redevelopment state is when the mammary gland starts producing 
colostrum in preparation of parturition (Hurley, 1989).  The dry period is important 
because, through these three stages, the mammary gland replicates epithelial cells and 
repairs damage (Capuco et al., 1997).  If cows are continuously milked and not given a 
break between calvings, the mammary gland cannot replace damaged epithelial cells.  
Cow with dry periods lasting less than 35 days run the risk of the mammary tissue not 
repairing damage which can lead to reduced milk production in the next lactation 
(Capuco et al., 1997). 
Risk of New Intramammary Infections 
 The dry period is also an important time for the management of the cow because 
it is the riskiest time for new IMI (Neave et al., 1950).  New IMI are 6.25 more likely in 
the first 21 days of the dry period than they are throughout the whole previous lactation 
(Neave et al., 1950).  Within the same lactation, IMI are 4 times as likely to occur within 
the first 15 days of the lactation than any other 15 day time period throughout the 
lactation (Erb et al., 1984).  Todhunter et al. (1991) and Taponen et al. (2007) have 
presented similar results, concluding that the dry period and the first two weeks of the 
lactation are the most likely times IMI occurs.  More recent research has shown that a 
cow’s SCC throughout the previous lactation may be associated with the risk of IMI 
during the dry period (Pantoja et al., 2009a, Henderson et al., 2016).  
By examining infection rates over the dry period, Pantoja et al. (2009a) concluded 
that cows that had a chronic infection (SCC over 200,000 cells/mL both at the time of dry 
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off and calving) had increased CM rates (2.7 times) compared to those that had a SCC < 
200,000 cells/mL at calving.  Cows that had a SCC > 200,000 at dry off had a greater risk 
of having CM at calving. Cows that had a SCC > 200,000 cells/mL at dry off and at 
calving had a greater risk of developing a CM case with the first 120 days in milk 
(Pantoja et al., 2009a).   
Research also suggests that the SCC throughout the previous lactation affected the 
risk of IMI through the dry period (Henderson et al., 2016).  Cows that had less than 25% 
(of a minimum of 5 test days) of their test day SCC above 200,000cells/mL throughout 
their lactation are more likely to cure an IMI over the dry period than those that had 
greater than 75% of their test day SCC over 200,000 cells/mL.  If cows had less than 25% 
of their test day SCC above 200,000 cells/mL they were also less likely to develop a new 
IMI during the dry period (Henderson et al., 2016).  This evidence suggests that both the 
SCC at dry off and throughout the lactation should be considered when making dry cow 
therapy decisions.  
Dry Cow Therapy 
 The use of IMMA at dry off is for two main reasons 1) to cure any existing IMI 
and 2) to prevent new IMI from occurring during the dry period.  When polled by the 
National Animal Health Monitoring System, only 9.2% of the surveyed dairy farmers in 
the U.S. do not use any IMMA at the time of dry off (USDA Animal and Plant Health 
Inspection Service, 2016).  Those that do use IMMA, two management types are used, 
either blanket dry cow therapy (BDCT) or selective dry cow therapy (SDCT).  In a 
BDCT scheme, all quarters of all cows are treated with IMMA at dry off.  When using 
SDCT, not all quarters of all cows are treated with IMMA.  Treatment is determined at a 
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cow or quarter level based on IMI status.  With a SDCT scheme, some cows may not 
receive IMMA at all.  In the U.S., 80.3% of surveyed dairy producers use BDCT 
compared to 10.6% that use some form of SDCT.  Of the 10.6% of survey producers that 
used SDCT, 6% used IMMA on 1 to 33% of their cows, 1% of farmers treated 34% to 
66%, and 3.5% of farmers treated 67% to 99% of their cows with IMMA at dry off 
(USDA Animal and Plant Health Inspection Service, 2016). 
Efficacy of Dry Cow Therapy  
Blanket Dry Cow Therapy versus no Dry Cow Therapy.  Pearson (1950) was one 
of the first to complete a study determining the effects of DCT when addressing concerns 
of IMI in non-lactating cows over the summer months.  Later studies worked on the 
development of an IMMA that would last over several weeks during the dry period 
(Smith et al., 1967a, Smith et al., 1967b), and BDCT became a recommendation for 
mastitis control (Dodd and Neave, 1970).  Since these early studies BDCT has repeatedly 
shown to decrease the incidence rate of IMI during the dry period and at calving 
(Schukken et al., 1993, Hogan et al., 1994, Hogan et al., 1995a, Bradley and Green, 2001, 
Berry and Hillerton, 2002).   
More recently, Halasa et al. (2009b, 2009c) completed a meta-analysis of 36 
papers to determine the effect of different dry cow therapy strategies on the ability to cure 
existing IMI and prevent new IMI.  The overall cure rate regardless of therapy 
management was 78%.  Quarters that were treated with an IMMA were 1.78 times more 
likely to have a cure success compared to those that were not treated (Halasa et al., 
2009b).  When it came to preventing new infections, Halasa et al. (2009c) concluded that 
DCT was more protective than no DCT.  However, this differed based on bacterial type.  
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Quarters treated with IMMA were 0.62 and 0.39 times less at risk of developing a 
Staphylococcus aureus and Streptococcus species IMI, respectively, than those not 
treated.  The effect of DCT on the development of a new IMI due to coliforms was not 
significant.  More recent research agrees that bacteria type may affect DCT success 
(Vasquez et al., 2018).   
 Blanket versus Selective Dry Cow Therapy.  The objective of SDCT is to reduce 
the IMMA use by only treating cows that have an IMI rather than using IMMA as a 
preventative measure.  So, for SDCT to be successful, the selection criteria used to treat 
cows is very important.  Rindsig et al. (1978) were one of the first to compare BDCT and 
SDCT.  To select cows that would receive IMMA at dry off, they used a history of CM, 
results from a California Mastitis Test, and cows having a SCC over 500,000 cells/mL.  
Since then, the California Mastitis Test (Poutrel and Rainard, 1981), mastitis history 
(Schultze, 1983), SCC data (Torres et al., 2008, Scherpenzeel et al., 2016), and culture 
results (Cameron et al., 2013, Cameron et al., 2014, Vasquez et al., 2018) have been 
common methods in the selection of cows to receive IMMA at dry off.  Culturing milk 
has been considered to be the gold standard for determining IMI (Oliver et al., 2004), but 
this can be time-consuming and costly.  Torres et al. (2008) completed an analysis to 
determine which selection criteria, based on SCC and CM history would result in the 
most efficient and accurate selection of cows with an IMI.  Results suggest treating cows 
with a SCC greater than 200,000 cells/mL or cows that had CM after 90 DIM would be 
most efficient.  Authors chose 90 days as a cut in DCT selection because they assumed a 
case of CM within the first 90 days may be associated with the previous dry period or 
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peak milk production.  Results by Cameron et al. (2013, 2014) suggest that farmers may 
be missing cows with IMI by using only SCC as selection criteria. 
According to the meta-analysis completed by Halasa et al. (2009b), SDCT leads 
to greater success than no treatment at all.  Selective therapy led to an overall cure rate of 
83% compared to 52% for those not using DCT (Halasa et al., 2009b).  When comparing 
BDCT to SDCT (California Mastitis Test of 2+), Rindsig et al. (1978) concluded that 
there was little difference between cure rates, with 85.4% and 88.2% of quarter curing 
over the dry period treated with BDCT and SDCT, respectively. In a more recent study, 
Cameron et al. (2014) observed no difference in cure rates at a quarter level, 84.5% and 
89.0% for BDCT and SDCT (culture positive), respectively.   
 Like data presented for cure rates, the risk of new IMI has been similar between 
BDCT and SDCT in some published literature.  Halasa et al. (2009c) suggested BDCT 
offered more protection than when SDCT was carried out at the quarter level rather than 
the cow level.  Treating at the cow level may be more protective because when treating 
only quarters with an IMI, producers may miss other quarters of the cows that may have a 
high SCC.  When examined at a cow level no differences in new IMI between BDCT and 
SDCT were reported (Halasa et al., 2009c).  Cameron et al. (2014) reported no 
differences in the risk of new IMI between BDCT and SDCT.  Though Cameron et al. 
(2014) agree with the meta-analysis presented by Halasa et al. (2009c), they suggest 
selection criteria is important in the success of SDCT. 
 Scherpenzeel et al. (2016) determined selection criteria also had an impact on the 
success of SDCT.  Herd-level increase in CM ranged from 11.6 when BDCT was used to 
14.5 cases per 10,000 cow days when primiparous cows with a SCC > 150,000 and 
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multiparous cows > 250,000 cows were treated.  When all cows with a SCC > 50,000 
cells/mL were treated, the lowest increase in CM occurred, with 11.8 cases per 10,000 
cow days.  When examining SCM, BDCT resulted in 38.8% of the herd having a SCC > 
200,000 cells/mL.  Greater than 48% of cows had a SCC > 200,000 cells/mL.  This rate 
occurred when primiparous cows with a SCC > 150,000 and multiparous cows > 250,000 
cows were treated for a total of 47.9% of cows receiving antibiotics at dry off. 
Teat Sealants.  Teat sealants (TS) are applied or infused directly in the teat 
cistern after the last milking of the cow’s lactation.  Sealants can be used in conjunction 
with IMMA or alone in a SDCT scheme.  When used with IMMA, TS are administered 
after the IMMA.  In a meta-analysis by Rabiee and Lean (2013), the use of a TS reduced 
the number of IMI by 25% and 73% compared to cows treated with just IMMA or no 
treatment, respectively.  Teat sealants also reduced the CM at calving by 29% when used 
alone and 48% when used with an IMMA.  Subsequent research also showed a decrease 
in IMI when using TS (Golder et al., 2016, McParland et al., 2019).   
Antibiotic Use.  Many countries such as those in the European Union, 
Scandinavia, and New Zealand now require the use of SDCT (Lam et al., 2017, 
McDougall, 2018) with hopes that SDCT will reduce the use of antibiotics.  Scherpenzeel 
et al. (2016) compared the total antibiotic use of BDCT and SDCT using different SDCT 
selection criteria in a stochastic model based on Dutch dairy farm data.  The use of 
antibiotics was based on an average daily dose (ADD) per CM case.  Scherpenzeel et al. 
(2016) found that the use of SDCT led to a maximum reduction in antimicrobial use of 
40%.  Scherpenzeel et al. (2016)  concluded that none of the SDCT scenarios led to an 
additional treatment that exceeded the total IMMA used with BDCT. 
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Economics of Dry Cow Therapy 
 In the U.S., surveyed producers spent $15.67 and $12.60 (2019 US$) per cow at 
dry off for IMMA plus TS and IMMA alone, respectively (USDA Animal and Plant 
Health Inspection Service, 2016).  When calculating the total cost of DCT, not only do 
treatment expenses (drugs and labor) need to be considered, but also the cost of CM and 
SCM associated with cases in the dry period need to be included (Huijps and Hogeveen, 
2007, Scherpenzeel et al., 2016, Scherpenzeel et al., 2018).  In Dutch dairy  farms, 
expenses ranged from (all in 2019 US$) $14.51 to $36.41 per cow for BDCT (IMMA 
only), $6.40 to $40.23 per cow for SDCT, and $5.58 to $57.55 cow when no DCT was 
used (Huijps and Hogeveen, 2007).  The cost of CM makes up the majority of the total 
cost of DCT (59%) at $26.37/cow when BDCT was used.  Clinical mastitis made up 82% 
of the total cost of DCT, at $30.43/cow, of the total cost when intramammary antibiotics 
were not used (Huijps and Hogeveen, 2007).  Scherpenzeel et al. (2016) presented similar 
results, that even though BDCT had the highest total cost, it reduced the overall cost of 
CM and SCM to the farm.  These results suggest that when fewer cows are treated at dry 
off, the more the cost of mastitis will impact the farm.  Scherpenzeel et al. (2016) 
concluded there comes a point when the cost of mastitis will outweigh the savings from 
not treating cows.   
 Scherpenzeel et al. (2018) completed an additional economic analysis using 
optimization modeling to analyze the benefit of SDCT.  The model allowed for the 
treatment of 0% to 100% of the herd.  Overall, economic benefit depended greatly on CM 
incidence and herd SCC.  Blanket dry cow therapy was never optimal compared to 
SDCT, and no DCT was only optimal compared to BDCT when CM incidence was low.  
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However, when CM rates and herd SCC were high, treating more cows lowered the total 
cost of DCT, with a range of $67.54/cow per yr when 85% of cows received treatment to 
$73.94 with no DCT (2019 US$).   
MILK PRICING IN THE UNITED STATES 
The US dairy market is made up of different Federal Milk Marketing Orders 
(FMMO).  The goal of the FMMO system is to provide order to the marketing of fluid 
milk between the processor or buyer and the dairy producer.  Through the FMMO, the 
government defines pricing rules that move milk between the farmer, the processor, and 
the consumer.  With the FMMO come three main regulations: 1) minimum prices are set, 
meaning market conditions can allow processors to pay higher prices, but they cannot pay 
below the minimum, 2) fluid grade (Grade A) milk is regulated at the farm level, and 3) 
the processors are regulated where prices are set at the milk plant where the milk is 
processed, not at the farm. 
 Within each of the FMMO, the pricing system is based on how the milk within 
that order is used.  The use of milk is broken down into four classes: Class I is used for 
fluid milk; Class II is used for soft dairy products such as ice cream or yogurt; Class III is 
used for hard cheeses, and Class IV is used for powdered dairy products (Bailey and 
Tozer, 2001).  The minimum prices are based on a blended price or the weighted average 
from the four classes based on usage in each of the FMMO. 
As a part of the Federal Agriculture Improvement and Reform Act of 1996, dairy 
pricing for FMMO in the US went through several changes (Bailey and Tozer, 2001).  
One change was the structure of FMMO themselves.  Federal milk marketing orders were 
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reduced from 31 to 11 (Figure 1.2).  By reducing the number of FMMO, pricing would 
be more consistent across larger regions of the US.   
As of January 1, 2000, multiple component price (MCP) took the place of the 
Basic Price Formula in setting milk prices.  In the Basic Pricing Formula, milk fat was 
the only component considered, and the value of milk was adjusted based on fat content 
of 3.5%.  Multiple component pricing determined a value for milk fat, protein, and other 
solids yields.  Producer Price Differential (PPD) is an additional variable in the MCP 
formula to account for the value of all the milk received in the FMMO minus the cost to 
manufacture it, or the uniform price minus the Class III milk price.  Uniform price 
represents the sum of the value of milk used across all four milk classes within the 
FMMO.  The primary objective of MCP is to reflect the value of products made from the 
milk.     
 After the consolidation of the FMMO, 6 of the 11 FMMO use MCP to price milk.  
Marketing orders using MCP include the Pacific Northwest, Upper Midwest, Northeast, 
Central, Mideast, and Southwest (Figure 1.2).  For these six FMMO the milk price paid 
to the farmer is calculated using the following equation (Congressional Research Service, 
2017). 
𝑀𝐶𝑃 = (𝐹 ∗ 𝐹$) + (𝑃 ∗ 𝑃$) + (𝑂 ∗ 𝑂$(+((
𝑀𝑌
100
) ∗ 𝑃𝑃𝐷) 
Where: 
MVMCP = Value of milk using MCP pricing scheme 
F = Pounds of fat shipped 
F$ = Price per pound of fat 
P = Pounds of protein shipped 
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P$ = Price per pound of protein 
O = Pounds of other solids shipped 
O$ = Price per pound of other solids 
MY = Total milk yield shipped by a herd 
PPD = Producer price differential 
 Cragle et al. (1986) completed an analysis to determine if farmers would be paid 
more if prices were adjusted for fat and protein rather than fat alone like in the Basic 
Price Formula.  Cragle et al. (1986) concluded that paying farmers based on fat and 
protein, rather than fat alone, could net the farmer an additional $0.07/cwt of milk.  More 
recently, Bailey et al. (2005) examined the effect of breed on farm income using the MCP 
scheme in the Mideast FMMO.  Bailey et al. (2005) determined that, though Jerseys 
produce higher component milk, the volume of milk produced by Holsteins made them 
more profitable.  By increasing the components produced by one standard deviation 
(0.37% fat and 0.15% protein for Holsteins and 0.50% fat and 0.23% protein for Jerseys), 
farms could increase their income over feed costs by 7.7% and 9.2% for Holsteins and 
Jerseys, respectively.  However, an increase in the total volume would have a greater 
impact on income over feed cost (Bailey et al., 2005). 
Four of the 11 FMMO, including Arizona, Southeast, Florida, and Appalachia 
price milk using a skim milk and butterfat pricing scheme.  In this pricing scheme, dairy 
farmers are paid based on total pounds of milk and butterfat shipped.  Prices of skim milk 
and fat in these FMMO are calculated with classified formulas.  For this reason, members 
of the dairy industry believe MCP allows for more transparency to farmers in how their 
milk is priced (Bailey and Tozer, 2001).  Because MCP values milk on its end use, dairy 
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farmers can estimate market changes by observing retail and wholesale milk commodity 
prices. 
 Though later retracted due fluctuations in the market, in Spring of 2018 National-
Jersey Inc., with support of 14 milk cooperatives, sent a proposal to the US Department 
of Agriculture – Agriculture Marketing Service to change milk pricing in the Appalachia 
and Southeast FMMO to a MCP scheme (USDA Agricultural Marketing Service, 2018b).  
Two additional proposals, one supporting the change to MCP (USDA Agricultural 
Marketing Service, 2018a) and one refuting (USDA Agricultural Marketing Service, 
2018c), both discuss how the change to MCP would change milk transportation, 
handling, and pooling but do not discuss how this change would affect the farm-gate 
prices to dairy farmers in the Appalachia and Southeast FMMO. 
 In an analysis of how MCP might impact the Southeastern US, Newton (2014) 
states that the value of milk produced from 2006 to 2013 would have increased by $25 
million and $44 million for Appalachia and Southeast FMMO, respectively.  However, 
the value of milk in the Florida FMMO would have decreased by $1 million.  Newton 
(2014) does warn that these values may not all come back to the dairy producer as they 
do not account for how processors might adjust to the pricing change.  More research is 
needed to determine how a pricing change to MCP would directly affect farmers in the 
Southeast. 
SUMMARY 
 Milk quality management is becoming increasingly important as pressure is being 
put on dairy farmers for lower SCC (Nickerson, 2012, Nolan, 2018) and less antibiotic 
use (Croney et al., 2012).  Somatic cell count remains the gold standard in evaluating 
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milk quality and udder health status at a herd level.  Research has shown a relationship 
between herd SCC and management practice adoption.  Though BDCT is still a 
recommended milk quality management practice in the US, dairy producers may soon be 
forced to adopt SDCT.  Most of the research determining the economics of milk quality 
management has been modeled under a Dutch dairy system where herd sizes are smaller 
and producers are no longer allowed to use BDCT.  Little to no research had been 
completed modeling a US dairy herd. 
 The following dissertation has three objectives.  The first is to determine the cost 
of herd SCC and how costs change after management practices have been implemented 
to control SCC in a modeled herd.  Next, the second objective is to determine if SDCT is 
more economical compared to BDCT by varying SDCT selection criteria in stochastic 
simulation models.  Finally, the third objective is to provide insight into the potential 
differences in farm gate milk checks when milk is priced under different pricing schemes. 
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Figure 1.1.  The total economic impact from disease when including both losses and 
expenditures, also known as the Loss-Expenditure Frontier (McInerney et al., 1992). 
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Figure 1.2.  Federal Milk Marketing Orders in the United States (USDA Agriculture 
Marketing Service, 2019a). 
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INTRODUCTION 
 Milk somatic cells are composed of epithelial cells and leukocytes.  No matter the 
infection status of the mammary gland of a dairy cow, somatic cells are present in milk.  
However, when the mammary gland becomes infected with microorganisms, most 
commonly bacteria (Bradley, 2002), the number of leukocytes and thus somatic cells in 
milk increases (Schalm et al., 1964, Schalm et al., 1966, Schalm and Ziv-Silberman, 
1968, Schukken et al., 2003).  Somatic cell count (SCC) is a measurement used in the 
dairy industry to determine the infection status of the mammary gland (Prescott and 
Breed, 1910, Miller et al., 1993).     
 Natzke et al. (1972) were one of the first to determine the differences between 
SCC of milk from cows with and without an intramammary infection and concluded that 
the average SCC of a healthy mammary gland was 200,000 cells/mL.  A SCC of under 
200,000 cells/mL is still considered a non-infected mammary gland (Dohoo and Leslie, 
1991, Pantoja et al., 2009b, Jadhav et al., 2018).  Even though a SCC threshold of 
200,000 cells/mL has been used to determine an intramammary infection, milk loss is 
associated with SCC levels lower than 200,000 cells/mL (Dürr et al., 2008, Hand et al., 
2012, Gonçalves et al., 2018, Hadrich et al., 2018)   
 At a bulk tank or herd level, the legal SCC in the United States is 750,000 
cells/mL (U.S. Food and Drug Administration, 2017).  However, dairy processors are 
now determining SCC thresholds for their producers.  To export milk products to the 
European Union, the 3-month rolling average SCC of milk must be < 400,000 cells/mL 
(Norman et al., 2011, USDA Agricultural Marketing Service, 2013).  For this reason, 
many processors have set their SCC threshold at 400,000 cells/mL.  This threshold 
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continues to decrease, with some processors demanding farms have a bulk tank SCC 
under 250,000 cells/mL (Nickerson, 2012, Nolan, 2018).   
 Little research has been conducted on the direct effect of management practice 
implementation on the change of bulk tank SCC.  However, multiple studies have 
examined the difference in management practice adoption between herds with differing 
SCC (Dufour et al., 2011).  In a review study, Dufour et al. (2011) concluded that many 
different management practices, such as teat disinfectants and blanket dry cow therapy, 
are implemented by farms with a low SCC (< 250,000 cells/mL).  Farm characteristics, 
such as housing design, bedding material, and milking equipment were also associated 
with herd SCC (Dufour et al., 2011).   
 Often the lack of adoption of management practices is due to cost (Jansen et al., 
2010).  When profit margins in the dairy industry begin to decrease, producers look for 
new ways to cut costs, and some management practices may be dropped from protocols.  
However, dairy producers must look at more than just the cost of the practice when 
making decisions.  They must determine the overall current and future economic impact 
of management practices. 
 The economic impact of management practices that prevent or cure diseases can 
be calculated by determining the practice’s effect on the total cost of the disease to a 
herd.  Disease costs are composed of expenses and losses of potential income (McInerney 
et al., 1992).  The costs of teat disinfection, dry cow therapy, and labor to control bulk 
tank SCC are expenses.  Losses are the economic impacts that might not be readily 
apparent to producers e.g., milk production loss, loss of potential premiums.   
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 Total costs associated with disease control strategies can be examined and, in a 
loss-expenditure analysis (McInerney et al., 1992), used to determine which strategies are 
the most economically optimal.  The economic optimum is the point in which a dollar 
spent on management practices (expenses) returns exactly a dollar in decreased losses.  
Besides McInerney et al. (1992), the use of the loss-expenditure method to determine the 
economic impact of milk quality has been limited.  Stott et al. (2002) used a similar 
method to determine the total cost of Staphylococcus aureus mastitis management, while 
Scherpenzeel et al. (2018) evaluated the effects of dry cow therapy on the cost of clinical 
mastitis to dairy farms.   
Another common modeling approach in dairy research has been stochastic 
simulation.  Stochastic simulation allows researchers to simulate real events and account 
for variation in inputs used in the model.  This modeling technique has been widely used 
by dairy researchers to estimate the costs of disease (Halasa et al., 2009a, Liang et al., 
2017, Dolecheck et al., 2019).  However, little research has been done using these 
economic modeling approaches to determine the economic effect of an elevated herd 
SCC. 
In our study, we combined the loss-expenditure analysis method with stochastic 
simulation in creating a model to determine how the cost of a herd SCC can be decreased 
through the adoption of new management practices.  Primary objectives of the study were 
1) to determine the economic losses associated with an elevated bulk tank SCC, 2) to 
determine the total cost of a herd’s new SCC after the adoption of different cost 
management practices, and 3) to determine the cost change of decreasing an elevated 
bulk tank SCC associated with adoption of management practices.  Secondary objectives 
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of the study were 1) to determine the change in SCC necessary for the implementation of 
management practices to be economically feasible and 2) to determine the impact of milk 
quality premium pricing on the economics of management practice adoption.   
MATERIALS AND METHODS 
Model Overview 
 A farm-level simulation model was developed with deterministic and stochastic 
components.  The deterministic component was developed using Excel 2013 (Microsoft, 
Seattle, Washington) and was first developed by Bewley et al. (2010) with additions by 
Dolecheck et al. (2016) and Liang et al. (2017).  Our model was updated to model three 
different Holstein herds using Dairy Records Management Systems (DRMS) (Dairy 
Records Management Systems, Raleigh, NC) data.  When collecting data from the 
DRMS database, limit options for “breed” to only include Holstein and no limit options 
for “state” or “region” were used.  The DRMS report was run on November 2, 2018, and 
collected records from every Holstein herd in the United States that was enrolled in the 
DRMS program.  Results from the DRMS report indicated that the average US Holstein 
herd processed through DRMS consisted of 205 milking cows with an average lactation 
yield of 10,336 kg and a SCC of 251,000 cells/mL.  These data were used to represent an 
average SCC herd in our analysis (Farm B).  The analysis also included two additional 
herds within one standard deviation of the average herd’s SCC.  The below-average herd 
(Farm A) had a SCC of 109,000 cells/mL, and the above-average herd (Farm C) had a 
SCC of 393,000 cells/mL.  Herd size and rolling herd average were kept constant 
between the three herds.   
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 The second component of the model used stochastic variables to simulate the total 
cost of herd SCC based on the effect of management practice implementation and their 
changes in the herd SCC.  Stochastic variables were created and simulations were done 
using the Excel add-in, @Risk (Palisade Corporation, Ithaca, NY).  Stochastic variables 
included milk price, management practice costs, resulting change in herd SCC, and milk 
yield loss associated with an elevated SCC.  Using historical milk price variation, 
predicted milk prices were estimated using the same process described by Bewley et al. 
(2010) and Liang et al. (2017) to create a stochastic milk price.  Historic milk prices were 
collected over a 10-year period from Gould and Bozic (2018).  Milk prices used in the 
model ranged from $0.31 to $0.51/kg of milk with an average of $0.42/kg of milk.  The 
total cost of the bulk tank SCC was calculated by summing the losses associated with an 
elevated SCC and the expenses of new management practice adoption. 
Losses 
 Losses from an elevated SCC were derived from potential unrealized milk 
production or losses associated with a SCC and loss of milk quality premiums.  To 
determine the milk yield losses associated with SCC, results from Hand et al. (2012) were 
applied based on each herd’s bulk tank SCC and multiplied by herd size.  Parity 
distribution of the herd was adopted from Dhuyvetter et al. (2007) to account for a parity 
effect in milk yield losses where 36.1%, 26.0%, and 37.9% of cows were in parities 1, 2, 
and 3+, respectively, in a simulated herd of 205 lactating cows.  Overall milk yield loss 
was calculated using the following equation: 
𝑀𝐿 = (0.361 ∗ 205 ∗ 𝑃𝐿1) + (0.260 ∗ 205 ∗ 𝑃𝐿2) + (0.379 ∗ 205 ∗ 𝑃𝐿3) 
Where: 
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ML = Total milk yield loss (kg/farm)  
PL1 = Milk yield loss (kg/cow) for parity 1 cows based on the SCC threshold of each 
farm. 
PL2 = Milk yield loss (kg/cow) for parity 2 cows based on the SCC threshold of each 
farm. 
PL3 = Milk yield loss (kg/cow) for parity 3 and greater cows based on the SCC threshold 
of each farm. 
 Milk quality premiums were calculated using $0.0055 per kg of milk per change 
in SCC premium level (Table 2.1).  To avoid inflation of losses associated with a 
premium for Farms B and C, it was assumed that they were only losing benefit from one 
bonus level, rather than the addition of all bonus levels, for a premium loss of $0.0055 
per kg of milk produced.  If the herd SCC decreased below a premium level or if no 
premiums were offered, authors assumed no losses were associated with lost premiums.  
Therefore, total losses were calculated using the following two equations where equation 
“A” was used when premiums levels were not met and “B” was used when premiums 
were met or when premiums were not offered. 
A) 𝑇𝐿 = (𝑀𝐿 ∗ 205 ∗ 𝑆𝑀𝑃) + (0.0055 ∗ 𝐻𝑀𝑌) 
B) 𝑇𝐿 = (𝑀𝐿 ∗ 205 ∗ 𝑆𝑀𝑃) 
Where: 
TL = Total losses per farm ($/farm per year) 
ML = Milk loss (kg per cow) associated with the bulk tank SCC 
SMP = Stochastic milk price ($/kg) 
HMY = Herd milk yield (kg/yr) before management practice adoption 
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Management Expenses  
 Three different management practices were analyzed based on the cost of 
implementation (Nolan, 2017).  Costs of each management practice were fit with a PERT 
distribution using the range presented by Nolan (2017) to make the variable stochastic.  
Management practices were defined as low, moderate, and high expense practices based 
on the most likely cost and variation in cost of each practice (Table 2.2).  Though the 
management practices were generalized based on expense, the costs of implementation 
were derived from common management practices used in the dairy industry to control 
mastitis and improve milk quality.  Costs of management practices were calculated on a 
per cow per year basis and multiplied by the herd size to obtain the total cost of the 
management practice for the herd. 
Change in Somatic Cell Count 
Because one of the primary objectives of the study was to determine the change in 
the total cost of a bulk tank SCC before and after management practice adoption, change 
in SCC was assumed to be constant across the three management practices analyzed.  
Keeping the change in SCC consistent between management practices ensured that the 
only difference between each management practice was the cost of adoption.  However, 
SCC change was specific for each of the three farms based on the original herd SCC of 
each farm.  Values for the change in SCC were fit to a PERT distribution to make the 
variable stochastic (Table 2.3).  By making the change in SCC a stochastic variable, 
authors were able to calculate a breakeven SCC where the economic benefits of 
management adoption were no longer feasible.  Little data exists showing the cause and 
effect relationships between the management practice adoption on herd SCC.  Therefore, 
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authors estimated changes in SCC that would result in both positive and negative 
economic benefits of management practice adoption.  Estimated changes included a wide 
distribution to satisfy the secondary objective of the study in determining the change in 
SCC necessary to make management practice adoption feasible.  The herds’ SCC after 
the implementation of the management practice was calculated by taking the difference 
between the original bulk tank SCC and the change in SCC. 
Benefits 
 Benefits from a lower SCC came in the form of increased milk production and 
potential milk quality premiums.  Estimating milk production increases were achieved by 
taking the differences in milk yield between SCC thresholds presented by Hand et al. 
(2012).  Results from Hand et al. (2012) were adapted to show the difference in milk 
yield with one SCC unit (1 cell/mL) change by taking the average of losses (kg/cow per 
year) from each SCC group of 100,000 cells/mL and dividing by 100,000.  For example 
the losses associated with a SCC between 100,000 cells/mL and 200,000 cells/mL were 
subtracted from the losses between 200,000 cells/mL and 300,000 cells/mL and divided 
by 100,000.  Results from the calculation were then used to estimate the increase in milk 
yield per 1 cell/mL associated with a farm decreased from one SCC group to another.  A 
table showing the losses presented by Hand et al. (2012) is located in the appendix (Table 
A.1). 
 Premiums were calculated by taking the new bulk tank SCC and determining the 
correct milk quality bonus.  Once the correct bonus level was determined, the associated 
price was multiplied by the total herd milk yield.  The total benefit of management 
practice adoption was calculated using the following equation. 
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𝑇𝐵 = ((𝐶𝑆𝐶𝐶 ∗ 𝑀𝐼 ∗ 𝑆𝑀𝑃 ∗ 𝐻𝑆) + (𝑃𝐿 ∗ 0.0055 ∗ 𝐻𝑀𝑌)) − 𝑀𝐸 
Where: 
TB = Total benefit ($/farm per year) 
CSCC = Change in herd SCC (cells/mL) 
MI = Milk yield increase (kg/cow per year) associated with the change in SCC 
SMP = Stochastic milk price ($/kg) 
HS = Lactating herd size 
PL = Number of premium levels changed due to change in SCC 
HMY = Herd milk yield (kg/year) 
ME = Management expenses ($/farm per year) 
Change in Cost  
 To accomplish objective 3, the total cost, including expenses and losses, described 
by McInerney et al. (1992) was calculated based on the farm’s new SCC.  The total cost 
change was calculated using the following equation. 
𝐶𝐶 = 𝑇𝐿 − (𝑇𝐿𝑁 + 𝑀𝐸) 
Where: 
CC = Cost change ($/farm per year) 
TL = Total economic losses ($/farm per year) associated with the base SCC  
TLN = Total economic losses ($/farm per year) associated with the new SCC (calculated 
as TL - TB) 
ME = Management expenses ($/farm per year) 
Simulation 
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 A single 1,000-iteration simulation was run collecting output variables including 
change in bulk tank SCC, total losses associated with the base SCC for each of the three 
farms, total cost (losses and expenses) associated with the new SCC, and the total cost 
change with management practice adoption.  The simulation was run using Latin 
Hypercube sampling with a static seed of 31,517 (Liang, 2013, Nolan, 2017, Dolecheck, 
2018).   
Upon completion of the simulation, each iteration was analyzed across the three 
farms and management practice costs.  Iterations were analyzed to determine the 
frequency of a positive benefit for each of the three management practices and compared 
across Farms A (109,000 cells/mL), B (251,000 cells/mL), and C (393,000 cells/mL).  
The total cost of the new SCC and the change in cost were also analyzed on a per 
iteration basis.  All iterations regarding the cost-benefit analysis of the three management 
practices and the total cost of the new SCC were further analyzed to complete a mean-
variance analysis to complete an economic risk analysis associated with the 
implementation of the three management practices.  
Statistical Analysis 
Results from the simulation for the total cost of the herd SCC were analyzed for 
significant differences before management practice adoption and across all three 
management practices for all farms.  Analyses were completed using Microsoft Excel 
Simetar (Simetar, College Station, TX) add-in.  The means of the cost of SCC associated 
with each management practice were compared to one another, by farm, using a two-
sample T-test to determine significant differences at P < 0.05. 
Mean-Variance Analysis 
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 After the simulation was run, the mean and variance of the total cost of the new 
SCC were collected across all farms and management practices.  For each management 
practice, the means were evaluated for the lowest total cost of the new SCC.  The 
variance for the total cost of the new SCC was evaluated for the lowest variance.  The 
combination of the lowest means and lowest variance was assumed to be the least risky 
management strategy. 
Sensitivity Analysis 
 To satisfy the secondary objectives of the study, a sensitivity analysis was 
completed by examining the relationship between the change in SCC of all farms and the 
change in the cost of SCC after the adoption of the high-cost management practice.  The 
high-expense management practice was used because it not only had the highest most 
likely cost but also had the most variation in cost.  Because of the variation in cost, 
authors were able to determine at what cost a management practice would no longer be 
feasible to adopt.   
Authors felt it was important to include the secondary objective of determining 
the impact of milk quality premium pricing on the economics of management practice 
adoption because of current trends in the United States dairy industry.  Many milk buyers 
and processors are no longer offering milk quality premiums, so a single simulation was 
run with all premiums levels set to $0.00/kg of milk.   
RESULTS 
 After the adoption of any management practice, herd SCC decreased from the 
base SCC for 98.8%, 99.7%, and 99.8% of the 1,000 simulated iterations for Farms A, B, 
and C, respectively.  Though herd SCC decreased from the base, each herd’s new SCC 
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still had associated economic losses because of the continued reduced milk production 
and potential premium losses associated with the farms’ new SCC.  Because the change 
in SCC was assumed to be the same across the different management practices, losses 
were only specific by farm.  Farms reached the next premium level in 91.9%, 61.0% and 
21.4% of the 1,000 iterations for Farms A, B, and C, respectively.  Not reaching the next 
premium level resulted in a yearly loss of $11,587.83, per farm, due to lost premiums 
alone.   
Total losses before and after management practice adoption were the lowest for 
Farm A and highest for Farm C.  After the implementation of the management practices, 
losses decreased by $13,463.56, $12,870.18, and $9,276.09 for Farms A, B, and C, 
respectively (Table 2.4A).  Though losses decreased after the adoption of a management 
practice, they were more variable before the adoption of management practices across all 
three farms (Figure 2.1A).   
Compared to when a premium was offered, the total losses associated with SCC 
decreased when no premium was offered.  The decrease in losses was because the loss in 
milk production associated with SCC was the only loss considered.  Losses decreased by 
$2,814.54, $5,801.73, and $6,787.34 for Farms A, B, and C, respectively, after the 
adoption of the management practices (Table 2.4B).  Losses were more variable after the 
adoption of the management practices when premiums were offered versus when they 
were not (Figure 2.1B).  These trends of variability continue when examining the effect 
of management practice adoption on the total cost of an elevated SCC to dairy herds. 
Low-Expense Management Practices 
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 Premium Offered.  The total cost of the low-expense management practice 
averaged $587.67 ± 222.24 per farm per year.  When examining the total cost of the 
herds’ new SCC, costs ranged from $10,102.94 to $18,282.88 (Table 2.5A).  The low-
expense management practice led to the new SCC costing the least to Farm A and most to 
Farm C when a milk quality premium was being offered (0A).  Regardless of farm type, 
the low-expense management practice significantly (P < 0.05) decreased the cost of SCC 
to the farms after adoption (Table 2.5A).   
The total change in the cost of herd SCC from before to after adoption of the low-
expense management practice was highest in Farm A and lowest in Farm C (Figure 
2.3A).  Farm A had a total change in cost of $12,875.90 when a premium for milk quality 
was offered (Table 2.6A).  When considering the variation in the total cost, at times, all 
farms had a higher cost associated with SCC after the implementation of the low-expense 
management practice.  When considering the variation in the total cost, less than 7% of 
iterations resulted in all farms having a higher cost associated with the herd SCC after the 
implementation of the low expense management practice. 
Variation in the cost change between the SCC before and after management 
practice adoption was strongly related to the change in SCC.  Of the 1,000 iterations, 
94.2%, 98.9%, and 99.1% of iterations resulted in the new SCC costing less for Farms A, 
B, and C, respectively.  For Farm A, SCC must have decreased by at least 3,979 cells/mL 
to see a decrease in the cost of the SCC (Figure 2.4).  At a change of 9,000 cells/mL a 
large increase in the change in cost can be seen in Figure 2.4 due to the farm receiving a 
premium for decreasing the SCC below 100,000 cells/mL.  To see a decrease in the cost 
of SCC after adoption of the low-expense management practice, the SCC must have 
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decreased by 6,310 and 7,672 cells/mL for Farms B and C, respectively.  Like in Farm A, 
a large increase in the change in the cost of SCC after adoption of the low-expense 
management practice is observed when each farm reaches the next premium level 
(Figures 2.6 and 2.8). 
No Premium Offered.  The total cost of SCC to the farm after adoption of the 
low-expense management practice ranged from $11,391.22 per year for Farm A to 
$15,374.69 per year for Farm C when premiums were not offered to the farms (Table 
2.5B).  The cost of SCC to the farm after adoption of the low-expense management 
practice were significantly (P < 0.05) less than the cost before adoption.  Unlike when 
premiums were offered, Farm C saw the greatest benefit from adoption of the low-
expense management practice (Figure 2.3B).  The average change in the cost of SCC to 
Farm C after adoption of the low-expense management practice was $6,199.68 per year 
(Table 2.6B).   
When premiums for milk quality are not offered, the same relationship between 
the farms’ change in SCC and the change in cost are observed.  However, the large 
increase once the farm dropped below the next premium SCC threshold is no longer 
present (Figures 2.5, 2.7, and 2.9).  The lowest change in SCC observed for Farms A, B, 
and C in which the cost in SCC decreased after adoption of the management practice was 
a decrease of 3,979, 6,310, and 7,672 cells/mL respectively.  However, farms needed to 
have a decrease in SCC of approximately 10,000 cells/mL before all iterations resulted in 
the positive economic benefit to the farm. 
Moderate-Expense Management Practices 
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 Premium Offered.  Cost of implementation of the moderate-expense management 
practice averaged $2,490.40 ± 378.30 per farm per year.  The total cost of the new SCC 
after the adoption of the moderate-expense management practice ranged from $12,005.72 
per year for Farm A to $20,185.66 per year for Farm C (Table 2.5A).  Though the cost 
was lowest for Farm A (Figure 2.2A), the adoption of the moderate-expense management 
practices significantly (P < 0.05) lowered the cost of SCC to each farm (Table 2.5A). 
Adopting the moderate-expense management practice was the most beneficial for 
Farm A.  The average change in cost ranged between $6,776.65 for Farm C to $10,973.12 
for Farm A (Table 2.6A).  When premiums were offered, 91.9%, 89.7%, and 92.7% of 
iterations resulted in a positive cost change for Farms A, B, and C, respectively.   
To result in a positive cost change after the adoption of a moderate-expense 
management practice, the SCC must have decreased by 9,013 cells/mL for Farm A, 
21,712 cells/mL for Farm B, and 18,923 cells/mL for Farm C.  Once each farm reached 
the next bonus level, the change in cost of SCC increased (Figures 2.4, 2.6, and 2.8).  
No Premium Offered.  When no premium was offered to the farms, the cost of 
SCC after adoption of the moderate-expense management practice was highest in Farm C 
and lowest in Farm B.  The cost of SCC after adoption of the moderate-expense 
management practice was $9,370.11 per year for Farm B.  Across all farms, the cost of 
SCC significantly (P < 0.05) decreased after the adoption of the management practice 
(Table 2.5B).   
The change in cost of SCC after the adoption of the moderate-expense 
management practice was lowest in Farm A ($324.10 per year) and highest in Farm C 
($4,296.90) (Figure 2.3).  Farms B and C saw a benefit from management practice 
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adoption in 89.7% and 92.7% of iterations, respectively (Figures 2.7 and 2.9).  However, 
unlike when premiums were offered, Farm A saw a decrease in the cost of SCC after 
adoption of the moderate-expense management practice in 59.3% of iterations (Figure 
2.5).  The decrease in iterations in which the cost of SCC was lower after management 
practice adoption suggests that when a premium is provided management practices 
become more economical.   
High-Expense Management Practices 
 Premium Offered.  Average costs of the high-expense management practice were 
$4,003.60 ± 2,116.91 per farm per year.  Based on the implementation of the high-
expense management practice, the cost of the new SCC was lowest in Farm A 
($13,889.28/farm per year) and highest in Farm C ($21,698.12/farm per year) (Table 
2.5A).  Across all farms, the cost of SCC significantly (P < 0.05) decreased after 
adoption of the high-expense management practice. 
 Farm A had the highest change ($9,460.67/farm per year) when premiums were 
being offered (Table 2.6A) (Figure 2.3A).  The frequency of iterations in which the 
change in cost of SCC was positive was 92.2%, 78.5%, and 77.5% for Farms A, B, and 
C, respectively (Figures 2.4, 2.6, and 2.8).  To have a positive change in the cost of SCC, 
Farm C needed to have the highest SCC change of at least 10,925 cells/mL.  In one 
iteration, Farms A and B had to decrease their SCC by 6,934 and 6,124 cells/mL, 
respectively, before the high expense management practice was a positive benefit.  When 
farms reached the SCC threshold to receive a premium, the change in cost of SCC 
increased dramatically. 
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 Not only did the high-expense management practice cost the farms the most on 
average, but it also had the most variation in cost.  This allowed the authors to determine 
at what cost a management practice no longer became economically feasible.  When 
premiums are being offered to the farm, Farm C was the only farm limited by the cost of 
the management practice.  Once the costs of the management practices increased above 
$47.88/cow per year, all total costs changes from lowering the herd SCC were negative 
for Farm C (Figure 2.10).  Farms A and B could spend over $50.00 per cow per year and 
still see a benefit of lower total SCC costs if they reached the SCC threshold for a 
premium.  If the threshold for the premium was not reached, management expenses as 
low as $3.38, $7.06, and $3.34 per cow per year resulted in higher total SCC costs than 
before adoption (Figure 2.10) for Farms A, B and C, respectively. 
 No Premium Offered.  Adoption of the high-expense management practice 
resulted in a significantly (P < 0.05) lower SCC cost for Farms B and C (Table 2.5B).  
Costs of SCC after adoption of a high-expense management practice ranged from 
$10,882.57 per year for Farm B to $12,590.24 per year for Farm C.  However, Farm C 
had the greatest change in cost, saving $2,784.44 per year (Table 2.6B).  When no 
premiums were offered, Farm A had a significant (P < 0.05) increase in the cost of SCC 
after adoption of the high-expense management practice (Table 2.5B).  Farm A averaged 
a negative change in cost (-$1,188.36/year) (Figure 2.3B), suggesting that investment in a 
high-expense management practice will rarely pay off for farms with a lower SCC.   
Only 35% of the iterations ran led to a positive cost change for Farm A (Figure 
2.5).  To ensure a positive change in the cost of SCC, Farm A had to decrease SCC by 
6,934 cells/mL (Figure 2.5).  In 71.3% and 77.3% of iterations, the cost of SCC 
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decreased for Farms B and C, respectively.  To result in a positive change in the cost of 
SCC, Farm B needed to decrease SCC by 6,124 cells/mL and Farm C needed to decrease 
by 10,925 cells/mL (Figures 2.7 and 2.9).  The maximum farms could spend and still 
benefit economically from the lower SCC was $26.63, $42.91, and $47.88/cow per year 
for Farms A, B, and C, respectively (Figure 2.11). 
Mean-Variance Analysis 
 A mean-variance analysis was completed across all management practices to help 
dairy farmers consider the financial risk of adopting a management practice.  When 
comparing the mean and variance for the effect of each management practice on the total 
cost of the new SCC, the low-expense management practice had the lowest mean cost 
and variance across all herd types when farms were offered a premium for milk quality 
(Table 2.7A).  The low-expense management practices also resulted in the lowest cost 
and variation when premiums were not offered (Table 2.7B). The mean and variance 
were higher when premiums were offered (Figure 2.12) compared to when they were not 
(Figure 2.13).  As expected, the low-cost management practice having the lowest total 
SCC cost and least variance suggests that it would be the least risky to implement 
regardless of whether premiums for milk quality are offered to farms. 
DISCUSSION 
Most of the economic research focused on milk quality in the dairy industry has 
focused the cost of clinical mastitis.  Little research has addressed costs associated with 
specific SCC, and the research that has been done is primarily on the losses associated 
with SCC.  One objective of our study was to determine the total cost of herd SCC by 
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considering both milk income losses (lost milk production and premiums) and the 
expenses of implementing new management practices to decrease SCC.   
 McInerney et al. (1992) first discussed the total economic impact of disease and 
completed an analysis determining the total cost of subclinical mastitis.  They concluded 
that subclinical mastitis had the least total economic impact on farmers who implemented 
all three management practices modeled (teat disinfection, dry cow therapy, and 
equipment maintenance) because the cost of subclinical mastitis to a farm was lowest 
when the farm used all three management practices.  Costs were lowest to the farm that 
used all the management practices because their adoption lowered subclinical mastitis 
incidence.  In our analysis, a more general approach was taken.  According to USDA 
Animal and Plant Health Inspection Service (2016), of the farms polled, 85%  used a pre-
milking teat disinfectant, 97% used a post-milking teat disinfectant, 97% treated clinical 
mastitis cases, and 93% treat every quarter of every cow at dry-off.  No information on 
the frequency of milking maintenance was reported by USDA Animal and Plant Health 
Inspection Service (2016).  These results suggest that most surveyed dairy farmers in the 
United States have adopted the original 5-point mastitis plan (Dodd and Neave, 1970) 
developed by the National Mastitis Council.  Because farmers have adopted practices 
modeled by McInerney et al. (1992) (teat disinfection and dry cow therapy), we decided 
to examine costs of general management practices rather than examining the adoption of 
specific management practices.  We believe this will allow our research to be relevant 
through time as more SCC management practices are developed.  However, costs were 
derived from management practices already on the market (USDA Animal and Plant 
Health Inspection Service, 2016, Nolan, 2017). 
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 In a simulation model, McInerney et al. (1992) concluded that subclinical mastitis 
had the least economic impact on farms that implemented the use of a teat disinfectant all 
year, applied dry cow therapy to every quarter of every cow at dry off, and tested and 
repaired milking equipment annually.  Subclinical mastitis cost the farm $4,109.35/farm 
per year (adjusted to 2019 US$).  The farm that was impacted the most by subclinical 
mastitis only implemented teat disinfection part of the year, did not dry cow treat, and did 
not perform milking machine maintenance ($9,829.50/farm per year) (2019 US$).  The 
reasons for the increased losses in this herd compared to the losses of a herd that did not 
adopt any of the practices were due to the increased costs of teat disinfection with no 
decrease in subclinical mastitis incidence rate because the disinfectant was only used part 
of the time. 
 Our model and the model used by McInerney et al. (1992) were similar in the way 
the cost of decreased milk quality was calculated to include 1) milk loss, 2) loss of milk 
quality premiums and 3) management practice expenses.  In our study, the total costs of 
the herd SCC seem higher than results presented by McInerney et al. (1992).  However, 
once accounting for inflation, currency conversion, and herd size, results presented by 
McInerney et al. (1992) fell within the range of our results.  McInerney et al. (1992) 
calculated milk quality costs for a 100-cow herd where ours were calculated for 205 
cows.  The $9,829.50 cost of subclinical mastitis presented above for a 100-cow herd is 
equivalent to $20,150.48 for a 205-cow herd, which is within the range of results 
presented in our study.  The range presented in our results is because of the modeling 
technique.  By using stochastic variables we were able to account for ranges of input 
variables.  Differences in results of our study and McInerney et al. (1992) may be due to 
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the assumptions made in each model and modeling technique.  Premiums in our model 
were lower with a $0.0055/kg of milk produced compared to a $0.03/kg (2019 US$) used 
by McInerney et al. (1992).  However, the milk yield per cow per year was much greater 
in our model (10,336 kg versus 4,900 kg) because we used current milk yield of a US 
herd whereas McInerney et al. (1992) used milk data from the United Kingdom in 1988.   
 Hadrich et al. (2018) estimated the total losses associated with a SCC above 
100,000 cells/mL using Dairy Herd Improvement data from US herds.  Losses from 
decreased milk yield ranged from $1.20/cow per day to $2.06/cow per day when the cow 
had a SCC above the 100,000 cell/mL threshold for one month and 10 months, 
respectively.  In our study, milk production economic losses due to an increased SCC 
were $0.13, $0.16, and $0.20/cow per day for Farms A, B, and C, respectively.  One of 
the main reasons for differences between the results presented by Hadrich et al. (2018) 
and ours is because we averaged the losses across the whole herd rather than examining 
the losses at the cow level.  When estimating losses at a cow level, Hadrich et al. (2018) 
compared milk income from cows with varying SCC and other individual cow 
characteristics and concluded that individual characteristics (e.g. breed, lactation, days in 
milk, and number of days with a SCC > 100,000 cells/mL) were highly influential of 
monetary losses.  Another difference in loss calculation was that they used milk price 
data from one point in time, whereas we used prices over a ten-year period in a stochastic 
simulation. 
 Additional income from SCC premiums contributed to whether or not the 
investment in management practices lowered the total cost of SCC in each of the three 
herds.  Dekkers et al. (1996) examined the effect of a $0.02/kg of milk (2019 US $) 
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penalty for herd SCC above 500,000 cells/mL in three out of four months.  Dekkers et al. 
(1996) concluded that lowering herd SCC led to significant increases in milk revenue 
with an average profit of $45.72/cow per year (2019 US$) when the SCC decreased by 
one linear score.  Under the pricing scheme in our model, dairy farmers could benefit by 
$56.52/cow per year by reaching the next premium structure level.  The frequency in 
which premiums were paid was highly dependent on the herds’ base SCC and how far the 
herds base SCC was from a premium level.  Producers received a premium on 91.9%, 
61.0%, and 21.4% of iterations for Farms A, B, and C, respectively.  The decreased 
percentage of iterations in which Farm C received a milk quality premium was due to the 
farm’s base SCC being 393,000 cells/mL, 93,000 cells/mL away from the next bonus 
level.  Farms A and B were much closer to reaching the next bonus at 9,000 and 51,000 
cells/mL, respectively.  The frequency of positive iterations in which farms received a 
premium was the reason cost alleviation was the highest in Farm A.  Once the premium 
was no longer offered, Farm C had the highest cost change.  When a premium is offered 
farmers should consider whether implementation of a new management practice will 
lower their SCC to the next premium or bonus level.  In the farms modeled, the closer the 
base SCC was to the next bonus level, the greater the average benefit from lowering the 
herd SCC.   
Over the past decade, the thresholds for acceptable milk SCC have been lowered 
by many processing plants and cooperatives (Norman et al., 2011).  Some milk buyers 
are no longer offering premiums (Nickerson, 2012) for SCC and have either adopted 
penalties or have eliminated an incentive system altogether.  We completed an additional 
simulation in which premiums for milk quality were no longer offered.  When premiums 
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were no longer offered, Farm C had the greatest cost change from the base to the new 
SCC across all three management practices.  These results suggest that farms with a 
higher SCC, Farms B and C in our model, have the most to gain economically from 
management practice adoption or other means to reduce SCC.  However, for Farm A, the 
frequency in which the moderate and high-cost management practices were economically 
beneficial decreased when no premiums were offered.  When considering the high-
expense management practice, the average change in the cost of SCC was negative.  
These results suggest that without the increased profit from potential premiums, the 
adoption of management practices might not be economically feasible for Farm A (low 
SCC farm). 
Not providing a premium to farmers for milk quality may decrease the incentive 
for dairy farmers to lower their SCC.  Valeeva et al. (2007) found that dairy farmers are 
more likely to take steps to lower their herd SCC when they are penalized for not meeting 
quality thresholds.  When premium incentives are in place, dairy farmers should view the 
potential income as a reason to improve their milk quality. 
By performing a two-sampled T-test analysis, we were able to determine if 
adoption of management practices would significantly (P < 0.05) decrease the cost of 
herd SCC.  Results indicated that regardless of whether premiums were offered, adoption 
the low-expense management practice resulted in significantly lower SCC costs than all 
other management practices (Tables 2.5A and 2.5B).  Because the cost of SCC was 
significantly lower, implementation of the low-expense management practice would be 
the most economically feasible.  Results from the mean-variance also indicate adoption 
of the low-expense management practice would be the least risky option for farmers.  
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Therefore, when implementing practices to lower herd SCC, farmers should start with 
low cost management practices first.  If the practice does not result in the desired SCC 
change, less income is lost.  Adopting a low cost management practice first becomes 
more important as SCC premiums become offered less often because the potential 
income from lowering SCC dramatically decreases when premiums are not offered. 
 Little research has been done examining the direct effect of management practice 
implementation on herd SCC.  Dufour et al. (2011) completed a review study examining 
the effect of management practices on herd SCC.  However, of the 36 papers analyzed 
the only papers that presented an examination of herd SCC before and after the 
implementation of a management practice were evaluating the change from a 
conventional to an automatic milking system (Klungel et al., 2000, Rasmussen et al., 
2001, Rasmussen et al., 2002).  Other studies have examined the relationship between the 
herd SCC and management practices that were already being used by the farm (Barkema 
et al., 1998a, Wenz et al., 2007, Schewe et al., 2015).  Because of the lack of research and 
our research objectives, we used estimated changes in SCC and PERT distributions. 
When building the range or distribution around the stochastic variables used in the 
model, we chose to use a PERT distribution.  The use of a PERT distribution allowed for 
the building of distributions in which little research has been published.  For example, 
with SCC, we were able to estimate a minimum, most likely, and maximum change in 
SCC rather than provide a mean and standard deviation to build the distribution. 
Within each farm, changes in SCC after implementation of a management 
practice were kept the same between each management practice to ensure that differences 
between management practices were from cost alone.  However, we assumed that the 
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implementation of the management practices would affect the three herds differently 
where the higher the base SCC, the more change a management practice would have on 
the new SCC.  Our distributions for the change in SCC resulted in some iterations where 
the new SCC was higher than the base.  We allowed for the increase in SCC above the 
base to model the occasions in which management practices are not implemented 
properly.  Not implementing a management practice correctly will cost more money to 
farmers than not adopting the management practice altogether.  A secondary objective of 
our study was to determine the SCC change necessary for the implementation of 
management practices to become feasible.  We felt by including a large range in the 
change in SCC rather than a specific change, we had a better chance of determining the 
decrease in SCC necessary for management practices to pay off. 
The use of DRMS data as a base herd does not represent average Holstein herd in 
the US, but rather the average Holstein herd that has data processed through DRMS.  
Though the use of DRMS records allowed for the simulation of farms using US farm 
data, only a fraction of farms are enrolled in DRMS.  As of 2017, 11,000 (Dairy Records 
Management Systems, 2017) of the 37,750 (USDA National Agricultural Statistics 
Service, 2017) (29%) licensed dairy farms in the US were enrolled in DRMS.   
We also chose differing herd SCC (low (109,000 cells/mL) and high (393,000 
cells/mL)) based on one standard deviation of the average SCC herd (251,000 cells/mL).  
For these reasons, results from our analysis are not be representative of all dairy herds but 
rather those with similar characteristics and assumptions as the simulated herds.  The 
fewer cows the farm milks, the more of an effect one or two cows might have on the 
herd’s SCC.  When one cow has a large impact on SCC, the most economical decision 
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may be to cull the cow from the herd.  The economics of culling have been examined 
extensively when determining the cost of mastitis (Bar et al., 2008a, Heikkila et al., 
2012).  However, examining the effect of culling on the economics of herd SCC was 
beyond the scope of this study.   
CONCLUSIONS 
Primary objectives of the study were 1) to determine the economic losses 
associated with an elevated bulk tank SCC, 2) to determine the total cost of a herd’s new 
SCC after the adoption of different cost management practices, and 3) to determine the 
cost change of decreasing an elevated bulk tank SCC associated with adoption of 
management practices.  Secondary objectives of the study were 1) to determine the 
change in SCC necessary for the implementation of management practices to be 
economically feasible and 2) to determine the impact of milk quality premium pricing on 
the economics of management practice adoption. When adopting management practices, 
producers should consider the costs compared to the benefits.  However, they must also 
consider the total impact of an elevated SCC to their farm.  The results from our 
simulations of a 205 cow Holstein herd suggest that low cost ($2.65/cow/yr) management 
practices often pay for themselves by lowering the total cost of an elevated herd SCC.  
However, moderate ($11.32/cow/yr) and high ($14.60/cow/yr) cost management 
practices can lead to a higher total cost of an elevated SCC depending on the herds’ base 
SCC.  These results also depend on the assumption that each management practice had 
the same effect on herd SCC.  Overall, the cost of SCC significantly decreased after 
adoption of any of the three management practices.  When herd SCC lowered enough to 
receive a premium, the cost of SCC to the farm was dramatically decreased.   
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Table 2.1.  Bulk tank somatic cell count (SCC) thresholds in which a premium of 
$0.0055/kg of milk was offered in a stochastic simulation model to estimate the economic 
benefit of lowering a herd somatic cell count. 
SCC premium level (cells/mL) 
SCC < 100,000 
100,000 < SCC < 200,000 
200,000 < SCC < 300,000 
300,000 < SCC < 400,000 
400,000 < SCC < 500,000 
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Table 2.2.  Minimum, most likely, and maximum costs ($/cow per yr) for different 
expense management practices used to create a PERT distribution in a stochastic 
simulation model to determine the economic benefit of management practice adoption in 
lowering the herd somatic cell count. 
 Distribution of expenses ($/cow per yr) 
Management practice Min Most Likely Max 
Low-Expense  $0.40   $2.65   $6.20  
Moderate-Expense  $8.65   $11.32   $18.96  
High-Expense1   $0.37   $14.60   $58.40  
1High-expense management practice not only had the highest most likely cost but also the 
largest distribution to determine at what specific cost management practices were no 
longer economically feasible. 
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Table 2.3.  The estimated distribution of change in herd somatic cell count (SCC) used to 
create a PERT distribution in a stochastic simulation model to determine the economic 
benefit of management practice1 adoption in lowering the herd somatic cell count for 
three simulated dairy farms. 
 Distribution of change in SCC 
Farm Min Most likely Max 
Farm A2 -10,000 30,000 60,000 
Farm B3 -10,000 60,000 120,000 
Farm C4 -10,000 70,000 140,000 
1Three different management practices were modeled to determine change in SCC cost 
after adoption of the management practice.  Authors assumed that all three management 
practices would have the same effect on herd SCC. 
2Farm A base SCC = 109,000 cells/mL 
3Farm B base SCC = 251,000 cells/mL 
4Farm C base SCC = 393,000 cells/mL 
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Table 2.4.  Mean (± standard deviation) losses ($/farm per yr) associated with a somatic 
cell count when three simulated dairy farms are A) offered a milk quality premium1 and 
B) not offered a milk quality premium before and after adoption of a management 
practice. 
A) 
 Losses before and after management practice adoption ($/farm per yr) 
Farm Before After Change 
Farm A2 $22,978.84 ± 1,208.31 $9,515.28 ± 4,138.86 $13,463.56  
Farm B3 $24,269.02 ± 1,345.16 $11,398.84 ± 7,820.47 $12,870.18  
Farm C4 $26,962.31 ± 1,630.85 $17,695.22 ± 7,118.68 $9,267.09  
 
B) 
 Losses before and after management practice adoption ($/farm per yr) 
Farm Before After Change 
Farm A2 $11,391.22 ± 1,208.31 $8,576.68 ± 1,617.65 $2,814.54  
Farm B3 $12,681.40 ± 1,345.16 $6,879.67 ± 2,563.78 $5,801.73  
Farm C4 $15,374.69 ± 1,630.85 $8,587.35 ± 2,982.15 $6,787.34  
1Premium = $0.0055/kg of milk 
2Farm A base SCC = 109,000 cells/mL 
3Farm B base SCC = 251,000 cells/mL 
4Farm C base SCC = 393,000 cells/mL 
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Table 2.5.  Mean (± standard deviation) total cost ($/farm per yr) of herd SCC before and after adoption of management practices 
when three simulated dairy farms are A) offered a milk quality premium1 and B) not offered a milk quality premium. 
A) 
 Cost of SCC before and after management practice adoption ($/farm per yr) 
Farm Before2 Low3 Moderate4 High5 
Farm A6 $22,978.84 ± 1,208.31a $10,102.94 ± 4,151.90b $12,005.72 ± 4,172.32c $13,889.28 ± 4,675.42d 
Farm B7 $24,269.02 ± 1,345.16a $11,986.50 ± 7,824.94b $13,889.28 ± 7,829.81c $15,401.74 ± 4,675.42d 
Farm C8 $26,962.31 ± 1,630.85a $18,282.88 ± 7,130.25b $20,185.66 ± 7,138.78c $21,698.12 ± 7,343.70d 
 
B) 
 Cost of SCC before and after management practice adoption ($/farm per yr) 
Farm Before2 Low3 Moderate4 High5 
Farm A6 $11,391.22 ± 1,208.31a $9,164.34 ± 1,636.04b $11,067.12 ± 1,680.15c $12,579.58 ± 2,692.95d 
Farm B7 $12,681.40 ± 1,345.16a $7,467.33 ± 2,577.44b $9,370.11 ± 2,592.92c $10,882.57 ± 3,267.01d 
Farm C8 $15,374.69 ± 1,630.85a $9,175.01 ± 2,999.89b $11,077.78± 3,015.49c $12,590.24 ± 3,598.76d 
1Premium = $0.0055/kg of milk 
2Before = losses associated with SCC before adoption of any management practice 
3Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
4Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
5High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
6Farm A base SCC = 109,000 cells/mL 
7Farm B base SCC = 251,000 cells/mL 
8Farm C base SCC = 393,000 cells/mL 
a-d Means within a row with a different superscript are significantly different (P < 0.05) 
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Table 2.6.  Mean (± standard deviation) of the change in cost ($/farm per yr) of herd SCC after adoption of management practices 
when three simulated dairy farms are A) offered a milk quality premium1 and B) not offered a milk quality premium. 
A) 
 Change in cost of SCC after management practice adoption ($/farm per yr) 
Farm Low2 Moderate3 High4 
Farm A5 $12,875.90 ± 4,053.36 $10,973.12 ± 4,073.69 $9,460.67 ± 4,571.82 
Farm B6 $12,282.52 ± 7,814.34 $10,379.74 ± 7,818.87 $8,867.28 ± 7,959.04 
Farm C7 $8,679.43 ± 7,064.43 $6,776.65 ± 7,072.57 $5,264.20 ± 7,265.93 
 
B) 
 Change in cost of SCC after management practice adoption ($/farm per yr) 
Farm Low2 Moderate3 High4 
Farm A5 $2,226.88 ± 1,361.93 $324.10 ± 1,412.88 -$1,188.36 ± 2,506.12 
Farm B6 $5,214.07 ± 2,559.09 $3,331.29 ± 2,573.64 $1,798.83 ± 3,226.87 
Farm C7 $6,199.68 ± 2,923.89 $4,296.90 ± 2,938.77 $2,784.44 ± 3,507.00 
1Premium = $0.0055/kg of milk 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
5Farm A base SCC = 109,000 cells/mL 
6Farm B base SCC = 251,000 cells/mL 
7Farm C base SCC = 393,000 cells/mL 
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Table 2.7.  The mean and variance of the total cost ($/farm per yr) of herd SCC after adoption of management practices when three 
simulated dairy farms are A) offered a milk quality premium1 and B) not offered a milk quality premium. 
A)  
Mean of total SCC cost by management practice  Variance of total SCC cost by management practice 
Farm Low2 Moderate3 High4  Low2 Moderate3 High4 
Farm A5 $10,102.94  $12,005.72  $13,518.18   17,238,230.00  17,408,280.00  21,859,580.00  
Farm B6 $11,986.50  $13,889.28  $15,401.74   61,229,710.00  61,305,930.00  63,678,500.00  
Farm C7 $18,282.88  $20,185.66  $21,698.12   50,840,470.00  50,962,180.00  53,929,900.00  
 
B)  
Mean of total SCC cost by management practice  Variance of total SCC cost by management practice 
Farm Low2 Moderate3 High4  Low2 Moderate3 High4 
Farm A5 $9,164.34 $11,067.12 $12,579.58      2,676,643  2,822,888  7,251,957  
Farm B6 $7,467.33 $9,370.11 $10,882.57      6,643,192  6,723,228  10,673,380  
Farm C7 $9,175.01 $11,077.78 $12,590.24      8,999,338  9,093,161  12,951,070  
1Premium = $0.0055/kg of milk 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
5Farm A base SCC = 109,000 cells/mL 
6Farm B base SCC = 251,000 cells/mL 
7Farm C base SCC = 393,000 cells/mL 
 
 
 64 
 
Figure 2.1.  Mean (± standard deviation) losses ($/farm per yr) associated with an 
elevated somatic cell count, when three simulated dairy farms are A) offered a milk 
quality premium1 and B) not offered a milk quality premium, before and after adoption of 
a management practice. 
A) 
 
B) 
 
 
1Premium = $0.0055/kg of milk 
2Farm A base SCC = 109,000 cells/mL 
3Farm B base SCC = 251,000 cells/mL 
4Farm C base SCC = 393,000 cells/mL 
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Figure 2.2.  Mean (± standard deviation) total cost ($/farm per yr) of herd somatic cell 
count (SCC) before and after adoption of management practices when three simulated 
dairy farms are A) offered a milk quality premium1 and B) not offered a milk quality 
premium. 
A) 
 
B) 
 
1Premium = $0.0055/kg of milk 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
5Before = losses associated with SCC before adoption of any management practice 
6Farm A base SCC = 109,000 cells/mL 
7Farm B base SCC = 251,000 cells/mL 
8Farm C base SCC = 393,000 cells/mL 
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Figure 2.3.  Mean (± standard deviation) of the change in cost ($/farm per yr) of herd 
somatic cell count (SCC) after adoption of management practices when three simulated 
dairy farms are A) offered a milk quality premium1 and B) not offered a milk quality 
premium. 
A) 
 
B) 
 
1Premium = $0.0055/kg of milk 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
5Farm A base SCC = 109,000 cells/mL 
6Farm B base SCC = 251,000 cells/mL 
7FarmC base SCC = 393,000 cells/mL 
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Figure 2.4.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
low SCC herd1 that is offered premiums2 for milk quality, after adoption of three different management practices. 
 
1Low SCC = base of 109,000 cells/mL 
2Premium = $0.0055/kg of milk 
3Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
4Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
5High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr
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Figure 2.5.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
low SCC herd1 that is not offered premiums for milk quality, after adoption of three different management practices. 
 
1Low SCC = base of 109,000 cells/mL 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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Figure 2.6.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
average SCC herd1 that is offered premiums2 for milk quality, after adoption of three different management practices. 
 
 
1Average SCC = base of 251,000 cells/mL 
2Premium = $0.0055/kg of milk 
3Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
4Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
5High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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Figure 2.7.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
average SCC herd1 that is not offered premiums for milk quality, after adoption of three different management practices. 
 
1Average SCC = base of 251,000 cells/mL 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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Figure 2.8.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
high SCC herd1 that is offered premiums2 for milk quality, after adoption of three different management practices. 
 
1High SCC = base of 393,000 cells/mL 
2Premium = $0.0055/kg of milk 
3Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
4Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
5High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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Figure 2.9.  The change in cost ($/farm per yr) from reducing herd somatic cell count (SCC) by the change in SCC, for a simulated 
high SCC herd1 that is not offered premiums for milk quality, after adoption of three different management practices. 
 
1High SCC = base of 393,000 cells/mL 
2Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
3Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
4High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr
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Figure 2.10.  The change in cost of somatic cell count (SCC) ($/farm per yr) from reducing herd SCC by management practice cost 
($/cow per yr) for three simulated dairy farms that are offered a premiums for milk quality1. 
 
1Premium = $0.0055/kg of milk 
2Farm A base SCC = 109,000 cells/mL 
3Farm B base SCC = 251,000 cells/mL 
4FarmC base SCC = 393,000 cells/mL 
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Figure 2.11.  The change in cost of somatic cell count (SCC) ($/farm per yr) from reducing herd SCC by management practice cost 
($/cow per yr) for three simulated dairy farms that are not offered a premiums for milk quality. 
 
1Farm A base SCC = 109,000 cells/mL 
2Farm B base SCC = 251,000 cells/mL 
3FarmC base SCC = 393,000 cells/mL 
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Figure 2.12.  The mean and variance of the cost of somatic cell count (SCC) ($/farm per yr) after adoption of management practices 
in three simulated dairy farms that are offered premiums for milk quality1. 
 
1Premium = $0.0055/kg of milk 
2Farm A base SCC = 109,000 cells/mL 
3Farm B base SCC = 251,000 cells/mL 
4FarmC base SCC = 393,000 cells/mL 
5Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
6Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
7High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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Figure 2.13.  The mean and variance of the cost of somatic cell count (SCC) ($/farm per yr) after adoption of management practices 
in three simulated dairy farms that are not offered premiums for milk quality. 
 
1Farm A base SCC = 109,000 cells/mL 
2Farm B base SCC = 251,000 cells/mL 
3FarmC base SCC = 393,000 cells/mL 
4Low cost = Most likely = $2.65/cow/yr with range from $0.40 to $6.20/cow per yr 
5Moderate cost = Most likely = $11.32/cow/yr with range from $8.65 to 18.96/cow per yr 
6High cost = Most likely = $14.60/cow/yr with range from $0.37 to $58.40/cow per yr 
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INTRODUCTION 
 Mastitis is one of the most common and costly diseases in the dairy industry 
(Hogeveen et al., 2011, Liang et al., 2017).  Mastitis can be infectious or non-infectious 
in origin (Bradley, 2002).  Non-infectious mastitis is typically caused by physical damage 
to the mammary gland while, more commonly, infectious mastitis is caused by 
microorganisms entering the gland.  The most common microorganism that causes an 
intramammary infection is bacteria (Bradley, 2002).  When signs of inflammation are 
visible, such as a swollen mammary gland or milk with clots or flakes, the intramammary 
infection is referred to as clinical mastitis (CM).  An intramammary infection with no 
visible signs of inflammation, but bacteria are present in the milk, is commonly known as 
subclinical mastitis (SCM) (Harmon, 1994).  Historically somatic cell count (SCC) has 
been used to determine if a cow has SCM.  When the SCC exceeds 200,000 cells/mL a 
cow is considered to have an intramammary infection (Natzke et al., 1972, Dohoo and 
Leslie, 1991, Jadhav et al., 2018).  Though a SCC of greater than 200,000 cells/mL is 
associated with an intramammary infection, milk loss can occur at SCC lower than 
100,000 cells/mL (Raubertas and Shook, 1982, Gonçalves et al., 2018, Hadrich et al., 
2018). 
Cows are most at risk for both CM and SCM during the dry period (Neave et al., 
1950, Erb et al., 1984, Pantoja et al., 2009a).  To control mastitis, the National Mastitis 
Council developed a 5-point plan to prevent new mastitis cases (Dodd and Neave, 1970) 
that is still used as a guide today (Hillerton and Booth, 2018).  One of the components of 
the plan is treating every quarter of every cow with an intramammary antibiotic (IMMA) 
at dry off, commonly referred to as blanket dry cow therapy (BT).    
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 Dry cow therapy (DCT) has two goals: 1) to prevent new intramammary 
infections during the dry period and 2) to treat existing intramammary infections at the 
time of dry off.  As of 2014, 80.3% of surveyed dairy farmers in 24 states of the United 
States (US) were treating all quarters of all cows at dry off (USDA Animal and Plant 
Health Inspection Service, 2016).  Because of highly debated use of antibiotics in animal 
agriculture, pressure is being put on policymakers to limit antibiotic use (Croney et al., 
2012).  Antibiotic regulation within the dairy industry has resulted in some countries, 
such as the Netherlands, Australia, and New Zealand, to discontinue the use of DCT to 
prevent new intramammary infections (Lam et al., 2017, McDougall, 2018).  Instead, 
farmers select cows that are to receive antibiotic treatment at dry off based on infection 
status of the cow.  This form of DCT is commonly referred to as selective dry cow 
therapy (ST). 
 Selective dry cow therapy has been shown to have positive results compared to no 
treatment with decreased incidences of new intramammary infections at calving at the 
cow and quarter level (Halasa et al., 2009b, Halasa et al., 2009c).  However, BT offered 
more protection than ST (Berry and Hillerton, 2002, Halasa et al., 2009c).  The success of 
ST may depend on the infection status of the mammary gland at dry off.  Cows that have 
a SCC greater than 200,000 cells/mL at dry off are more likely to have a case of CM in 
the following lactation (Pantoja et al., 2009a, Henderson et al., 2016).  The difference in 
protection raised questions of how BT and ST compare economically and how selection 
criteria for ST affect the economics of DCT. 
 Economic analyses between the two DCT methods have been completed by 
researchers in Great Britain and the Netherlands where ST is required (Berry et al., 2004, 
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Scherpenzeel et al., 2016, Scherpenzeel et al., 2018).  Results of these studies have shown 
that little difference exists between the costs of BT and ST and that mastitis incidence 
throughout the dry period and early in the next lactation play a crucial role in the 
selection of the preferred practice. 
 Though many economic analyses have been completed comparing the costs of BT 
and ST, little research has been done modeling the US dairy system.  A gap in the 
literature also exists in determining how input costs and herd demographics might 
influence economic outcomes.  The objectives of our study were to 1) determine the costs 
of BT and ST in a simulated US dairy herd, 2) determine if different selection criteria 
would lead to decreased costs of ST compared to BT, and 3) to determine how input costs 
and herd demographics would impact optimal DCT decisions. 
MATERIALS AND METHODS 
Model Overview 
 A stochastic simulation model was created using Microsoft Excel (Microsoft 
Corporation, Redmond, WA) with @Risk add-in (Palisade Corporation, Ithaca, NY).  
The simulation model was developed to model different dry off therapy schemes in a 
simulated US dairy herd.  Five different dry off schemes were modeled based on dry off 
SCC and parity.  Dry-off therapy schemes included blanket dry cow therapy (BT), no 
therapy (NT), and three ST schemes that were based on the SCC groups shown in Table 
3.1.  For each of the three ST schemes only certain SCC groups received treatment with 
antibiotics at dry off.  Treatment of groups 4 and 9 were considered ST scheme 1 (ST1), 
treatment of groups 3, 4, 8, and 9 were considered ST scheme 2 (ST2), and treatment of 
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groups 2, 3, 4, 7, 8, and 9 were considered ST scheme 3 (ST3).  With BT serving as the 
base, costs of NT and the three ST schemes were compared to the cost of BT. 
Herd Demographics 
 Dairy herd data were collected from Dairy Records Management Systems 
(DRMS) (Dairy Records Management Systems, Raleigh, NC).  When collecting 
information from the DRMS database, the only limit option used was “breed” to only 
include Holsteins.  The average Holstein herd enrolled in the DRMS program as of 
December 2018 consisted of 205 cows with a SCC of 251,000 cells/mL and a cull rate of 
38.6%.  To model herds with differing SCC, two additional herds were analyzed by 
taking one standard deviation from the mean SCC (251,000 cells/mL).  A low SCC herd 
had a SCC of 109,000 cells/mL, and a high SCC herd had a SCC of 393,000 cells/mL.   
Somatic Cell Count Groups 
Using DRMS test day data, distributions of cows within each of the nine SCC 
groups were created for the three herds.  To create the distributions, the following 
analysis was completed in SAS 9.4 (SAS Institute, Cary, NC).  Test day data from every 
cow in every herd enrolled in DRMS (n = 18,151) were compiled from January 2015 to 
December 2017.  To be included in the analysis, Holstein cows had to have data from at 
least four test days within a single lactation and a lactation length between 240 and 365 
days.  To remove any outliers in the dataset, cows must also have been within two 
standard deviations of the average lactation age and greater than the first percentile in 
lactation milk yield.  Only the most recent lactation was analyzed for those cows that 
completed two lactations within two years.  Herds that did not have at least five cows that 
met those criteria were deleted from further analysis (n = 7,393).  Similar cleaning 
 82 
 
analyses were used by Raubertas and Shook (1982) and Nolan (2017) when working with 
test day SCC data. 
Three separate datasets were created based on the average weighted SCC of the 
herds throughout 2016.  Herds that did not have 2016 herd SCC data were removed from 
the datasets (n = 2,984).  Datasets included herds with SCC ≤ 109,000 cells/mL (n = 
1,840), 109,000 cells/mL < SCC < 393,000 cells/mL (n = 3,738), and SCC ≥ 393,000 
cells/mL (n = 2,196).  Using the FREQ procedure in SAS 9.4, each of the three datasets 
were analyzed to determine the percentages of cows that fell into the nine SCC groups 
based on their SCC on the last test day of the lactation before dry off (Table 3.1).  To 
determine the total number of cows that would be dried off throughout the year, the 
percentage that fell into each group was multiplied by the herd size times the culling rate.  
Like Scherpenzeel et al. (2018), authors also assumed that 10% of the cows being culled 
would have been dried off before culling.  Given that the average herd simulated had 205 
cows with a cull rate of 38.6%, 133 cows were assumed to be dried off throughout the 
year. 
Cost of Dry Cow Therapy 
Drug Cost.  The authors assumed that every cow that was designated to be treated 
received 4 tubes of IMMA, while cows in the NT group did not.  The cost of treatment 
totaled $11.32/cow for antibiotics (Valley Vet Supply, 2018).  The total treatment cost to 
the herd was calculated using the following formula: 
𝑇𝐶$ = 𝑇 ∗ 𝐶 
Where: 
TC$ = The total cost of treatment per herd per year  
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T = The cost of treatment (IMMA) ($/cow) 
C = The number of cows treated annually 
 Labor Cost.  Labor costs differed between BT and ST.  The authors assumed that 
BT would be administered in the parlor at dry off by milking labor.  Selective dry cow 
therapy would be administered outside of the milking parlor by management labor.  The 
hourly wage was $12.47/hr for milking labor and $33.47/hr for management labor 
(Bureau of Labor Statistics, 2019).  The authors assumed, based on experience, that the 
time for treatment was 0.16 and 0.25 hours/cow for BT and ST, respectively.  Though 
inputs for the cost of labor were different between the two treatment options, the formula 
was the same: 
𝐿$ = 𝑊 ∗ 𝐻 ∗ 𝐶 
Where: 
L$ = The total labor cost per herd per year 
W = Hourly wage ($/hr)  
H = Hours per cow  
C = Number of cows treated 
Mastitis Incidence Rates.  Little research examining the effect of using multiple 
SCC thresholds as selection criteria for IMMA at dry off on mastitis incidence rate has 
been completed.  Scherpenzeel et al. (2018) estimated mastitis incidence rates using two 
different data sources (Barkema et al., 1998b, Scherpenzeel et al., 2014).  Data from 
Barkema et al. (1998b) and Scherpenzeel et al. (2014) were collected from farms in the 
Netherlands.  To adapt the SCC groups used by Scherpenzeel et al. (2018), authors 
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created an index value to estimate mastitis incidence rates based on SCM incidence rates 
from DRMS data.  
Subclinical mastitis incidence rates were derived by performing further analysis 
on the three datasets used in the “Somatic Cell Count Groups” section of this paper.  To 
qualify for further analysis, cows in each of the three datasets needed to have test day 
data from either the first or second test day of the next lactation (n = 581,232) 
representing the first test of the lactation.  If the first test day of the cow’s lactation was 
greater than 100 days in milk (n = 384), they were removed from the dataset.  Cows that 
had a first test day somatic cell count above 200,000 cells/mL were considered to have 
SCM (n = 89,993).  Using the FREQ procedure in SAS, the incidence of SCM was 
determined for each dry off SCC group.   
Within CM and SCM groups, incidence rates were also different between cows 
that did (CM(+)/SCM(+)) and did not (CM(-)/SCM(-)) receive IMMA at dry off.  The 
infection rate derived from the DRMS data was used as the SCM (+) incidence rates 
(Table 3.2).  Because the dry off procedures of DRMS data were not known, authors 
assumed all cows in the DRMS dataset received intramammary antibiotics at dry off 
(SCM(+)).  To account for the incidence rates of the CM(+), CM(-), and SCM(-) 
categories, an index value was created using the SCM(+) incidence rates collected from 
the DRMS data along with the incidence rates presented by Scherpenzeel et al. (2018).  
Index values were created using the following equation: 
𝐼𝐼𝑅 =
𝑆𝐼𝑅
𝑆𝑆𝐶𝑀(+)
∗ 𝐷𝑆𝐶𝑀(+) 
Where: 
IIR = Index incidence rate (%) 
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SIR = Incidence rates (%) for CM or SCM presented by Scherpenzeel et al. (2018) 
SSCM(+) = Subclinical mastitis incidence rate (%) for cows receiving intramammary 
antibiotics at dry off presented by Scherpenzeel et al. (2018) 
DSCM(+) = Subclinical mastitis incidence rate (%) for cows receiving intramammary 
antibiotics at dry off derived from Dairy Records Management Systems data 
 The equation was used to determine the estimated incidence rates at calving for 
dry off SCC groups 4 and 9 for CM(+), CM(-), and SCM(-).  To calculate the incidence 
rates for the remaining dry off SCC groups, the percent change in incidence rate starting 
with groups 4 and 9 from each succeeding group was calculated from the incidence rates 
derived from the DRMS data.  The change in incidence rate from each SCC dry off group 
was then applied to the CM(+), CM(-), and SCM(-) categories (Table 3.2).  An example 
of the calculation used to determine the estimated incidence rates is shown in the 
Appendix (Tables A.2 to A.8). 
Mastitis Costs.  The cost of clinical mastitis was derived from Rollin et al. (2015), 
with an average cost of $444/case (2015 US$).  Subclinical mastitis cost was calculated 
independently for each SCC group based on milk loss throughout the lactation associated 
with an increase in the first test SCC (Nolan, 2017).  Average milk loss associated with a 
first test SCC between 200,000 and 1,600,000 cells/mL was 68 kg per lactation for each 
increase in 100,000 cells/mL when averaged across parities 2 and 3.  Milk loss was then 
multiplied by the 2019 average uniform milk price to date as of September 2019 
($0.38/kg) (USDA Agricultural Marketing Service, 2019) to get an average cost per case 
of subclinical mastitis of $25.84 per case.  The total cost of mastitis to the farm was 
calculated using the following formula across all five DCT schemes: 
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𝑀𝐶$ = ∑ 𝐶𝑀 ∗ 𝐼𝐶𝑀 ∗ 𝐶 + 𝑆𝐶𝑀 ∗ 𝐼𝑆𝐶𝑀 ∗ 𝐶
9
𝑖=1
 
Where: 
MC$ = Total mastitis cost ($/farm per yr) 
CM = Clinical mastitis cost ($/case) 
ICM = Incidence rate of clinical mastitis (%) 
C = The number of cows in each of the nine SCC dry off groups  
SCM = Subclinical mastitis cost ($/case) 
ISCM = Incidence rate of subclinical mastitis (%) 
 Total therapy costs for each of the 5 DCT schemes were calculated with the 
following formula: 
𝐷𝐶𝑇$ = 𝑇𝐶$ + 𝐿$ + 𝑀𝐶$ 
Where: 
DCT$ = The total cost of dry cow therapy per herd per year 
TC$ = Total treatment cost per herd per year 
L$ = Total labor costs per herd per year 
MC$ = Total mastitis costs per herd per year 
Though the total cost of DCT were calculated with the same base formula above, slight 
changes were made to accommodate each DCT scheme.  Labor costs for each ST scheme 
were only summed across the cows that were treated with IMMA at dry off.  Total costs 
for NT did not include the costs for drugs or labor because of the lack of treatment.  
However, they did include the costs associated with mastitis in the next lactation.   
Simulation 
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 A single 1,000-iteration simulation was run collecting output variables, including 
the total cost of BT, NT, ST1, ST2, and ST3 therapy schemes.  The differences between 
BT and all other therapy schemes were also collected.  Input variables included CM and 
SCM costs, estimated time of treatment for both BT and ST schemes, and labor costs 
associated with BT and ST schemes.  A PERT distribution was fit to all input variables 
(Table 3.3).  The distribution around the cost of CM was derived from Rollin et al. 
(2015), and the cost of SCM was derived by taking the minimum and maximum milk loss 
presented by Nolan (2017) times the milk price.  Because milk loss makes up the 
majority of the costs associated with mastitis (Huijps et al., 2008, Halasa et al., 2009a, 
Liang et al., 2017), authors assumed that costs of CM and SCM would both increase or 
decrease from iteration to iteration during a simulation.  To account for both costs 
moving in the same direction during the simulation, a 90% @Risk correlation coefficient 
was set between the two variables.  Distributions for labor costs were not presented by 
Bureau of Labor Statistics (2019), so they were estimated by authors based on known 
labor costs.  Minimum and maximum values for the time of treatment were rounded to 
the nearest hundredths place and values for wages were rounded to the nearest $0.50.   
A PERT distribution was also fit to the incidence rates of mastitis with the 
minimum being half the original value and the maximum being double the most likely 
(original) value (Table 3.4).  Values in Table 3.4 were rounded to the nearest tenths 
place.  The weighted average CM and SCM incidence rates were calculated for each 
DCT option (Table 3.5).  Weighted averages were formulated by taking the percentage of 
cows in each SCC group for all three herds and multiplying by the respective incidence 
rates associated with the treatment scheme.  For example, when calculating the weighted 
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average incidence rate for ST1, the percentage of cows in dry off groups 4 and 9 were 
multiplied by the incidence rates associated with treating those cows.  The percentage of 
cows in the remaining groups were multiplied by the incidence rates associated with no 
treatment.  The incidence rates of each SCC group were then summed together resulting 
in the weighted average incidence rate.  Weighted average incidence rates corresponding 
to each treatment scheme were then compared to BT to determine the difference needed 
for each DCT scheme to cost less than BT. 
The simulation was run using Latin Hypercube sampling with a static seed of 
31,517 (Liang, 2013, Nolan, 2017, Dolecheck, 2018).  After the simulation, a frequency 
analysis was completed on the differences in costs of treatment schemes.  With BT 
serving as the base, the frequency analysis was completed to determine the percent of 
iterations in which BT was the lowest-cost treatment option. 
Statistical Analysis 
 Results from the simulation for the total cost of each of the 5 DCT were analyzed 
for significant difference across each of the three herd types.  Analyses were completed 
using Microsoft Excel Simetar (Simetar, College Station, TX) add-in.  The means of each 
DCT cost were compared to one another, by herd type, using a two-sample T-test to 
determine significant differences at P < 0.05. 
Sensitivity Analysis 
 An objective of this study was to determine what factors affect the economics of 
different treatment schemes.  To accomplish this, multiple simulations were run by 
changing the PERT distribution around each input variable.  Additional simulations were 
run in which a PERT distribution was created around the herd size, making it a stochastic 
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variable.  Different scenarios were evaluated through simulation by modifying the 
distributions to determine their sensitivity.  After each simulation, a frequency analysis 
was completed to determine the change in frequency that BT was the lowest-cost 
treatment option. 
RESULTS 
Overall Simulation 
 Regardless of herd SCC, BT had the lowest average cost, while NT was the 
highest across all three simulated herds (Table 3.6).  The mean cost of BT was 
significantly lower (P < 0.05) than all other DCT schemes across all herd types (Table 
3.6).  Overall costs ranged from $10,637.35 (BT, low SCC herd) to $14,685.33 per herd 
per year (NT, high SCC herd).  When comparing the differences in costs of each 
treatment scheme to BT, ST3 had the least difference in cost across all herd types (Table 
3.7).  Of the three ST schemes, ST3 had a significantly lower (P < 0.05) mean cost across 
all three herd types, suggesting that the more cows that received intramammary 
antibiotics at dry off, the less the DCT scheme would cost the farm.  The total costs of 
DCT in all schemes increased across all three herds as average SCC increased (Figure 
3.1).  However, the high SCC herd experienced the least difference between BT and ST2 
and ST3 (Figure 3.2).  Some iterations resulted in other DCT schemes costing less than 
BT.  However, BT was optimal in greater than 82% of the iterations across all DCT 
schemes and herd types (Figure 3.3).   
When the incidence rate for mastitis was held constant, and only the cost variables 
were changed, the cost of CM and SCM led to the most variation in the differences 
between the cost of BT and the other treatments.  When examining the difference 
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between BT and ST1 for the low SCC herd, CM cost had the greatest impact on the 
difference between the two DCT costs (Figure 3.4).  When examining just the difference 
between BT and ST1 for the low SCC herd, the average difference was $1,506.64.  
Because of the variation in CM cost, the difference between BT and ST1 could range 
from $601.10 to $2,441.93.  As shown in Figure 3.4, none of the cost related inputs alone 
led to BT costing more to a farm than ST1.  These results were consistent across all DCT 
schemes.  So, additional simulations were run changing the distribution of one variable at 
a time, while holding the others in a constant state, to determine at what value each 
variable led to iterations in which BT costs were not lower than other treatment decisions 
in 100% of the iterations run.  The distributions were changed with each simulation to 
find a distribution large enough in which BT resulted in a higher cost than other DCT 
schemes.  Authors stopped running simulations when they felt that the distributions 
around each variable were becoming unrealistic. 
Clinical Mastitis Cost 
 Two simulations were run in which CM cost was the only stochastic input, while 
all other variables were held constant.  In the first simulation, the distribution of CM cost 
was kept as the original used in the model with the cost of CM ranging from $244.00 to 
$644.00.  All of the iterations in the first simulation resulted in BT having the lowest cost 
across all herd types and DCT schemes.  When the size of the distribution was increased 
to a range from $111.00 to $777.00, BT was no longer optimal in all iterations.  Using the 
larger distribution resulted in NT, ST1, ST2, and ST3 DCT schemes having a lower cost 
than BT in some scenarios (Figure 3.5) across the three different SCC herds.  The 
maximum cost of a CM case in the iterations in which BT was no longer optimal differed 
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between DCT scheme and herd type (Tables 3.8, 3.9, and 3.10).  Selective therapy 
scheme 3 needed the lowest CM cost to become more economical than BT regardless of 
herd SCC (Figure 3.6).  For the high SCC herd, ST3 did not have any iterations in which 
the cost of ST3 was lower than BT.  In the low and average SCC herds, associated with 
the inputs modeled, the cost of CM would have to be below $166.56 and $123.30, 
respectively, before producers should consider switching from BT to ST3 (Tables 3.8 and 
3.9). 
 Figure 3.7 displays the relationship between the cost of CM and the difference 
between BT and ST3 for the low SCC herd.  When examining the differences in the costs 
of BT and ST3 for a low SCC herd, the difference in cost between the two treatments 
increased as the cost of CM decreased.  This trend is similar across all treatment and herd 
types. 
Subclinical Mastitis Cost 
 Multiple iterations were run in which the distributions of SCM costs increased.  
Though SCM costs accounted for a large variation in the differences in the costs of BT 
and other treatment schemes, as shown in Figure 3.4, when modeled alone, none of the 
iterations led to a scenario in which BT was not the optimal treatment decision.  The lack 
of iterations in which BT was not optimal may be because of the lower costs associated 
with SCM compared to CM.  
Labor Cost 
 Both changes in labor wages and hrs associated with ST were simulated.  
However, after multiple simulations, none of the iterations resulted in BT being higher in 
costs than any of the other treatment methods.  Authors decided to stop simulations as 
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wages and time became unrealistic.  Instead, additional simulations were run with BT 
labor. 
 Though reaching unrealistic values, authors continued to run simulations to 
determine what wages and time would lead to iterations in which BT was not the lowest 
cost across all treatment types.  The labor wage and time of treatment in which BT was 
no longer optimal was dependent on DCT scheme.  A simulation was run where labor 
wages associated with the BT scheme ranged between $10.50 and $90.00/hr that resulted 
in iterations in which BT was no longer the lowest-cost treatment option across all DCT 
schemes and herd types.  Wages had to increase to a cost of $81.10, $83.70, and 
$84.06/hr before ST1 would cost less than BT for low, average, and high SCC herds, 
respectively (Tables 3.8, 3.9, and 3.10).  For all herd types, even with a distribution 
including $90.00/hr for labor, NT never resulted in a lower cost than BT (Figure 3.8).  
When comparing BT to the ST schemes, labor wages for BT had to increase the least for 
ST3 to become the optimal treatment decision (Figure 3.9).  At an hourly wage of $70.52, 
$70.24 and $69.65/hr ST3 would cost less than BT for low, average, and high SCC herds, 
respectively.  Figure 3.10 displays the relationship between the increase in labor wages 
and the difference between BT and ST3 costs.  At the time of the current study where 
$70.00/hr is an unrealistic wage, labor wages should not be a deciding factor when 
considering BT to other DCT schemes.  
When including a distribution of time ranging from 0.08 to 0.50 hrs, BT was not 
the lowest cost treatment scheme in all iterations.  Blanket therapy was still optimal in 
100% of iterations when compared to NT.  However, all three ST schemes were optimal 
at times (Figure 3.11).  Regardless of herd SCC, the time of treatment in which BT was 
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no longer optimal were similar (Tables 3.8, 3.9, and 3.10).  When treatment times were 
0.39, 0.40, and 0.40 hrs, ST1 would cost less than BT for low, average, and high SCC 
herds.  The time to complete BT had to increase the least for ST3 to become optimal 
(Figure 3.12).  Blanket therapy treatment could take 0.34, 0.34, and 0.33 hrs before ST3 
would become more feasible for low, average, and high SCC herds, respectively (Tables 
3.8, 3.9, and 3.10).  As BT time increased, the difference in cost between ST3 and BT 
decreased (Figure 3.13). 
Herd Size 
 Additional simulations with herd size fit to a PERT distribution were run to 
determine if herd size affected DCT decisions.  However, after simulations included a 
distribution of 20 to 7,000 cows in which BT was still the optimal treatment option in 
100% of iterations, authors stopped the herd size analysis.   
Mastitis Incidence Rate 
 An additional simulation was run where all costs were held constant, and only 
CM and SCM incidence rates were treated as stochastic variables.  The distribution of 
CM and SCM incidence rates (Table 3.4) ranged from half to double the estimated most 
likely incidence rate value for each SCC group.  Values in Table 3.4 were rounded to the 
nearest tenths place.  Frequencies in which BT was the lowest cost DCT scheme ranged 
from approximately 88% to 98% depending on the DCT scheme being compared and 
herd SCC (Figure 3.14).   
When using NT, clinical mastitis incidence rates had to be within 2.1% of the 
incidence rate of BT for NT to be feasible (Table 3.8).  These incidence rates decreased 
with the use of the ST schemes (Table 3.8, 3.9 and 3.10).  Selective dry cow therapy 
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scheme 3 needed to have incidence rates closest to BT to be economically feasible across 
all herds (Figure 3.15).  When ST3 cost less than BT, the incidence rates for ST3 were 
within 1.0%, 0.7%, and 0.1% of the BT incidence rates for low, average, and high SCC 
herds, respectively (Tables 3.8, 3.9, and 3.10).  As the difference in CM incidence rates 
increased between ST3 and BT, the difference between the total cost of the therapies 
increased across all herds (Figure 3.17).  This relationship was similar for SCM. 
 The incidence rate of SCM when using ST3 had to be within 12.5% of BT for 
ST3 to cost less than BT in the high SCC herd (Table 3.10).  The difference in incidence 
rates were higher for low and average SCC herds (Figure 3.16).  To have the lower cost 
compared to all other treatment options, NT required the least difference in incidence 
rates from BT (Tables 3.8, 3.9, and 3.10).   
DISCUSSION 
Recently, ST has become a mandatory practice in multiple countries, such as the 
Netherlands and Australia (Lam et al., 2017, McDougall, 2018).  For this reason, multiple 
studies have been completed examining the costs and economic benefits between BT and 
ST (Berry et al., 2004, Huijps and Hogeveen, 2007, Scherpenzeel et al., 2016) with the 
most recent study being completed by Scherpenzeel et al. (2018).  However, little 
research has focused on a US dairy system. 
Past models can be used as a reference when determining the benefit of ST to US 
dairy farms, but many differences exist between the US dairy systems and other systems 
around the world.  One of the main differences is that the size of the herd modeled is 
different than those in the United Kingdom and Netherlands models.  Both Scherpenzeel 
et al. (2016) and Scherpenzeel et al. (2018) modeled a Dutch herd with an average of 100 
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cows, while the herd modeled in our study was a 205-cow Holstein herd.  Other 
differences are within the modeling schemes, such as dry off treatment decision processes 
and individual model inputs.   
 Berry et al. (2004) compared the benefits of BT and ST using a decision tree 
model at the cow level rather than a herd level in the United Kingdom.  By doing so, 
Berry et al. (2004) were able to determine optimal treatment decisions on a cow by cow 
basis by taking into account pathogen-specific decisions as well.  Berry et al. (2004) 
concluded that the cost of DCT averaged from $51.84 and $114.54 per cow per year 
(2019 US$) for cows that did and did not receive treatment, respectively.  The large range 
in the results presented by Berry et al. (2004) may be due to the modeling of different 
mastitis pathogens.  Our results fall into the range presented by Berry et al. (2004), with a 
range of $51.88 to $71.63 per cow per year (2019 US$) depending on the herd type and 
treatment used.  One reason for the difference in the variation in costs between the 
current model and the model presented by Berry et al. (2004) is due to the difference in 
modeling types.  Berry et al. (2004) modeled at the cow level with bacterial culture being 
the deciding factor of whether a cow received antibiotics at dry off or not.  Taking milk 
cultures of cows before dry off allows farmers to make a more educated DCT decision at 
the cow level.  However, taking the culture takes time and adds expenses.  The additional 
expenses of culturing and the cost associated with specific bacteria types could be the 
reason for the larger variation in cost presented by Berry et al. (2004).  Bacteria type has 
an effect on the total cost of mastitis because of pathogen-specific milk losses and 
response to treatment (Pinzon-Sanchez et al., 2011, Nolan, 2017).  Another difference 
was the modeling of treatment decisions using specific cow information rather than 
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generalizing treatment decisions across a dairy herd.  Other models have looked at a 
whole herd approach.   
Huijps and Hogeveen (2007), Scherpenzeel et al. (2016), and Scherpenzeel et al. 
(2018) have all modeled the costs and benefits of BT vs. ST in a Dutch system.  Similar 
modeling techniques were used in all three studies as were used in the current analysis. 
Somatic cell count groups, CM incidence rates, and SCM incidence rates were modeled 
very similarly to Scherpenzeel et al. (2016) and Scherpenzeel et al. (2018).  However, we 
believe incidence rates were one of the most limiting factors in the model.  Very little 
research has been done examining the incidence rates of mastitis in the next lactation 
when DCT is administered based on SCC.  Though research in the US has been 
completed on selection criteria on dry cow therapy success (Patel et al., 2017, Vasquez et 
al., 2018), authors could find no US studies that had broken ST dry off decisions by nine 
different dry off SCC groups.  Scherpenzeel et al. (2018) used two different sources when 
determining mastitis incidence rates for their model.   
In our analysis, we decided to use the CM and SCM incidence rates presented by 
Scherpenzeel et al. (2018) as a base while trying to account for differences in incidence 
rates in the US.  Though limited potentially by herd demographics such as region and 
size, the use of DRMS data allowed for the estimation of SCM incidence rates for cows 
treated with IMMA at dry off (SCM(+)).  Because the treatment status of the cows in the 
DRMS data was not known, authors assumed all quarters of all cows to be treated with 
IMMA but not with a teat sealant.  Treatment assumptions were made based on results 
from a National Animal Health Monitoring System survey in which 80.3% of surveyed 
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dairy farmers stated they used IMMA on all cows at dry off while only 36.9% of 
producers used a teat sealant (USDA Animal and Plant Health Inspection Service, 2016).   
Though CM incidence rates came from estimated values, they were similar to US-
based studies (Godden et al., 2003, Pantoja et al., 2009a).  By making incidence rate a 
stochastic variable by herd type and SCC group, a wide range of incidence rates were 
able to be accounted for, decreasing the risk of the incidence rates not being accurate.  
The use of incidence rates from Scherpenzeel et al. (2018) in the indexed values allowed 
for the estimation of CM(+), CM(-), and SCM(-) incidence rates for nine different SCC 
groups and more complete comparison between their results.  Our model could be used in 
the future as more research is completed on ST or when the data from other dairy record-
keeping systems are used as input variables in the analysis.   
By using a weighted average of CM and SCM incidence rates, authors were able 
to compare a single incidence rate between DCT schemes.  Both CM and SCM incidence 
rates were highest in NT and lowest in BT.  Selective therapy and NT schemes had to 
have CM rates within 3% of the BT rate to become economically feasible.  The 
difference in incidence rates became as small as 0.1% for ST to be feasible in the high 
SCC herd.  These results suggest that for the simulated farms to use ST, CM incidence 
must be as low as when using BT.   
Incidence rates of SCM could be within 25% of BT for ST and NT schemes to be 
economically feasible.  The increase of incidence rates associated with SCM may be 
because SCM and CM simulations were run simultaneously.  Running the simulations 
simultaneously could result in an iteration where the CM incidence rate associated with 
ST was low while the SCM mastitis incidence rate was high.  The low CM incidence rate 
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would have a greater impact on the total cost of the DCT therapy scheme to the farm 
because the cost of a case of CM was much higher than that of SCM.  In future 
simulation models, the effect of CM and SCM incidence rates should be run separately.   
  Clinical and subclinical mastitis incidence was the main variable of interest in 
Huijps and Hogeveen (2007), Scherpenzeel et al. (2016), and Scherpenzeel et al. (2018).  
An additional goal of our study was to determine if cost variables would influence which 
treatment schemes were economically optimal.  By examining multiple inputs, we were 
able to determine what other variables US farmers should consider when making DCT 
decisions. 
Both Scherpenzeel et al. (2016) and Scherpenzeel et al. (2018) assumed the time 
to treat and labor wages were the same across both treatment types.  However, in our 
study, the authors assumed there would be an increase in the associated with ST.  The 
increase in time for ST would allow personnel to review data to determine which cows 
would need treatment, sort those cows, and perform dry off procedures.  Authors also 
assumed that a farm manager outside of the milking parlor would complete ST, whereas 
BT would be administered by milkers in the milking parlor resulting in less time at a 
lower hourly wage.  Authors found that BT cost more to farmers than ST only when 
unrealistic thresholds associated with labor were analyzed.  Benefits of ST were not seen 
until labor wages reached over $55.00/hr, and the time of treatment for BT reached close 
to 0.50/hr per cow.  Even at unrealistic values, NT never resulted in BT costing less.  The 
lack of iterations in which NT cost less suggests that the cost of mastitis is greater than 
the labor savings associated with not treating cows at dry off.  
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 The expense that led to the most variation in the optimal treatment decision was 
the cost of mastitis.  When the cost of mastitis dropped below $250.00 per case, ST was, 
at times, an optimal DCT option.  When calculating the cost of mastitis cases, milk price 
is the most influential variable (Shim et al., 2004, Huijps et al., 2008, Liang et al., 2017).  
For this reason, milk prices may affect DCT decisions.  However, more research is 
needed to determine at what milk price decisions might be influenced.  
  Overall, Huijps and Hogeveen (2007), Scherpenzeel et al. (2016), Scherpenzeel 
et al. (2018) concluded that ST schemes cost less to dairy farmers than BT.  Results 
presented in this analysis suggest that when modeled in a simulated US dairy system, BT 
costs less to dairy farmers than any ST scheme.  Differences in the conclusion between 
our model and previous models are possibly due to the increased mastitis incidence that 
were derived from DRMS data and differences in model inputs.  For example, 
Scherpenzeel et al. (2016) and Scherpenzeel et al. (2018) used calculated costs of CM of 
approximately $244 and $267 (US$)/case, respectively.  Authors felt the use of $444/case 
presented by Rollin et al. (2015) would be a more accurate representation of a cost of CM 
associated with the dry period because their calculation was for the cost of CM within the 
first 30 days of a lactation.  The estimation of the cost of SCM in our model was also 
higher than that used by Scherpenzeel et al. (2016) and Scherpenzeel et al. (2018) as both 
studies calculated the cost of SCM using milk losses associated with an increase in SCC 
at any point in the lactation.  The use of milk loss associated with a first test day SCC 
presented by Nolan (2017) would be more representative of milk loss due to a SCM case 
around the time of calving. 
CONCLUSIONS 
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 The objectives of this study were to 1) determine the costs of BT and ST to a 
simulated US dairy herd, 2) determine if different selection criteria would lead to 
decreased costs of ST compared to BT, and 3) to determine how input costs and herd 
demographics would impact optimal DCT decisions.  Overall, our simulations resulted in 
BT costing significantly less than NT and ST dry cow therapy schemes.  In the simulated 
herds used in our study, farmers could save close to $9.75/cow per year by using BT 
compared to ST schemes.  Results from our analysis suggest that when using ST 
schemes, the more cows that receive IMMA at dry off, the less cost the DCT scheme will 
have to the farm.  The cost of mastitis should be considered when making DCT decisions.  
As mastitis costs decrease, ST became a more feasible therapy option.  However, the 
variables that led to the greatest variability in DCT costs were CM and SCM incidence 
rates.   
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Table 3.1.  The percent of cows1 in each dry off groups (1 to 9) based on cow somatic cell count (SCC) (SCC*1,000 cells/mL) and 
parity on the last test day of the lactation in herds with differing SCC. 
   
Percent of cows in a herd 
Group Dry off SCC (cells/mL*1000)2 Parity Low SCC3 Average SCC4 High SCC5 
1 0 to 50 1 23% 20% 18% 
2 51 to 100 1 8% 8% 8% 
3 101 to 150 1 3% 4% 4% 
4 > 150 1 7% 9% 12% 
5 0 to 50 2+ 42% 35% 27% 
6 51 to 100 2+ 6% 8% 9% 
7 101 to 150 2+ 3% 4% 5% 
8 151 to 250 2+ 3% 4% 5% 
9 > 250 2+ 5% 8% 12% 
1Percent of cows in each group were collected from Dairy Records Management Systems test day data from January 2015 to 
December 2017 with 7,020 herds included in the analysis. 
2Dry off SCC = SCC at the last test of the cow’s lactation 
3Low SCC herds had SCC < 109,000 cells/mL 
4Average SCC herd had SCC between 109,000 and 251,000 cells/mL 
5High SCC herds had a SCC > 251,000 cells/mL 
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Table 3.2.  Estimated incidence rates of clinical and subclinical mastitis1, based on dry off groups (1 to 9), collected from Dairy 
Records Management Systems test-day data2 from Holstein cows that calved between January 2015 and December 2017. 
   
Incidence rate in next lactation3    
Clinical Mastitis Subclinical Mastitis 
Group Dry off SCC (cells/mL*1,000) Parity Treat (+)4 Treat (-)5 Treat (+)6 Treat (-) 
1 0 to 50 1 11.53% 16.02% 9.05% 20.02% 
2 51 to 100 1 14.97% 20.80% 11.75% 26.00% 
3 101 to 150 1 17.48% 24.28% 13.72% 30.35% 
4 > 150 1 25.32% 35.17% 19.87% 43.96% 
5 0 to 50 2+ 10.08% 14.81% 13.72% 22.70% 
6 51 to 100 2+ 11.77% 17.31% 16.03% 26.53% 
7 101 to 150 2+ 13.49% 19.82% 18.36% 30.38% 
8 151 to 250 2+ 15.56% 22.87% 21.18% 35.05% 
9 > 250 2+ 21.44% 31.51% 29.19% 48.31% 
1Cows with a first test of the lactation with a SCC greater than 200,000 cells/ mL were considered to have subclinical mastitis 
2Data from Dairy Records Management Systems were used to derive the incidence rate of subclinical mastitis in cows that received intramammary antibiotics at 
dry off 
3Incidence rate of clinical and subclinical mastitis within the first 100 days of the next lactation 
4Treat (+) = estimated incidence rates in the next lactation for cows that received intramammary antibiotics at dry off 
5Treat (-) = estimated incidence rates in the next lactation for cows that did not receive intramammary antibiotics at dry off 
6Incidence rates of the subclinical mastitis – Treat (+) group were derived from Dairy Records Management Systems data.  These data were then used to create 
an estimate for the incidence rates of the remaining three groups by creating an index value from the incidence rates presented by Scherpenzeel et al. (2018).  
Index values were created using the following equation: 
IIR =
SIR
SSCM(+)
∗ DSCM(+) 
Where: 
IIR = Index incidence rate 
SIR = Incidence rate presented by Scherpenzeel et al. (2018) 
SSCM(+) = Subclinical mastitis incidence rate for cows receiving intramammary antibiotics at dry off presented by Scherpenzeel et al. (2018) 
DSCM(+) = Subclinical mastitis incidence rate for cows receiving intramammary antibiotics at dry off derived from Dairy Records Management Systems data 
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Table 3.3.  Minimum, most likely, and maximum values for dry cow therapy costs 
variables entered into a PERT distribution to calculate dry cow therapy costs in a 
simulated dairy herd. 
Variable Min Most Likely Max 
CM Cost ($/case)1 $244.00 $444.00 $644.00 
SCM Cost ($/case)2 $5.65 $25.84 $56.21 
ST Time (hrs)3 0.16 0.30 0.50 
BT Time (hrs)4 0.08 0.16 0.25 
ST Wages ($/hr)5 $26.50 $33.47 $40.50 
BT Wages ($/hr)6 $10.50 $12.47 $14.50 
1CM Cost = Cost of clinical mastitis ($/case) 
2SCM Cost = Cost of subclinical mastitis ($/case) 
3ST Time = Time of treatment using selective dry cow therapy (hrs) 
4BT Time = Time of treatment using blanket dry cow therapy (hrs) 
5ST Wage = Hourly wage paid to labor performing selective dry cow therapy ($/hr) 
6BT Wage = Hourly wage paid to labor performing blanket dry cow therapy ($/hr) 
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Table 3.4.  Minimum, most likely (ML), and maximum values used for estimated mastitis incidence rates based on mastitis type and 
treatment decision (+/-) entered into a PERT distribution as part of a simulation model to calculate dry cow therapy costs in a 
simulated dairy herd. 
  Incidence rate in next lactation   
Clinical Mastitis Subclinical Mastitis   
Treat (+)1 Treat (-)2 Treat (+) Treat (-) 
Group Dry off SCC Min ML Max Min ML Max Min ML Max Min ML Max 
1 0–50 5.8% 11.5% 23.1% 8.0% 16.0% 32.0% 4.5% 9.1% 18.1% 10.0% 20.0% 40.0% 
2 51–100 7.5% 15.0% 29.9% 10.4% 20.8% 41.6% 5.9% 11.8% 23.5% 13.0% 26.0% 52.0% 
3 101–150 8.7% 17.5% 35.0% 12.1% 24.3% 48.6% 6.9% 13.7% 27.4% 15.2% 30.4% 60.7% 
4 >150 12.7% 25.3% 50.6% 17.6% 35.2% 70.3% 9.9% 19.9% 39.7% 22.0% 44.0% 87.9% 
5 0–50 5.0% 10.1% 20.2% 7.4% 14.8% 29.6% 6.9% 13.7% 27.4% 11.4% 22.7% 45.4% 
6 51–100 5.9% 11.8% 23.5% 8.7% 17.3% 34.6% 8.0% 16.0% 32.1% 13.3% 26.5% 53.1% 
7 101–150 6.7% 13.5% 27.0% 9.9% 19.8% 39.6% 9.2% 18.4% 36.7% 15.2% 30.4% 60.8% 
8 151–250 7.8% 15.6% 31.1% 11.4% 22.9% 45.7% 10.6% 21.2% 42.4% 17.5% 35.1% 70.1% 
9 >250 10.7% 21.4% 42.9% 15.8% 31.5% 63.0% 14.6% 29.2% 58.4% 24.2% 48.3% 96.6% 
1Treat (+) = estimated mastitis incidence rates in the next lactation for cows that received intramammary antibiotics at dry off 
2Treat (-) = estimated clinical mastitis incidence rates in the next lactation for cows that did not receive intramammary antibiotics at 
dry off 
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Table 3.5.  Weighted average of clinical and subclinical mastitis incidence rates 
throughout the dry period and into the next lactation associated with herd somatic cell 
count and dry cow therapy treatment options. 
 
Clinical Mastitis Subclinical Mastitis 
Treatment Low1 Average2 High3 Low Average High 
BT4 14.1% 15.0% 16.1% 15.4% 16.3% 17.5% 
NT5 20.2% 21.5% 23.0% 28.4% 30.1% 32.2% 
ST16 18.9% 19.6% 20.4% 25.5% 26.1% 26.6% 
ST27 18.5% 19.0% 19.7% 24.5% 24.8% 25.2% 
ST38 17.7% 18.2% 18.9% 22.9% 23.0% 23.3% 
1Low SCC herds had SCC < 109,000 cells/mL 
2Average SCC herd had SCC between 109,000 and 251,000 cells/mL 
3High SCC herds had a SCC > 251,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with a 
SCC > 250,000 cells/mL treated 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with a 
SCC > 150,000 cells/mL treated 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with a 
SCC > 100,000 cells/mL treated 
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Table 3.6.  Mean (± standard deviation) total costs of different dry cow therapy schemes used in simulated dairy herds with differing 
somatic cell counts. 
 Herd somatic cell count 
Dry off scheme Low1 Average2 High3 
Blanket4 $10,637.35 ± 1,813.74a $11,181.28 ± 1,877.44a $11,851.88 ± 1,994.69a 
No treatment5 $12,918.96 ± 2,717.66b $13,687.99 ± 2,800.85b $14,685.33 ± 2,965.71b 
ST16 $12,403.51 ± 2,549.09c $12,961.54 ± 2,555.46c $13,655.70 ± 2,603.78c 
ST27 $12,270.88 ± 2,494.69c,d $12,785.76 ± 2,480.11c,d $13,456.06 ± 2,519.17c,d 
ST38 $12,108.82 ± 2,406.26d $12,608.58 ± 2,377.02d $13,260.96 ± 2,400.46d 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with an SCC > 250,000 cells/mL treated 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with an SCC > 150,000 cells/mL treated 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with an SCC > 100,000 cells/mL treated 
a-d Means within a column with a different superscript are significantly different (P < 0.05) 
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Table 3.7.  Mean (± standard deviation) differences in dry cow therapy costs when using different dry cow therapy schemes in 
simulated dairy herds with differing somatic cell counts. 
 Herd somatic cell count  
Low1 Average2 High3 
Blanket4 vs No Treatment5 $2,281.61 ± 1,859.34 $2,519.75 ± 1,816.13 $2,833.46 ± 1,886.88 
Blanket vs ST16 $1,766.16 ± 1,669.87 $1,793.30 ± 1,490.21 $1,803.82 ± 1,306.60 
Blanket vs ST27 $1,633.53 ± 1,625.79 $1,617.52 ± 1,422.09 $1,604.18 ± 1,222.18 
Blanket vs ST38 $1,471.47 ± 1,546.47 $1,440.34 ± 1,343.97 $1,409.08 ± 1,122.04 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with an SCC > 250,000 cells/mL treated 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with an SCC > 150,000 cells/mL treated 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with an SCC > 100,000 cells/mL treated 
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Table 3.8.  The frequency of iterations and the value of dry cow therapy cost variables in which different dry cow therapy schemes 
cost less than blanket dry cow therapy in a simulated low somatic cell count herd1. 
   Dry cow therapy scheme comparisons 
Variable Variable Distribution Frequency2 and value BT3 vs NT4 BT vs ST15 BT vs ST26 BT vs ST37 
CM Cost ($/case)8 $111.00 to $777.00 
Frequency 1.3% 1.6% 1.3% 0.5% 
Value12 $186.19 $193.68 $186.19 $165.56 
BT Wages ($/hr)9 $10.50 to $90.00 
Frequency 0.0% 1.2% 4.1% 9.7% 
Value13 N/A $81.10 $76.02 $70.52 
BT Time (hrs)10 0.08 to 0.50 hrs 
Frequency 0.0% 6.8% 11.9% 19.4% 
Value14 N/A 0.39 0.36 0.34 
Mastitis IR11 Half to Double IR Frequency 5.4% 8.2% 10.1% 12.2% 
Clinical mastitis  Value15 2.1% 1.7% 1.4% 1.0% 
Subclinical mastitis  Value15 21.8% 25.4% 24.9% 22.0% 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Frequency = the percent of iterations in which compared dry cow therapy scheme cost less than blanket dry cow therapy 
3Blanket therapy = all cows received intramammary antibiotics at dry off 
4No treatment = no cows received intramammary antibiotics at dry off 
5ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with an SCC > 250,000 cells/mL treated 
6ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with an SCC > 150,000 cells/mL treated 
7ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with an SCC > 100,000 cells/mL treated 
8CM Cost = The cost of clinical mastitis ($/case) 
9BT Time = Time of treatment using blanket dry cow therapy (hrs) 
10BT Wage = Hourly wage paid to labor performing blanket dry cow therapy ($/hr) 
11Mastitis IR = Population incidence rate of clinical and subclinical mastitis 
12Value = the maximum CM cost in which the respective therapy option would cost less than BT 
13Value = the maximum wage paid to BT labor in which the respective therapy option would cost less than BT 
14Value = the maximum time to treat when using BT in which the respective therapy option would cost less than BT 
15Value = the maximum difference in CM or SCM incidence rate, comparing the respective therapy option to BT, in which the 
respective therapy would cost less than BT  
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Table 3.9.  The frequency of iterations and the value of dry cow therapy cost variables in which different dry cow therapy schemes 
cost less than blanket dry cow therapy in a simulated average somatic cell count herd1. 
   Dry cow therapy scheme comparisons 
Variable Variable Distribution Frequency2 and value BT3 vs NT4 BT vs ST15 BT vs ST26 BT vs ST37 
CM Cost ($/case)8 $111.00 to $777.00 
Frequency 0.8% 0.4% 0.6% 0.1% 
Value12 $173.84 $178.28 $166.53 $123.30 
BT Wages ($/hr)9 $10.50 to $90.00 
Frequency 0.0% 1.0% 4.0% 10.0% 
Value13 N/A $83.70 $76.54 $70.24 
BT Time (hrs)10 0.08 to 0.50 hrs 
Frequency 0.0% 19.3% 29.8% 38.4% 
Value14 N/A 0.40 0.37 0.34 
Mastitis IR11 Half to Double IR Frequency 2.8% 4.9% 6.6% 8.3% 
Clinical mastitis  Value15 1.8% 1.5% 1.2% 0.7% 
Subclinical mastitis  Value15 21.8% 17.6% 22.7% 14.4% 
1Average SCC herd had a SCC of 251,000 cells/ml 
2Frequency = the percent of iterations in which compared dry cow therapy scheme cost less than blanket dry cow therapy 
3Blanket therapy = all cows received intramammary antibiotics at dry off 
4No treatment = no cows received intramammary antibiotics at dry off 
5ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with an SCC > 250,000 cells/mL treated 
6ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with an SCC > 150,000 cells/mL treated 
7ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with an SCC > 100,000 cells/mL treated 
8CM Cost = The cost of clinical mastitis ($/case) 
9BT Time = Time of treatment using blanket dry cow therapy (hrs) 
10BT Wage = Hourly wage paid to labor performing blanket dry cow therapy ($/hr) 
11Mastitis IR = Population incidence rate of clinical and subclinical mastitis 
12Value = the maximum CM cost in which the respective therapy option would cost less than BT 
13Value = the maximum wage paid to BT labor in which the respective therapy option would cost less than BT 
14Value = the maximum time to treat when using BT in which the respective therapy option would cost less than BT 
15Value = the maximum difference in CM or SCM incidence rate, comparing the respective therapy option to BT, in which the 
respective therapy would cost less than BT  
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Table 3.10.  The frequency of iterations and the value of dry cow therapy cost variables in which different dry cow therapy schemes 
cost less than blanket dry cow therapy in a simulated high somatic cell count herd1. 
   Dry cow therapy scheme comparisons 
Variable Variable Distribution Frequency2 and value BT3 vs NT4 BT vs ST15 BT vs ST26 BT vs ST37 
CM Cost ($/case)8 $111.00 to $777.00 
Frequency 0.4% 0.3% 0.1% 0.0% 
Value12 $158.68 $155.30 $123.30 N/A 
BT Wages ($/hr)9 $10.50 to $90.00 
Frequency 0.0% 1.0% 3.8% 10.8% 
Value13 N/A $84.06 $76.41 $69.65 
BT Time (hrs)10 0.08 to 0.50 hrs 
Frequency 0.0% 0.4% 3.8% 10.8% 
Value14 N/A 0.40 0.37 0.33 
Mastitis IR11 Half to Double IR Frequency 2.4% 3.5% 4.1% 4.7% 
Clinical mastitis  Value15 2.0% 1.1% 0.7% 0.1% 
Subclinical mastitis  Value15 20.4% 16.0% 20.0% 12.5% 
1High SCC herd had a SCC of 393,000 cells/ml 
2Frequency = the percent of iterations in which compared dry cow therapy scheme cost less than blanket dry cow therapy 
3Blanket therapy = all cows received intramammary antibiotics at dry off 
4No treatment = no cows received intramammary antibiotics at dry off 
5ST1 = 1st parity cows with SCC > 150,000 cells/mL treated and 2+ parity cows with an SCC > 250,000 cells/mL treated 
6ST2 = 1st parity cows with SCC > 100,000 cells/mL treated and 2+ parity cows with an SCC > 150,000 cells/mL treated 
7ST3 = 1st parity cows with SCC > 50,000 cells/mL treated and 2+ parity cows with an SCC > 100,000 cells/mL treated 
8CM Cost = The cost of clinical mastitis ($/case) 
9BT Time = Time of treatment using blanket dry cow therapy (hrs) 
10BT Wage = Hourly wage paid to labor performing blanket dry cow therapy ($/hr) 
11Mastitis IR = Population incidence rate of clinical and subclinical mastitis 
12Value = the maximum CM cost in which the respective therapy option would cost less than BT 
13Value = the maximum wage paid to BT labor in which the respective therapy option would cost less than BT 
14Value = the maximum time to treat when using BT in which the respective therapy option would cost less than BT 
15Value = the maximum difference in CM or SCM incidence rate, comparing the respective therapy option to BT, in which the 
respective therapy would cost less than BT  
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Figure 3.1.  Mean (± standard deviation) costs of different dry cow therapy schemes used 
in simulated dairy herds with differing somatic cell counts. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
a-d Means within same bar fill with a different superscript are significantly different (P < 
0.05) 
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Figure 3.2.  Mean (± standard deviation) differences in dry cow therapy costs when using 
different dry cow therapy schemes in simulated dairy herds with differing somatic cell 
counts. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.3.  Frequency of a 1,000 iteration simulation in which blanket dry cow therapy 
cost less than different dry cow therapy schemes in simulated dairy herds. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.4.  A tornado graph depicting the range of the difference in the total cost 
between blanket1 and selective dry cow therapy2 schemes associated with the change of 
cost variables for a simulated dairy herd with a low SCC (109,000 cells/mL).  The 
average cost difference was $1,506.643. 
 
 
1Blanket dry cow therapy = all cows treated with intramammary antibiotic 
2Selective dry cow therapy scheme = treating only 1st parity cows with SCC > 150,000 
cells/mL and 2+ parity cows with an SCC > 250,000 cells/mL 
3Value is the average difference in total cost of blanket dry cow and selective dry cow 
therapy scheme. 
4CM Cost = Cost of clinical mastitis ($/case) 
5SCM Cost = Cost of subclinical mastitis ($/case) 
6Blanket Time = Time of treatment using blanket dry cow therapy (hrs) 
7Blanket Labor = Hourly wage paid to labor performing blanket dry cow therapy ($/hr) 
8Selective Time = Time of treatment using selective dry cow therapy (hrs) 
9Selective Labor = Hourly wage paid to labor performing selective dry cow therapy ($/hr) 
 
 
$1,600.04
$1,582.97
$1,611.84
$1,627.13
$2,413.23
$2,441.93
$1,443.38
$1,376.42
$1,402.47
$1,388.47
$664.51
$601.10
300 800 1300 1800 2300 2800
Selective Labor⁹
Selective Time⁸
Blanket Labor⁷
Blanket Time⁶
SCM Cost⁵
CM Cost⁴
Min Max
 115 
 
Figure 3.5.  Frequency of a 1,000 iteration simulation in which blanket dry cow therapy 
cost less than different dry cow therapy schemes in simulated dairy herds when comparing 
clinical mastitis case cost that ranged from $111.00 to $777.00/case. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.6.  The maximum cost of a case of clinical mastitis in which a compared dry cow 
therapy scheme cost less than blanket dry cow therapy in simulated dairy herds. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off.   
No cost of ST3 associated with the high herd because the total cost of ST3 was never 
lower than Blanket therapy when the cost of CM changed. 
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Figure 3.7.  Changes in the difference between the cost of blanket dry cow therapy1 and a 
selective dry cow therapy2 (ST3) scheme as the cost of clinical mastitis changes for 
simulated dairy herds with low3, average4, and high5 somatic cell counts. 
 
1Blanket dry cow therapy = all cows treated with intramammary antibiotic 
2Selective dry cow therapy scheme = 1st parity cows with SCC > 50,000 cells/mL and 2+ 
parity cows with an SCC > 100,000 cells/mL treated with an intramammary antibiotic at 
dry off.  Defined as ST3 in text of paper. 
3Low SCC herd had a SCC of 109,000 cells/ml 
4Average SCC herd had a SCC of 251,000 cells/mL 
5High SCC herd had a SCC of 393,000 cells/mL 
 
$0.00
$100.00
$200.00
$300.00
$400.00
$500.00
$600.00
$700.00
$800.00
-$1,000.00 $0.00 $1,000.00 $2,000.00 $3,000.00
C
o
st
 o
f 
cl
in
ic
al
 m
as
ti
ti
s 
($
/c
as
e)
Difference in dry cow therapy scheme cost (ST3 - BT)
Low
Average
High
 118 
 
Figure 3.8.  Frequency of a 1,000 iteration simulation in which blanket dry cow therapy 
cost less than different dry cow therapy schemes in simulated dairy herds when comparing 
wages paid for labor ($10.50 to $90.00/hr) using a blanket dry cow therapy scheme. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.9.  The minimum wage paid to labor performing blanket dry cow therapy in 
which a compared dry cow therapy scheme cost less than blanket dry cow therapy in 
simulated dairy herds. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
6ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.10.  Changes in the difference between the cost of blanket dry cow therapy1 and 
a selective dry cow therapy2 (ST3) scheme as the associated labor wage changes for 
simulated dairy herds with low3, average4, and high5 somatic cell counts. 
1Blanket dry cow therapy = all cows treated with intramammary antibiotic 
2Selective dry cow therapy scheme = 1st parity cows with SCC > 50,000 cells/mL and 2+ 
parity cows with an SCC > 100,000 cells/mL treated with an intramammary antibiotic at 
dry off.  Defined as ST3 in text of paper. 
3Low SCC herd had a SCC of 109,000 cells/ml 
4Average SCC herd had a SCC of 251,000 cells/mL 
5High SCC herd had a SCC of 393,000 cells/mL 
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Figure 3.11.  Frequency of a 1,000 iteration simulation in which blanket dry cow therapy 
cost less than different dry cow therapy schemes in simulated dairy herds when 
comparing time (0.08 to 0.50 hrs) of treatment for labor . 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.12.  The minimum time for performing blanket dry cow therapy in which a 
compared dry cow therapy scheme cost less than blanket dry cow therapy in simulated 
dairy herds. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
6ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.13.  Changes in the difference between the cost of blanket dry cow therapy1 and 
selective dry cow therapy2 (ST3) scheme as clinical mastitis incidence rate of the ST 
scheme increases in simulated dairy herds with low3, average4, and high5 somatic cell 
counts. 
 
1Blanket dry cow therapy = all cows treated with intramammary antibiotic 
2Selective dry cow therapy scheme = 1st parity cows with SCC > 50,000 cells/mL and 2+ 
parity cows with an SCC > 100,000 cells/mL treated with an intramammary antibiotic at 
dry off.  Defined as ST3 in text of paper. 
3Low SCC herd had a SCC of 109,000 cells/ml 
4Average SCC herd had a SCC of 251,000 cells/mL 
5High SCC herd had a SCC of 393,000 cells/mL 
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Figure 3.14.  Frequency of a 1,000 iteration simulation in which blanket dry cow therapy 
cost less than different dry cow therapy schemes in simulated dairy herds when 
comparing mastitis incidence rates. 
 
1Low SCC herd had a SCC of 109,000 cells/ml 
2Average SCC herd had a SCC of 251,000 cells/mL 
3High SCC herd had a SCC of 393,000 cells/mL 
4Blanket therapy = all cows received intramammary antibiotics at dry off 
5No treatment = no cows received intramammary antibiotics at dry off 
6ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
7ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.15.  The maximum difference1 in the weighted average clinical mastitis 
incidence rate in which a compared dry cow therapy scheme cost less than blanket dry 
cow therapy in simulated dairy herds. 
 
1Difference = mastitis incidence rate using respective dry cow therapy scheme minus 
mastitis incidence rate using BT 
2Low SCC herd had a SCC of 109,000 cells/ml 
3Average SCC herd had a SCC of 251,000 cells/mL 
4High SCC herd had a SCC of 393,000 cells/mL 
5Blanket therapy = all cows received intramammary antibiotics at dry off 
6No treatment = no cows received intramammary antibiotics at dry off 
7ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
9ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.16.  The maximum difference1 in the weighted average subclinical mastitis 
incidence rate in which a compared dry cow therapy scheme cost less than blanket dry 
cow therapy in simulated dairy herds. 
 
1Difference = mastitis incidence rate using respective dry cow therapy scheme minus 
mastitis incidence rate using BT 
2Low SCC herd had a SCC of 109,000 cells/ml 
3Average SCC herd had a SCC of 251,000 cells/mL 
4High SCC herd had a SCC of 393,000 cells/mL 
5Blanket therapy = all cows received intramammary antibiotics at dry off 
6No treatment = no cows received intramammary antibiotics at dry off 
7ST1 = 1st parity cows with SCC > 150,000 cells/mL and 2+ parity cows with an SCC > 
250,000 cells/mL treated with an intramammary antibiotic at dry off 
8ST2 = 1st parity cows with SCC > 100,000 cells/mL and 2+ parity cows with an SCC > 
150,000 cells/mL treated with an intramammary antibiotic at dry off 
9ST3 = 1st parity cows with SCC > 50,000 cells/mL and 2+ parity cows with an SCC > 
100,000 cells/mL treated with an intramammary antibiotic at dry off 
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Figure 3.17.  Differences in the cost of blanket dry cow therapy1 (BT) and selective dry 
cow therapy2 (ST3) scheme by the difference3 in clinical mastitis incidence rate of ST in 
dairy herds with low4, average5, and high somatic cell counts6. 
 
1Blanket dry cow therapy = all cows treated with intramammary antibiotic 
2Selective dry cow therapy scheme = 1st parity cows with SCC > 50,000 cells/mL and 2+ 
parity cows with an SCC > 100,000 cells/mL treated with an intramammary antibiotic at 
dry off.  Defined as ST3 in text of paper. 
3Difference = mastitis incidence rate when using ST3 minus mastitis incidence rate using 
BT 
3Low SCC herd had a SCC of 109,000 cells/ml 
4Average SCC herd had a SCC of 251,000 cells/mL 
5High SCC herd had a SCC of 393,000 cells/mL 
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The effect of milk pricing formula on gross milk check payments to Southeastern United States 
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INTRODUCTION 
Since January 1st, 2000, after the passing of the Federal Agriculture Improvement 
and Reform Act of 1996, US dairy farmers have been paid for milk with two different 
pricing formulas.  All but four of the Federal Milk Marketing Orders (FMMO) are paid 
using multiple component pricing (MCP).  Of the four FMMOs that do not use the 
multiple component pricing scheme, three are in the Southeastern United States 
(Appalachia (5), Southeast (7), and Florida (6)).  In 2018, a dairy interest group in the 
Southeast submitted hearing requests to have the USDA potentially change the milk 
pricing structure in the Southeast and Appalachia FMMO.  The hearing request proposed 
the FMMOs change to a multiple component pricing scheme (USDA Agricultural 
Marketing Service, 2018b).  The interest in the change in pricing structure comes with the 
question, how would a multiple component pricing scheme impact the farm gate milk 
check to dairy farmers in the Southeast? 
CURRENT PRICING SCHEME 
The Southeastern United States is considered a milk deficit area, meaning that 
fluid milk production in the region does not satisfy the processors’ demand.  Demand is 
statisfied by shipping milk in from outside marketing orders.  Because of the need for 
fluid milk in the Southeast, milk is priced to account for the total volume shipped.  Milk 
in the Appalachia, Southeast, and Florida FMMO is valued using a skim-fat pricing 
scheme.  In the skim-fat pricing structure, the farmer is paid for the amount of skim 
(fluid) milk and butterfat that the farm produces.  Milk is valued with the skim-butterfat 
pricing scheme using the following formula: 
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𝑀𝑖𝑙𝑘 𝑣𝑎𝑙𝑢𝑒 ($ 𝑐𝑤𝑡⁄ )
= [((𝑙𝑏𝑠 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑚𝑖𝑙𝑘 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑 − 𝑙𝑏𝑠 𝑜𝑓 𝑓𝑎𝑡)/100)
∗ 𝑠𝑘𝑖𝑚 𝑚𝑖𝑙𝑘 𝑝𝑟𝑖𝑐𝑒 ($ 𝑐𝑤𝑡⁄ )]
+ ([𝑙𝑏𝑠 𝑜𝑓 𝑓𝑎𝑡 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑 ∗ 𝑏𝑢𝑡𝑡𝑒𝑟𝑓𝑎𝑡 𝑝𝑟𝑖𝑐𝑒 ($ 𝑙𝑏⁄ )]  
By paying farmers for the amount of skim milk they produce, total volume is 
encouraged to help meet the processor demand.  However, dairy farmers are not paid for 
other components, like protein, which is vital for cheese production.  One reason for the 
difference in pricing schemes may be the lack of cheese plants in the Southeast.  
According to Dairy Foods (2019), the Southeast FMMO has three cheese plants, and 
Appalachia has two.  However, each FMMO has 30 fluid milk plants. 
MULTIPLE COMPONENT PRICING 
Federal milk marketing orders employing the MCP scheme value milk based on 
its fat, protein, and other solids yields.  An additional consideration in the MCP system is 
the producer price differential.  Producer price differential accounts for the value of all of 
the milk produced in an FMMO minus the cost of production of manufactured dairy 
products.  Some FMMOs that are using the multiple component pricing scheme also pay 
for milk quality with a somatic cell count (SCC) adjustment.  A SCC adjustment is 
implemented as a penalty for herds with an SCC above 350,000 cells/mL.  Overall, 
multiple component pricing values milk using the following equation:  
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𝑀𝑖𝑙𝑘 𝑣𝑎𝑙𝑢𝑒 ($ 𝑐𝑤𝑡⁄ )
= (𝑙𝑏𝑠 𝑜𝑓 𝑓𝑎𝑡 𝑠ℎ𝑖𝑝𝑝𝑒𝑑 ∗ 𝑓𝑎𝑡 𝑝𝑟𝑖𝑐𝑒 ($ 𝑙𝑏⁄ ))
+ (𝑙𝑏𝑠 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑠ℎ𝑖𝑝𝑝𝑒𝑑 ∗ 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑝𝑟𝑖𝑐𝑒 ($ 𝑙𝑏⁄ ))
+ (𝑙𝑏𝑠 𝑜𝑓 𝑜𝑡ℎ𝑒𝑟 𝑠𝑜𝑙𝑖𝑑𝑠 𝑠ℎ𝑖𝑝𝑝𝑒𝑑 ∗ 𝑜𝑡ℎ𝑒𝑟 𝑠𝑜𝑙𝑖𝑑𝑠 𝑝𝑟𝑖𝑐𝑒 ($ 𝑙𝑏⁄ ))
+ ((
𝑡𝑜𝑡𝑎𝑙 𝑚𝑖𝑙𝑘 𝑦𝑖𝑒𝑙𝑑 𝑠ℎ𝑖𝑝𝑝𝑒𝑑
100
)
∗ 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑟 𝑝𝑟𝑖𝑐𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙 ($ 𝑐𝑤𝑡⁄ )) − 𝑆𝐶𝐶 𝑎𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 
 
MCP VS SKIM-BUTTERFAT PRICING IN THE SOUTHEAST 
 Newton (2014) determined that the Southeast region, including the Southeast, 
Appalachia, and Florida FMMO would have increased producer milk value by a total of 
$68 million from 2006 to 2013 if milk were priced using MCP.  However, this additional 
value may not come back directly to the farmer.  Newton (2014) indicates that benefits to 
the farmer would depend on the FMMO response to MCP.  Marketing orders may 
redistribute pool dollars or change premium structures, which could impact farm milk 
checks.  One pool adjustment that is commonly made in FMMOs is transportation 
adjustments.  Transportation adjustments are made for milk that is shipped from supply to 
distribution plants when Class I milk is needed (Congressional Research Service, 2017).  
Adjustments in transportation costs could impact milk prices paid to the farmer. 
USING HERD INFORMATION 
Utilizing Dairy Records Management System (DRMS) test day data to evaluate 
individual farms allows for a more accurate representation of the returns to a farm if an 
MCP scheme was adopted.  Overall, 43,814 herd test day records from 2012 through 
2018 were collected and analyzed.  Using the MCP equation above, each cow’s test day 
fat, protein, and other solids percent were multiplied by their respective prices to 
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determine the value of milk each cow produced during that test day.  Pricing values in 
each of the equations were collected from the USDA Agricultural Marketing Service 
(2019).  The multiple component pricing values were then compared to the value of milk 
using the skim-butterfat pricing equation. 
MCP VS SKIM-BUTTERFAT PRICING AT A HERD LEVEL 
When examining the prices by the milk produced by each farm per test day, 
multiple component pricing resulted in a higher milk value ($20.74/cwt) compared to 
when milk was priced with the skim-butterfat value ($20.51/cwt).  Farms had the 
potential to make $0.23/cwt more per test day when milk was priced using the multiple 
component pricing scheme.  When comparing across FMMO, milk value was higher 
when priced with multiple component pricing than when priced with skim-butterfat 
pricing for both the Appalachia and Southeast FMMO across all years (Figure 4.1).  The 
Southeast FMMO had the greatest range in differences from $0.27/cwt in 2017 to 
$0.72/cwt in 2014.  The only year in which Appalachia had greater differences than the 
Southeast was 2017.  In 2017, producer price differentials in the Southeast and 
Appalachia were within $0.25/cwt of each other, but in most other years the Southeast 
received around $0.50 more than Appalachia.   
When comparing milk values at a state level, MCP resulted in a higher value 
across all states (Figure 4.2).  Observed differences from state to state could be due to 
production as well as the producer price differential payments.  States that were in the 
Southeast FMMO tended to have higher milk values.  Kentucky and Tennessee are 
unique because they are split between two different FMMOs.  In the data presented in 
Figure 4.2, Kentucky farms are assumed to ship milk to the Appalachia FMMO and their 
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prices are lower than other states.  However, when Kentucky farms ship milk to the 
Southeast FMMO the prices they would receive are closer to the other states.   
Farms that were primarily Holstein (≥ 75% Holstein cows tested on test day) were 
more profitable when milk was priced using the skim-butterfat pricing scheme.  Milk 
price differed by $0.01/cwt by breed type when priced with MCP (Figure 4.3).  These 
results may suggest that when milk is priced using MCP, the value of protein helps herds 
that are not primarily Holstein close the gap on the difference in milk value from Holstein 
herds.   
When the value of skim milk contributed the most to the total milk value, farmers 
were paid more than when butterfat contributed the most to the total value.  When the 
value of skim milk was ≥ 50% of the total milk value, under the skim-butterfat pricing 
scheme, farmers made $3.06 more per cwt than if the value paid for fat made up more 
than 50% of the total milk value.  For MCP, when the value of protein contributed the 
most to the total value of milk, dairy farmers were paid $2.78 more per cwt than when the 
value of fat contributed the most. 
If milk protein percentage ranged from 2.92% to 3.02%, skim-butterfat pricing 
paid more per cwt of milk.  Even when fat production was relatively high (3.87% to 
4.12%), only 38% of test day records resulted in MCP having a higher milk value (Table 
4.1).  Farms that had a milk protein percentage over 3.02% were paid more when milk 
was priced using MCP.  When protein percent increased above 3.02% greater than 88.4% 
of test days resulted in milk being more valuable when priced with MCP  
TAKE-HOME MESSAGE 
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Overall, when milk was valued using MCP, farmers were paid more per test day.  
When milk was valued using the skim-butterfat formula, producers were paid more when 
the value of skim milk contributed the most to the total value of milk.  So, increasing 
total milk yield may be more profitable than trying to improve specific components.  
Under the MCP scheme, farms in which the value of protein contributed the most to the 
total milk value were paid more per test day.  Farms with below-average protein 
production (< 3.03%) would be paid more under a skim-butterfat pricing scheme.   
Farms that were primarily Holstein (≥ 75% Holstein cows tested on test day) were 
paid more than other herds when milk was priced using skim-butterfat pricing.  However, 
when milk was priced using MCP, the value of milk between the two different herd types 
was less than $0.01/cwt.  Bailey et al. (2005) concluded that increasing the overall 
volume of milk rather than focusing on specific components led to more value when 
comparing the value of milk using MCP in Holstein and Jersey herds.  The difference in 
results suggests that a more complete analysis should be completed with the current 
dataset. 
The results of the research presented are preliminary.  Values presented in this 
paper are from mean observations only.  Statistical analyses are being completed to 
determine if differences between the pricing schemes are statistically significant.  
Additional research is being done testing the interaction of pricing and herd specific 
variables.  These results are also based on farm-level data and do not consider how a 
pricing scheme change may affect the overall price change to dairy farmers.  For 
assumptions made in the current analysis refer to the Appendix. 
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Table 4.1.  Milk value under multiple component (MCP) and skim-butterfat (S-BF) pricing 
schemes associated with herd average protein and fat production. 
Protein Fat MCP Value S-BF Value Frequency1 
2.92% to 3.02% 3.30% to 3.56% $19.68 $19.78 14.9% 
2.92% to 3.02% 3.57% to 3.87% $20.17 $20.21 26.2% 
2.92% to 3.02% 3.87% to 4.12% $20.82 $20.84 38.1% 
 
3.03% to 3.16% 
 
3.30% to 3.56% 
 
$20.23 
 
$20.05 
 
88.4% 
3.03% to 3.16% 3.57% to 3.87% $20.77 $20.52 93.6% 
3.03% to 3.16% 3.87% to 4.12% $21.35 $21.05 94.8% 
 
3.17% to 3.29% 
 
3.30% to 3.56% 
 
$20.63 
 
$20.13 
 
96.1% 
3.17% to 3.29% 3.57% to 3.87% $21.24 $20.71 95.2% 
3.17% to 3.29% 3.87% to 4.12% $21.92 $21.35 95.6% 
1Frequency = the percent of test day observations in which MCP led to higher milk value.
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Figure 4.1.  The difference1 in the mean value of milk when milk is priced using multiple component pricing and skim-butterfat 
pricing schemes by year for Appalachia and Southeast Federal Milk Marketing Orders. 
 
1Difference = multiple component pricing minus skim-butterfat
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Figure 4.2.  Mean milk value ($/cwt) when milk is valued using multiple component pricing (MCP) and skim-butterfat (S-BF) pricing 
schemes by state. 
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Figure 4.3.  Mean value of milk ($/cwt) under multiple component price (MCP) and 
skim-butterfat (S-BF) pricing schemes by herd breed. 
 
1Holstein herds were defined as a herd with ≥ 75% Holstein cows on test day 
2Other herds were defined as a herd with less than 75% Holstein cows on test day 
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RESEARCH SUMMARY 
This dissertation had three objectives, all based on current trends in the US dairy 
industry.  The legal limit of somatic cell count (SCC) is 750,000 cells/mL in the US.  
However, within the last 10 years dairy processors are demanding lower SCC thresholds.  
To meet these demands, milk quality management on farms is very important.  However, 
when profit margins are tight, dairy farmers may be reluctant to adopt new management 
practices.  Throughout our literature search, we found little research being done 
examining the economics of SCC management.  So, the first objective was to determine 
the cost of a particular herd SCC and how costs change after management practices have 
been implemented to control SCC.  This was accomplished by using stochastic 
simulation to model how the adoption of different cost management practices affects the 
total change in cost of herd SCC.  The benefits of management practice adoption 
included increased herd milk yield and potential milk quality premiums from decreasing 
the herd SCC.  Results from our analysis indicate that by adopting management practices, 
the simulated farms could significantly lower their cost of SCC.  These results were 
highly dependent on the farms’ base SCC and how close they were to a SCC premium.  
When premiums for milk quality were offered, economics associated with the adoption of 
management practices became more beneficial.   
However, when premiums were not offered, the economics benefits associated 
with management practice adoption dramatically decreased to the point the high cost 
management practice was no longer feasible to the herd with a low SCC.  The lack of 
benefit indicates that, in some situations, if farms have a low SCC they may actually 
loose profit by adopting practices to decrease their SCC even further.   
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In our analysis, farms could benefit by almost $12,000 per year by receiving a 
premium of $0.005 for every kg of milk produced.  Research has shown that providing 
farmers an incentive, they are more willing to meet the demands brought upon them.  
Though economic losses associated with milk loss due to a high SCC are indirect, they 
too should be thought of as an incentive by farmers.  In our simulations, economic losses 
from lost milk production alone were as high as $15,000/farm per yr.  By educating dairy 
farmers on the indirect costs of SCC farmers we hope to show the additional incentive to 
lowering herd SCC. 
One area that was not modeled in our research was the impact of management 
practice and other diseases of dairy cattle.  For example, the adoption of certain 
management practices might have a positive effect on transition cow diseases or 
lameness.  By not accounting for additional diseases the benefits of the management 
practices model may be underestimated.  Future research that modeled the effects of 
management practice adoption on multiple diseases would provide a more accurate 
economic benefit to the farmer. 
Because of pressure to decrease the use of antibiotics in animal agriculture, one 
management practice that might soon be taken away from dairy farmers in the US is the 
use of blanket dry cow therapy.  When reviewing the literature, many studies comparing 
the economics of blanket vs. selective dry cow therapy were based on a Dutch dairy 
system.  Authors could find little to no research comparing the costs in US dairy herds.  
So, the second objective was to determine if selective dry cow therapy is more 
economical compared to blanket dry cow therapy by varying selective dry cow therapy 
selection criteria.  Research was completed by modeling the cost of dry cow therapy to 
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simulated dairy farms using stochastic simulation.  In most simulation iterations, the cost 
of blanket dry cow therapy to the farms was less than selective dry cow therapy.  The 
average costs of blanket and selective dry cow therapy were significantly less than when 
the simulated farms used no therapy at all.  When modeling the costs of dry cow therapy, 
we considered the cost of labor, the costs of clinical and subclinical mastitis, and mastitis 
incidence rate.   
Unlike other published data, we assumed that blanket dry cow therapy and 
selective dry cow therapy would have different labor costs.  We assumed that selective 
dry cow therapy would be carried out by management labor at a higher hourly wage.  The 
assumption was also made that the time of treatment would be longer to account for 
viewing of records to determine whether cows needed to receive treatment and sorting of 
cows that needed to be dried off.  By completing the labor analysis, we concluded that 
labor costs of blanket dry cow therapy would have to increase to unrealistic levels before 
other therapy options would become economically feasible.  Therefore, labor savings 
should not be the only consideration if when choosing dry cow therapy options. 
Overall, results were dependent on the cost of clinical mastitis and clinical and 
subclinical mastitis incidence rates.  As both the cost of clinical mastitis and mastitis 
incidence rates decreased, selective dry cow therapy became more economical.  
However, a large portion of the cost of a case of mastitis is due to milk loss.  We did not 
consider milk price when calculating the cost of dry cow therapy treatments.  Future 
research examining the effect of milk price on optimal treatment options would provide 
farmers with more information in making dry cow therapy treatment decisions. 
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Because farmers in the US may be required to use selective dry cow therapies in 
the future.  Our research was focused at costs at the farm level.  However, the limitation 
of the use of blanket dry cow therapy will most likely have impacts on the entire dairy 
industry.  More research is needed on how a policy change might affect milk supply and 
therefore the economics at not only the farm level but the processor and consumer levels 
as well. 
Within the last year, different dairy industry groups in the Southeastern US have 
sent hearing requests to the United States Department of Agriculture to change how milk 
is priced in the Appalachia and Southeast Federal Milk Marketing Orders.  Currently, 
milk pricing schemes in the two Milk Marketing Orders price milk based on the skim and 
butterfat value.  Most other Federal Milk Marketing Orders price milk using multiple 
component pricing, which considers the values of fat, protein and other solids in the milk.  
Most research comparing the two pricing schemes has looked at the overall impact in the 
Southeast; very little research has been done at the farm level.  The third objective of our 
research was to provide insight into the potential differences in farm gate milk checks 
when milk is priced under different pricing schemes.  To accomplish the third objective, 
the milk pricing schemes were compared using individual cow production data from 
farms in the Appalachia and Southeast Federal Milk Marketing Orders.  In a preliminary 
analysis of the data, pricing milk with multiple component pricing led to higher milk 
values.  However, results were dependent on milk component production of the farms 
analyzed.  Farms that had lower protein production (< 3.0%) were paid less when milk 
was priced using the multiple component pricing methods compared to the skim-butterfat 
formula.  Preliminary results also indicated that pricing variables specific to the multiple 
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component pricing formula may affect whether or not dairy farmers in the Southeast 
would benefit from a pricing scheme change.  More research is needed to determine how 
herd demographics and price data may affect prices at a farm level.   
Because milk in the Southeast is primarily used for fluid dairy products future 
research should focus on how the demand for fluid products is decreasing while the 
demand for processed dairy products is increasing.  This switch in demand may favor a 
pricing change at the farm level but the total economic impact of the dairy industry at the 
processor level should also be considered.  
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Table A.1.  Milk yield losses (kg/cow/yr) associated with a herd somatic cell count 
(SCC) threshold Hand et al. (2012). 
SCC Threshold (SCC*1,000 cells/mL) Lactation 
Upper SCC  Lower SCC 1 2 3+ 
100 200 165 348 381 
200 300 196 372 423 
300 400 253 444 503 
400 500 314 526 561 
500 600 327 555 614 
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In Chapter 3 of this dissertation, estimates for mastitis incidence rates were calculated using the steps shown in the following tables.  
The bolded/italicized values will be used in an example equation under each table.  
 
Table A.2.  Step 1: Mastitis incidence rates used by Scherpenzeel et al. (2018) in a dry cow therapy cost analysis and used in the US 
dairy systems model as a base for mastitis incidence rate adjustment. 
   
Incidence rate in next lactation 
   
Clinical Mastitis Subclinical Mastitis 
SCC Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) 
1 0 to 50 1 9.90% 11.80% 4.80% 7.20% 
2 51 to 100 1 9.10% 10.80% 10.60% 19.00% 
3 101 to 150 1 13.50% 18.20% 8.20% 17.70% 
4 > 150 1 14.40% 20.00% 11.30% 25.00% 
5 0 to 50 2+ 12.80% 20.10% 7.30% 17.30% 
6 51 to 100 2+ 15.20% 26.80% 13.60% 18.80% 
7 101 to 150 2+ 9.00% 19.10% 15.70% 24.80% 
8 151 to 250 2+ 16.50% 24.10% 18.40% 31.70% 
9 > 250 2+ 16.60% 24.40% 22.60% 37.40% 
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Table A.3.  Step 2: Each value in Table A.1 is divided by the value in column Subclinical mastitis Treat(+) by row1. 
   
Incidence rate in next lactation 
   
Clinical Mastitis Subclinical Mastitis 
SCC Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) 
1 0 to 50 1 2.1 2.5 1.0 1.5 
2 51 to 100 1 0.9 1.0 1.0 1.8 
3 101 to 150 1 1.6 2.2 1.0 2.2 
4 > 150 1 1.3 1.8 1.0 2.2 
5 0 to 50 2+ 1.8 2.8 1.0 2.4 
6 51 to 100 2+ 1.1 2.0 1.0 1.4 
7 101 to 150 2+ 0.6 1.2 1.0 1.6 
8 151 to 250 2+ 0.9 1.3 1.0 1.7 
9 > 250 2+ 0.7 1.1 1.0 1.7 
1Example equation: 0.099/0.048 = 2.1 
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Table A.4.  Step 3: Mastitis incidence rates that were derived from Dairy Records Management Systems test day data. 
   
Incidence rate in next lactation 
   
Clinical Mastitis Subclinical Mastitis 
Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) 
1 0 to 50 1   9.05%  
2 51 to 100 1   11.75%  
3 101 to 150 1   13.72%  
4 > 150 1   19.87%  
5 0 to 50 2+   13.72%  
6 51 to 100 2+   16.03%  
7 101 to 150 2+   18.36%  
8 151 to 250 2+   21.18%  
9 > 250 2+   29.19%  
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Table A.5.  Step 4: Each value in Table A.2 is multiplied by the column Subclinical Mastitis Treat(+) in Table A.3 by row1. 
   
Incidence rate in next lactation 
   
Clinical Mastitis Subclinical Mastitis 
Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) 
1 0 to 50 1 18.7% 22.2%** 9.1% 13.6% 
2 51 to 100 1 10.1% 12.0% 11.8% 21.1% 
3 101 to 150 1 22.6% 30.5% 13.7% 29.6% 
4 > 150 1 25.3% 35.2% 19.9% 44.0% 
5 0 to 50 2+ 24.1% 37.8%** 13.7% 32.5% 
6 51 to 100 2+ 17.9% 31.6% 16.0% 22.2% 
7 101 to 150 2+ 10.5% 22.3% 18.4% 29.0% 
8 151 to 250 2+ 19.0% 27.7% 21.2% 36.5% 
9 > 250 2+ 21.4% 31.5% 29.2% 48.3% 
1Example equation: 2.1*0.0905 = 18.7% 
2Because lowest SCC groups had the highest incidence rate as indicated by (**) only the values for Groups 4 and 9 were kept. 
 
  
 
1
5
0
 
Table A.6.  Step 5: The percent change was calculated by row from groups 4 to 1 and 9 to 5 for column Subclinical Mastitis Treat(+)1. 
   
Incidence rate in next lactation  
   
Clinical Mastitis Subclinical Mastitis  
Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) % Change 
1 0 to 50 1   9.1%  -0.23 
2 51 to 100 1   11.8%  -0.14 
3 101 to 150 1   13.7%  -0.31 
4 > 150 1   19.9%   
5 0 to 50 2+   13.7%  -0.14 
6 51 to 100 2+   16.0%  -0.13 
7 101 to 150 2+   18.4%  -0.13 
8 151 to 250 2+   21.2%  -0.27 
9 > 250 2+   29.2%   
1Example equation: (0.137-0.199)/0.199 = -0.31 
Example equation: (0.212 – 0.292)/0.292 = -0.27 
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Table A.7.  Step 6: The percent change column is applied to Groups 4 and 9 (values from Table A.4) and carried on throughout each 
row1. 
   
Incidence rate in next lactation  
   
Clinical Mastitis Subclinical Mastitis  
Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) % Change 
1 0 to 50 1   9.05%  -0.23 
2 51 to 100 1 14.97%  11.75%  -0.14 
3 101 to 150 1 17.48% 
 
13.72%  -0.31 
4 > 150 1 25.32% 35.17% 19.87% 43.96%  
5 0 to 50 2+   13.72%  -0.14 
6 51 to 100 2+   16.03%  -0.13 
7 101 to 150 2+ 13.49%  18.36%  -0.13 
8 151 to 250 2+ 15.56% 
 
21.18%  -0.27 
9 > 250 2+ 21.44% 31.51% 29.19% 48.31%  
1Example equation: 0.2532 + (0.2532 * -0.31) = 17.48% 
 0.1748 + (0.1748 * -0.14) = 14.97% 
Example equation: 0.2144 + (0.2144 * -0.27) = 15.56% 
 0.1556 + (0.1556 * -0.13) = 13.49% 
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Table A.8.  The final estimates for mastitis incidence rate used in Chapter 3 of this dissertation to calculate the costs of dry cow 
therapy. 
   
Incidence rate in next lactation 
   
Clinical Mastitis Subclinical Mastitis 
Group Dry off SCC (cells/mL*1,000) Parity Treat (+) Treat (-) Treat (+) Treat (-) 
1 0 to 50 1 11.53% 16.02% 9.05% 20.02% 
2 51 to 100 1 14.97% 20.80% 11.75% 26.00% 
3 101 to 150 1 17.48% 24.28% 13.72% 30.35% 
4 > 150 1 25.32% 35.17% 19.87% 43.96% 
5 0 to 50 2+ 10.08% 14.81% 13.72% 22.70% 
6 51 to 100 2+ 11.77% 17.31% 16.03% 26.53% 
7 101 to 150 2+ 13.49% 19.82% 18.36% 30.38% 
8 151 to 250 2+ 15.56% 22.87% 21.18% 35.05% 
9 > 250 2+ 21.44% 31.51% 29.19% 48.31% 
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State and Herd Data used in Chapter 4: 
 
States included in the analysis were assigned to the following Federal Milk Marketing 
Orders: 
 
Appalachia: 
North Carolina 
South Carolina 
Kentucky 
Virginia 
 
Southeast: 
Louisiana 
Arkansas 
Missouri 
Tennessee 
Alabama 
Mississippi 
Georgia 
 
Individual cow test day data were cleaned using the following steps: 
1. Lactations had to be between 1 and 10. 
2. Test day – days in milk were between 1 and 610 
3. Milk yield was greater than the 1st percentile – 4.53 kg/day 
4. Test day protein had to fall between the 1st and 99th percentiles – 1% to 5% 
5. Test day fat had to fall between the 1st and 99th percentiles – 1% to 7% 
 
After cleaning cow level data herds had to meet the following criteria 
1. Had to have at least 20 cows at each test day meet the criteria above 
2. Average protein production had to fall within the 10th and 90th percentiles – 
2.92% to 3.28% 
3. Average fat production had to fall within the 10th and 90th percentiles – 3.31% to 
4.12% 
4. Average milk yield had to fall within the 1st and 99th percentiles 6.35 kg to 55.79 
kg 
5. One herd was removed for size being greater than 20,000 cows 
6. After cleaning of herd data total herd test day records totaled 43,814 
 154 
 
REFERENCES 
 
Alhussien, M. N. and A. K. Dang. 2018. Milk somatic cells, factors influencing their 
release, future prospects, and practical utility in dairy animals: An overview. Vet. 
World 11(5):562. 
Ali, A. K. A. and G. E. Shook. 1980. An optimum transformation for somatic cell 
concentration in milk. J. Dairy Sci. 63(3):487-490. 
Bailey, K. and P. Tozer. 2001. An evaluation of federal order reform. J. Dairy Sci. 
84(4):974-986. 
Bailey, K. W., C. M. Jones, and A. J. Heinrichs. 2005. Economic returns to Holstein and 
Jersey herds under multiple component pricing. J. Dairy Sci. 88(6):2269-2280. 
Bar, D., Y. T. Grohn, G. Bennett, R. N. Gonzalez, J. A. Hertl, H. F. Schulte, L. W. Tauer, 
F. L. Welcome, and Y. H. Schukken. 2008a. Effects of repeated episodes of 
generic clinical mastitis on mortality and culling in dairy cows. J. Dairy Sci. 
91(6):2196-2204. 
Bar, D., L. W. Tauer, G. Bennett, R. N. Gonzalez, J. A. Hertl, Y. H. Schukken, H. F. 
Schulte, F. L. Welcome, and Y. T. Grohn. 2008b. The cost of generic clinical 
mastitis in dairy cows as estimated by using dynamic programming. J. Dairy Sci. 
91(6):2205-2214. 
Barkema, H. W., Y. H. Schukken, T. J. Lam, M. L. Beiboer, G. Benedictus, and A. 
Brand. 1998a. Management practices associated with low, medium, and high 
somatic cell counts in bulk milk. J. Dairy Sci. 81(7):1917-1927. 
Barkema, H. W., Y. H. Schukken, T. J. Lam, M. L. Beiboer, H. Wilmink, G. Benedictus, 
and A. Brand. 1998b. Incidence of clinical mastitis in dairy herds grouped in three 
categories by bulk milk somatic cell counts. J. Dairy Sci. 81(2):411-419. 
Bartlett, P. C., G. Y. Miller, C. R. Anderson, and J. H. Kirk. 1990. Milk production and 
somatic cell count in Michigan dairy herds. J. Dairy Sci. 73(10):2794-2800. 
Bennett, R. 1992. The use of ‘economic’quantitative modelling techniques in livestock 
health and disease-control decision making: a review. Prev. Vet. Med. 13(1):63-
76. 
Berry, E. A. and J. E. Hillerton. 2002. The effect of selective dry cow treatment on new 
intramammary infections. J. Dairy Sci. 85(1):112-121. 
Berry, E. A., H. Hogeveen, and J. E. Hillerton. 2004. Decision tree analysis to evaluate 
dry cow strategies under UK conditions. J. Dairy Res. 71(4):409-418. 
Bewley, J. M., Boehlje, A. W. Gray, H. Hogeveen, S. J. Kenyon, S. D. Eicher, and M. M. 
Schutz. 2010. Stochastic simulation using @Risk for dairy business investment 
decisions. Agr. Finance Rev. 70(1):97-125. 
Bradley, A. 2002. Bovine mastitis: an evolving disease. Vet. J. 164(2):116-128. 
Bradley, A. J. and M. J. Green. 2001. An investigation of the impact of intramammary 
antibiotic dry cow therapy on clinical coliform mastitis. J. Dairy Sci. 84(7):1632-
1639. 
Brooker, B. 1978. Characteristic cell fragments in bovine milk. J. Dairy Res. 45(1):21-24. 
Bureau of Labor Statistics. 2019. Agriculture Workers. Accessed May 5, 2018. 
https://www.bls.gov/ooh/farming-fishing-and-forestry/agricultural-workers.htm 
 155 
 
Cameron, M., G. P. Keefe, J. P. Roy, I. R. Dohoo, K. A. MacDonald, and S. L. 
McKenna. 2013. Evaluation of a 3M Petrifilm on-farm culture system for the 
detection of intramammary infection at the end of lactation. Prev. Vet. Med. 
111(1-2):1-9. 
Cameron, M., S. L. McKenna, K. A. MacDonald, I. R. Dohoo, J. P. Roy, and G. P. 
Keefe. 2014. Evaluation of selective dry cow treatment following on-farm culture: 
risk of postcalving intramammary infection and clinical mastitis in the subsequent 
lactation. J. Dairy Sci. 97(1):270-284. 
Capuco, A. V., R. M. Akers, and J. J. Smith. 1997. Mammary growth in Holstein cows 
during the dry period: Quantification of nucleic acids and histology. J. Dairy Sci. 
80(3):477-487. 
Congressional Research Service. 2017. Federal Milk Marketing Orders: An overview. 
Accessed September 18, 2019. 
https://www.everycrsreport.com/files/20171213_R45044_e4ac19d6f59816bf4713
dae1f7aa554d5049b263.pdf 
Cragle, R., M. Murphy, S. Williams, and J. Clark. 1986. Effects of altering milk 
production and composition by feeding on multiple component milk pricing 
systems. J. Dairy Sci. 69(1):282-289. 
Croney, C., M. Apley, J. Capper, J. Mench, and S. Priest. 2012. Bioethics symposium: 
the ethical food movement: What does it mean for the role of science and 
scientists in current debates about animal agriculture? J. Anim. Sci. 90(5):1570-
1582. 
Dairy Foods. 2019. Dairy Plants USA Directory. Accessed December 10, 2019. 
https://www.dairyfoods.com/directories/7376-dairy-plants-usa 
Dairy Records Management Systems. 2017. About Us. Accessed January 30, 2020. 
https://www.drms.org/Support/About-Us 
de Haas, Y., H. W. Barkema, and R. F. Veerkamp. 2002. The effect of pathogen-specific 
clinical mastitis on the lactation curve for somatic cell count. J. Dairy Sci. 
85(5):1314-1323. 
Dekkers, J. C., T. Van Erp, and Y. H. Schukken. 1996. Economic benefits of reducing 
somatic cell count under the milk quality program of Ontario. J. Dairy Sci. 
79(3):396-401. 
Dhuyvetter, K. C., T. L. Kastens, M. Overton, and J. Smith. 2007. Cow culling decisions: 
costs or economic opportunity? Pages 173-187 in Proc. Western Dairy Manage. 
Conf., Reno, NV 
Dijkhuizen, A. A. and R. S. Morris. 1997. Animal health economics: principles and 
applications. University of Sydney, Post-Graduate Foundation in Veterinary 
Science. 
Dodd, F. and F. Neave. 1970. Mastitis Control. National Institute of Research in 
Dairying, Biennial Reviews. Reading, England:Pages 21-60. 
Dohoo, I. R. and K. E. Leslie. 1991. Evaluation of changes in somatic cell counts as 
indicators of new intramammary infections. Prev. Vet. Med. 10(3):225-237. 
Dolecheck, K. 2018. Dairy cattle hoof disease costs and considerations for prevention. 
Theses and Dissertations--University of Kentucky Animal and Food Sciences. 84. 
Dolecheck, K., G. Heersche, and J. Bewley. 2016. Retention payoff–based cost per day 
open regression equations: Application in a user-friendly decision support tool for 
 156 
 
investment analysis of automated estrus detection technologies. J. Dairy Sci. 
99(12):10182-10193. 
Dolecheck, K., M. Overton, T. Mark, and J. Bewley. 2019. Use of a stochastic simulation 
model to estimate the cost per case of digital dermatitis, sole ulcer, and white line 
disease by parity group and incidence timing. J. Dairy Sci. 102(1):715-730. 
Dufour, S., A. Frechette, H. W. Barkema, A. Mussell, and D. T. Scholl. 2011. Invited 
review: effect of udder health management practices on herd somatic cell count. J. 
Dairy Sci. 94(2):563-579. 
Dürr, J. W., R. I. Cue, H. G. Monardes, J. Moro-Méndez, and K. M. Wade. 2008. Milk 
losses associated with somatic cell counts per breed, parity and stage of lactation 
in Canadian dairy cattle. Livest. Sci. 117(2-3):225-232. 
Emanuelson, U. and C. Nielsen. 2017. Short communication: Weak associations between 
mastitis control measures and bulk milk somatic cell counts in Swedish dairy 
herds. J. Dairy Sci. 100(8):6572-6576. 
Erb, H. N., R. D. Smith, R. B. Hillman, P. A. Powers, M. C. Smith, M. E. White, and E. 
G. Pearson. 1984. Rates of diagnosis of six diseases of Holstein cows during 15-
day and 21-day intervals. Am. J. Vet. Res. 45(2):333-335. 
Godden, S., P. Rapnicki, S. Stewart, J. Fetrow, A. Johnson, R. Bey, and R. Farnsworth. 
2003. Effectiveness of an internal teat seal in the prevention of new 
intramammary infections during the dry and early-lactation periods in dairy cows 
when used with a dry cow intramammary antibiotic. J. Dairy Sci. 86(12):3899-
3911. 
Golder, H. M., A. Hodge, and I. J. Lean. 2016. Effects of antibiotic dry-cow therapy and 
internal teat sealant on milk somatic cell counts and clinical and subclinical 
mastitis in early lactation. J. Dairy Sci. 99(9):7370-7380. 
Gonçalves, J. L., R. I. Cue, B. G. Botaro, J. A. Horst, A. A. Valloto, and M. V. Santos. 
2018. Milk losses associated with somatic cell counts by parity and stage of 
lactation. J. Dairy Sci. 101(5):4357-4366. 
Gould, B. W. and M. Bozic. 2018. Understanding Dairy Markets. Accessed May 5, 2018. 
http://future.aae.wisc.edu/ 
Green, L. E., Y. H. Schukken, and M. J. Green. 2006. On distinguishing cause and 
consequence: do high somatic cell counts lead to lower milk yield or does high 
milk yield lead to lower somatic cell count? Prev. Vet. Med. 76(1-2):74-89. 
Hadrich, J. C., C. A. Wolf, J. Lombard, and T. M. Dolak. 2018. Estimating milk yield 
and value losses from increased somatic cell count on US dairy farms. J. Dairy 
Sci. 101(4):3588-3596. 
Halasa, T., M. Nielen, R. B. M. Huirne, and H. Hogeveen. 2009a. Stochastic bio-
economic model of bovine intramammary infection. Livest. Sci. 124(1-3):295-
305. 
Halasa, T., M. Nielen, T. van Werven, and H. Hogeveen. 2010. A simulation model to 
calculate costs and benefits of dry period interventions in dairy cattle. Livest. Sci. 
129(1-3):80-87. 
Halasa, T., M. Nielen, A. C. Whist, and O. Osteras. 2009b. Meta-analysis of dry cow 
management for dairy cattle. Part 2. Cure of existing intramammary infections. J. 
Dairy Sci. 92(7):3150-3157. 
 157 
 
Halasa, T., O. Osteras, H. Hogeveen, T. van Werven, and M. Nielen. 2009c. Meta-
analysis of dry cow management for dairy cattle. Part 1. Protection against new 
intramammary infections. J. Dairy Sci. 92(7):3134-3149. 
Hand, K. J., A. Godkin, and D. F. Kelton. 2012. Milk production and somatic cell counts: 
a cow-level analysis. J. Dairy Sci. 95(3):1358-1362. 
Harmon, R. J. 1994. Physiology of mastitis and factors affecting somatic cell counts. J. 
Dairy Sci. 77(7):2103-2112. 
Heald, C. W., G. M. Jones, S. C. Nickerson, W. N. Patterson, and W. E. Vinson. 1977. 
Preliminary evaluation of the Fossomatic Somatic Cell Counter for analysis of 
individual cow samples in a central testing laboratory. J. Food Prot. 40(8):523-
526. 
Heikkila, A. M., J. I. Nousiainen, and S. Pyorala. 2012. Costs of clinical mastitis with 
special reference to premature culling. J. Dairy Sci. 95(1):139-150. 
Henderson, A. C., C. D. Hudson, A. J. Bradley, V. E. Sherwin, and M. J. Green. 2016. 
Prediction of intramammary infection status across the dry period from lifetime 
cow records. J. Dairy Sci. 99(7):5586-5595. 
Hill, A. W., K. G. Hibbitt, and J. Davies. 1982. Particles in bulk milk capable of causing 
falsely high electronic cell counts. J. Dairy Res. 49(2):171-177. 
Hillerton, E. and J. M. Booth. 2018. The five-point mastitis control plan-A revisory 
tutorial! Pages 3-19 in Proc. National Mastitis Council 57th Annual Meeting, 
Tuscon, AZ. . National Mastitis Council, Verona, WI 
Hoare, R. J., P. J. Nicholls, and R. F. Sheldrake. 1982. Investigations into falsely elevated 
somatic cell counts of bulked herd milk. J. Dairy Res. 49(4):559-565. 
Hogan, J., K. Smith, D. Todhunter, P. Schoenberger, and D. Shuster. 1995a. Efficacy of 
recombinant bovine interleukin-2 as an adjunct to dry cow therapy. J. Dairy Sci. 
78(5):1062-1067. 
Hogan, J., W. Weiss, D. Todhunter, K. Smith, and P. Schoenberger. 1992a. Efficacy of 
an Escherichia coli J5 mastitis vaccine in an experimental challenge trial. J. Dairy 
Sci. 75(2):415-422. 
Hogan, J. S., K. L. Smith, D. A. Todhunter, and P. S. Schoenberger. 1992b. Field trial to 
determine efficacy of an Escherichia coli J5 mastitis vaccine. J. Dairy Sci. 
75(1):78-84. 
Hogan, J. S., K. L. Smith, D. A. Todhunter, P. S. Schoenberger, R. P. Dinsmore, M. B. 
Canttell, and C. S. Gabel. 1994. Efficacy of dry cow therapy and a 
Propionibacterium acnes product in herds with low somatic cell count. J. Dairy 
Sci. 77(11):3331-3337. 
Hogan, J. S., W. P. Weiss, K. L. Smith, D. A. Todhunter, P. S. Schoenberger, and L. M. 
Sordillo. 1995b. Effects of an Escherichia coli J5 vaccine on mild clinical 
coliform mastitis. J. Dairy Sci. 78(2):285-290. 
Hogeveen, H., K. Huijps, and T. J. Lam. 2011. Economic aspects of mastitis: new 
developments. NZ. Vet. J. 59(1):16-23. 
Hogeveen, H. and M. Van Der Voort. 2017. Assessing the economic impact of an 
endemic disease: the case of mastitis. Rev. Sci. Tech. 36(1):217-226. 
Huijps, K. and H. Hogeveen. 2007. Stochastic modeling to determine the economic 
effects of blanket, selective, and no dry cow therapy. J. Dairy Sci. 90(3):1225-
1234. 
 158 
 
Huijps, K., T. J. Lam, and H. Hogeveen. 2008. Costs of mastitis: Facts and perception. J. 
Dairy Res. 75(1):113-120. 
Hurley, W. L. 1989. Mammary gland function during involution. J. Dairy Sci. 
72(6):1637-1646. 
Hutton, C., L. Fox, and D. Hancock. 1990. Mastitis control practices: Differences 
between herds with high and low milk somatic cell counts. J. Dairy Sci. 
73(4):1135-1143. 
Jadhav, P. V., D. N. Das, K. P. Suresh, and B. R. Shome. 2018. Threshold somatic cell 
count for delineation of subclinical mastitis cases. Vet. World 11(6):789-793. 
Jansen, J., G. van Schaik, R. J. Renes, and T. J. Lam. 2010. The effect of a national 
mastitis control program on the attitudes, knowledge, and behavior of farmers in 
the Netherlands. J. Dairy Sci. 93(12):5737-5747. 
Jayarao, B. M., S. R. Pillai, A. A. Sawant, D. R. Wolfgang, and N. V. Hegde. 2004. 
Guidelines for monitoring bulk tank milk somatic cell and bacterial counts. J. 
Dairy Sci. 87(10):3561-3573. 
Jones, G. M., R. E. Pearson, G. A. Clabaugh, and C. W. Heald. 1984. Relationships 
between somatic cell counts and milk production. J. Dairy Sci. 67(8):1823-1831. 
Kehrli, M. E. and D. E. Shuster. 1994. Factors affecting milk somatic sells and their role 
in health of the bovine mammary gland. J. Dairy Sci. 77(2):619-627. 
Kelly, A., D. Tiernan, C. O'sullivan, and P. Joyce. 2000. Correlation between bovine milk 
somatic cell count and polymorphonuclear leukocyte level for samples of bulk 
milk and milk from individual cows. J. Dairy Sci. 83(2):300-304. 
Klungel, G. H., B. A. Slaghuis, and H. Hogeveen. 2000. The effect of the introduction of 
automatic milking systems on milk quality. J. Dairy Sci. 83(9):1998-2003. 
Laevens, H., H. Deluyker, Y. Schukken, L. De Meulemeester, R. Vandermeersch, E. De 
Muelenaere, and A. De Kruif. 1997. Influence of parity and stage of lactation on 
the somatic cell count in bacteriologically negative dairy cows. J. Dairy Sci. 
80(12):3219-3226. 
Lam, T., J. Jansen, and R. J. Wessels. 2017. The RESET Mindset Model applied on 
decreasing antibiotic usage in dairy cattle in the Netherlands. Ir. Vet. J. 70(1):5. 
Lee, C.-S., F. P. Wooding, and P. Kemp. 1980. Identification, properties, and differential 
counts of cell populations using electron microscopy of dry cows secretions, 
colostrum and milk from normal cows. J. Dairy Res. 47(1):39-50. 
Liang, D. 2013. Estimating the economic losses from diseases and extended days open 
with a farm-level stochastic model. Theses and Dissertations--University of 
Kentucky Animal and Food Sciences. 22. 
Liang, D., L. M. Arnold, C. J. Stowe, R. J. Harmon, and J. M. Bewley. 2017. Estimating 
US dairy clinical disease costs with a stochastic simulation model. J. Dairy Sci. 
100(2):1472-1486. 
Madsen, P. S. 1975. Fluoro-opto-electronic cell-counting on milk. J. Dairy Res. 
42(2):227-239. 
McDermott, M. P., H. N. Erb, and R. P. Natzke. 1982. Predictability by somatic cell 
counts related to prevalence of intrammary infection within herds. J. Dairy Sci. 
65(8):1535-1539. 
 159 
 
McDougall, S. 2018. Selective dry cow therapy: The New Zealand perspective Pages 
132-139 in Proc. National Mastitis Council 57th Annual Meeting, Tuscon, AZ, 
National Mastitis Council. National Mastitis Council, Verona, WI. 
McInerney, J. P., K. S. Howe, and J. A. Schepers. 1992. A framework for the economic 
analysis of disease in farm livestock. Prev. Vet. Med. 13(2):137-154. 
McParland, S., P. Dillon, J. Flynn, N. Ryan, S. Arkins, and A. Kennedy. 2019. Effect of 
using internal teat sealant with or without antibiotic therapy at dry-off on 
subsequent somatic cell count and milk production. J. Dairy Sci. 102(5):4464-
4475. 
Miller, R. H., M. J. Paape, R. Filep, and S. Link. 1993. Flow cytometric analysis of 
neutrophils in cows' milk. Am. J. Vet. Res. 54(12):1975-1979. 
Natzke, R. P., R. W. Everett, and D. S. Postle. 1972. Normal milk somatic cell counts. J. 
Milk Food Technol. 35(5):261-263. 
Neave, F., F. Dodd, and E. Henriques. 1950. Udder infections in the dry period. J. Dairy 
Res. 17(1):37-49. 
Newton, J. 2014. Hoard's Dairyman: Would component pricing work in the Southeast? 
Accessed September 18, 2019. https://hoards.com/article-13241-would-
component-pricing-work-in-the-southeast.html 
Nickerson, S. C. 2012. Are U.S. dairy farms ready for a drop in the SCC legal limit? 
Accessed October 20, 2019. https://dairy-cattle.extension.org/are-u-s-dairy-farms-
ready-for-a-drop-in-the-scc-legal-limit/ 
Nolan, D. T. 2017. An examination of milk quality effects on milk yield and dairy 
production economics in the Southeastern United States. Theses and 
Dissertations--University of Kentucky Animal and Food Sciences. 71. 
Nolan, D. T. 2018. Co-ops on milk quality: ‘We must continue to decrease SCC’. 
Accessed November 20, 2019. https://www.progressivedairy.com/topics/herd-
health/co-ops-on-milk-quality-we-must-continue-to-decrease-scc 
Norman, H. D., J. E. Lombard, J. R. Wright, C. A. Kopral, J. M. Rodriguez, and R. H. 
Miller. 2011. Consequence of alternative standards for bulk tank somatic cell 
count of dairy herds in the United States. J. Dairy Sci. 94(12):6243-6256. 
Oliver, S., R. Gonzalez, J. Hogan, B. Jayarao, and W. Owens. 2004. Microbiological 
procedures for the diagnosis of bovine udder infection and determination of milk 
quality. Verona WI, USA: National Mastitis Council. 
Pantoja, J. C., C. Hulland, and P. L. Ruegg. 2009a. Somatic cell count status across the 
dry period as a risk factor for the development of clinical mastitis in the 
subsequent lactation. J. Dairy Sci. 92(1):139-148. 
Pantoja, J. C., D. J. Reinemann, and P. L. Ruegg. 2009b. Associations among milk 
quality indicators in raw bulk milk. J. Dairy Sci. 92(10):4978-4987. 
Patel, K., S. Godden, E. Royster, J. Timmerman, B. Crooker, and N. McDonald. 2017. 
Pilot Study: Impact of using a culture-guided selective dry cow therapy program 
targeting quarter-level treatment on udder health and antibiotic use. Bovine Pract. 
51:48-57. 
Pearson, J. 1950. The use of penicillin in the prevention of C. Pyogenes infection of the 
non-lactating udder. Vet. Rec. 62:166-168. 
 160 
 
Persson, K., C. H. Sandgren, and H. Rodriguez-Martinez. 1992. Studies of endotoxin-
induced neutrophil migration in bovine teat tissues, using indium-111-labeled 
neutrophils and biopsies. Am. J. Vet. Res. 53(12):2235-2240. 
Pillai, S., E. Kunze, L. Sordillo, and B. M. Jayarao. 2001. Application of differential 
inflammatory cell count as a tool to monitor udder health. J. Dairy Sci. 
84(6):1413-1420. 
Pinzon-Sanchez, C., V. E. Cabrera, and P. L. Ruegg. 2011. Decision tree analysis of 
treatment strategies for mild and moderate cases of clinical mastitis occurring in 
early lactation. J. Dairy Sci. 94(4):1873-1892. 
Poutrel, B. and P. Rainard. 1981. California Mastitis test guide of selective dry cow 
therapy. J. Dairy Sci. 64(2):241-248. 
Prescott, S. C. and R. S. Breed. 1910. The determination of the number of body cells in 
milk by a direct method. Am. J. Public Hygiene 20(3):663-664. 
Pyorala, S. 2002. New strategies to prevent mastitis. Reprod. Domest. Anim. 37(4):211-
216. 
Rabiee, A. R. and I. J. Lean. 2013. The effect of internal teat sealant products (Teatseal 
and Orbeseal) on intramammary infection, clinical mastitis, and somatic cell 
counts in lactating dairy cows: a meta-analysis. J. Dairy Sci. 96(11):6915-6931. 
Rasmussen, M. D., M. Bjerring, P. Justesen, and L. Jepsen. 2002. Milk quality on Danish 
farms with automatic milking systems. J. Dairy Sci. 85(11):2869-2878. 
Rasmussen, M. D., J. Y. Blom, L. A. H. Nielsen, and P. Justesen. 2001. Udder health of 
cows milked automatically. Livest. Prod. Sci. 72(1-2):147-156. 
Raubertas, R. F. and G. E. Shook. 1982. Relationship between lactation measures of 
somatic cell concentration and milk yield. J. Dairy Sci. 65(3):419-425. 
Rindsig, R. B., R. G. Rodewald, A. R. Smith, and S. L. Spahr. 1978. Complete versus 
selective dry cow therapy for mastitis control. J. Dairy Sci. 61(10):1483-1497. 
Rivas, A. L., F. W. Quimby, J. Blue, and O. Coksaygan. 2001. Longitudinal Evaluation 
of Bovine Mammary Gland Health Status by Somatic Cell Counting, Flow 
Cytometry, and Cytology. J. Vet. Diagn. Invest. 13(5):399-407. 
Rollin, E., K. C. Dhuyvetter, and M. W. Overton. 2015. The cost of clinical mastitis in 
the first 30 days of lactation: An economic modeling tool. Prev. Vet. Med. 
122(3):257-264. 
Sadeghi-Sefidmazgi, A., M. Moradi-Shahrbabak, A. Nejati-Javaremi, S. R. Miraei-
Ashtiani, and P. R. Amer. 2011. Estimation of economic values and financial 
losses associated with clinical mastitis and somatic cell score in Holstein dairy 
cattle. Animal. 5(1):33-42. 
Sant’Anna, A. C. and M. J. R. Paranhos da Costa. 2011. The relationship between dairy 
cow hygiene and somatic cell count in milk. J. Dairy Sci. 94(8):3835-3844. 
Schalm, O. W., E. J. Carroll, and J. Lasmanis. 1964. The leukocyte barrier and serologic 
investigations of experimental coliform (Aerobacter Aerogenes) mastitis in cattle. 
Am. J. Vet. Res. 25:90-96. 
Schalm, O. W., J. Lasmanis, and E. J. Carroll. 1966. Significance of leukocytic 
infiltration into the milk in experimental Streptococcus agalactiae mastitis in 
cattle. Am. J. Vet. Res. 27(121):1537-1546. 
Schalm, O. W. and G. Ziv-Silberman. 1968. Reactions following intrarnarnmary infusion 
of E. coli endotoxin. Vet. Rec. 100. 
 161 
 
Schepers, A. J., T. J. Lam, Y. H. Schukken, J. B. Wilmink, and W. J. Hanekamp. 1997. 
Estimation of variance components for somatic cell counts to determine 
thresholds for uninfected quarters. J. Dairy Sci. 80(8):1833-1840. 
Scherpenzeel, C., I. Den Uijl, G. van Schaik, R. O. Riekerink, J. Keurentjes, and T. Lam. 
2014. Evaluation of the use of dry cow antibiotics in low somatic cell count cows. 
J. Dairy Sci. 97(6):3606-3614. 
Scherpenzeel, C. G. M., I. E. M. den Uijl, G. van Schaik, R. Riekerink, H. Hogeveen, and 
T. Lam. 2016. Effect of different scenarios for selective dry-cow therapy on udder 
health, antimicrobial usage, and economics. J. Dairy Sci. 99(5):3753-3764. 
Scherpenzeel, C. G. M., H. Hogeveen, L. Maas, and T. Lam. 2018. Economic 
optimization of selective dry cow treatment. J. Dairy Sci. 101(2):1530-1539. 
Schewe, R. L., J. Kayitsinga, G. A. Contreras, C. Odom, W. A. Coats, P. Durst, E. P. 
Hovingh, R. O. Martinez, R. Mobley, S. Moore, and R. J. Erskine. 2015. Herd 
management and social variables associated with bulk tank somatic cell count in 
dairy herds in the eastern United States. J. Dairy Sci. 98(11):7650-7665. 
Schreiner, D. and P. Ruegg. 2002. Effects of tail docking on milk quality and cow 
cleanliness. J. Dairy Sci. 85(10):2503-2511. 
Schreiner, D. A. and P. L. Ruegg. 2003. Relationship between udder and leg hygiene 
scores and subclinical mastitis. J. Dairy Sci. 86(11):3460-3465. 
Schukken, Y. H., J. Vanvliet, D. Vandegeer, and F. J. Grommers. 1993. A randomized 
blind trial on dry cow antibiotic infusion in a low somatic cell count herd. J. Dairy 
Sci. 76(10):2925-2930. 
Schukken, Y. H., D. J. Wilson, F. Welcome, L. Garrison-Tikofsky, and R. N. Gonzalez. 
2003. Monitoring udder health and milk quality using somatic cell counts. Vet. 
Rec. 34(5):579-596. 
Schultze, W. D. 1983. Effects of a selective regimen of dry cow therapy on 
intramammary infection and on antibiotic sensitivity of surviving pathogens. J. 
Dairy Sci. 66(4):892-903. 
Shim, E. H., R. D. Shanks, and D. E. Morin. 2004. Milk loss and treatment costs 
associated with two treatment protocols for clinical mastitis in dairy cows. J. 
Dairy Sci. 87(8):2702-2708. 
Shook, G. E., R. L. B. Kirk, F. L. Welcome, Y. H. Schukken, and P. L. Ruegg. 2017. 
Relationship between intramammary infection prevalence and somatic cell score 
in commercial dairy herds. J. Dairy Sci. 100(12):9691-9701. 
Smith, A., F. Neave, F. Dodd, A. Jones, and D. Gore. 1967a. The persistence of 
cloxacillin in the mammary gland when infused immediately after the last milking 
of lactation. J. Dairy Res. 34(1):47-57. 
Smith, A., F. Neave, and A. Jones. 1967b. The persistence of penicillin G in the 
mammary gland when infused immediately after the last milking of lactation. J. 
Dairy Res. 34(1):59-64. 
Steeneveld, W., T. van Werven, H. W. Barkema, and H. Hogeveen. 2011. Cow-specific 
treatment of clinical mastitis: an economic approach. J. Dairy Sci. 94(1):174-188. 
Stott, A., G. Jones, G. Gunn, M. Chase‐Topping, R. Humphry, H. Richardson, and D. 
Logue. 2002. Optimum replacement policies for the control of subclinical mastitis 
due to S. aureus in dairy cows. J. Agric. Econ. 53(3):627-644. 
 162 
 
Swinkels, J. M., H. Hogeveen, and R. N. Zadoks. 2005. A partial budget model to 
estimate economic benefits of lactational treatment of subclinical Staphylococcus 
aureus mastitis. J. Dairy Sci. 88(12):4273-4287. 
Taponen, S., J. Koort, J. Björkroth, H. Saloniemi, and S. Pyörälä. 2007. Bovine 
intramammary infections caused by coagulase-negative staphylococci may persist 
throughout lactation according to amplified fragment length polymorphism-based 
analysis. J. Dairy Sci. 90(7):3301-3307. 
Todhunter, D. A., K. L. Smith, J. S. Hogan, and P. S. Schoenberger. 1991. Gram-negative 
bacterial infections of the mammary gland in cows. Am. J. Vet. Res. 52(2):184-
188. 
Torres, A. H., P. J. Rajala-Schultz, F. J. Degraves, and K. H. Hoblet. 2008. Using dairy 
herd improvement records and clinical mastitis history to identify subclinical 
mastitis infections at dry-off. J. Dairy Res. 75(2):240-247. 
Troendle, J. A., L. W. Tauer, and Y. T. Grohn. 2017. Optimally achieving milk bulk tank 
somatic cell count thresholds. J. Dairy Sci. 100(1):731-738. 
U.S. Food and Drug Administration. 2017. Grade "A" Pasteurized Milk Ordinance. 
Accessed September 3, 2018. https://www.fda.gov/media/114169/download 
USDA Agricultural Marketing Service. 2013. European Health Certification Program. 
Accessed September 3, 2019. 
https://www.ams.usda.gov/sites/default/files/media/Official%20EU%20Health%2
0Certification%20Program%20document.pdf 
USDA Agricultural Marketing Service. 2018a. The Kroger Company additional proposal 
for hearing on multiple component pricing for Orders 5 & 7. Accessed September 
18, 2019. 
https://www.ams.usda.gov/sites/default/files/media/KrogerHearingProposalSouth
eastAppalachianFMMO.PDF 
USDA Agricultural Marketing Service. 2018b. National All-Jersey Inc. Proposal for 
hearing on multiple component pricing for Orders 5 & 7. Accessed September 18, 
2019. 
https://www.ams.usda.gov/sites/default/files/media/NationalAllJerseyHearingReq
uest.pdf 
USDA Agricultural Marketing Service. 2018c. Tennessee Dairy Producers Association 
opposition to changing current skim/butterfat pricing in orders 5&7 to Multiple 
Component Pricing. Accessed September 18, 2019. 
https://www.ams.usda.gov/sites/default/files/media/TennesseeDairyProducersAss
ociationProposal.pdf 
USDA Agricultural Marketing Service. 2019. National Dairy Product Prices. Accessed 
September 5, 2019. 
https://mpr.datamart.ams.usda.gov/menu.do?path=Products/Dairy/All%20Dairy 
USDA Animal and Plant Health Inspection Service. 2016. Milk quality, milking 
procedures, and mastitis on U.S. dairies, 2014. Accessed October 4, 2017. 
https://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy14/Dairy
14_dr_Mastitis.pdf 
USDA National Agricultural Statistics Service. 2017. Census of agriculture. Accessed 
November 4, 2019. 
 163 
 
https://www.nass.usda.gov/Publications/AgCensus/2017/Full_Report/Volume_1,_
Chapter_1_US/usv1.pdf 
Valeeva, N. I., T. J. Lam, and H. Hogeveen. 2007. Motivation of dairy farmers to 
improve mastitis management. J. Dairy Sci. 90(9):4466-4477. 
Valley Vet Supply. 2018. Intramammary Antibiotic Costs. Accessed March 1, 2018. 
https://www.valleyvet.com/ct_detail.html?pgguid=30E079B9-7B6A-11D5-A192-
00B0D0204AE5 
van den Borne, B. H., T. Halasa, G. van Schaik, H. Hogeveen, and M. Nielen. 2010. 
Bioeconomic modeling of lactational antimicrobial treatment of new bovine 
subclinical intramammary infections caused by contagious pathogens. J. Dairy 
Sci. 93(9):4034-4044. 
Vasquez, A. K., D. V. Nydam, C. Foditsch, M. Wieland, R. Lynch, S. Eicker, and P. D. 
Virkler. 2018. Use of a culture-independent on-farm algorithm to guide the use of 
selective dry-cow antibiotic therapy. J. Dairy Sci. 101(6):5345-5361. 
Wenz, J. R., S. M. Jensen, J. E. Lombard, B. A. Wagner, and R. P. Dinsmore. 2007. Herd 
management practices and their association with bulk tank somatic cell count on 
United States dairy operations. J. Dairy Sci. 90(8):3652-3659. 
Wiggans, G. R. and G. E. Shook. 1987. A lactation measure of somatic cell count. J. 
Dairy Sci. 70(12):2666-2672. 
 
 164 
 
VITA 
 Derek Thomas Nolan grew up on a dairy farm in Northeast Iowa.  Upon 
graduation of Startmont High School in 2009, he attended Iowa State University.  While 
at Iowa State, Derek served as President of the Iowa State Dairy Science Club and was a 
member of the Dairy Challenge Team.  He was also a member of the College of 
Agriculture and Life Sciences Student Council.  Derek graduated from Iowa State 
University with a Bachelor’s Degree in Dairy Science in 2013. 
 Derek completed his MS at the University of Kentucky in 2017.  While studying 
under Dr. Jeffrey Bewley, his work focused on milk quality management and economics.  
Derek has presented his work at annual American Dairy Science Association and 
National Mastitis Council meetings.  He has also presented at two international meetings 
in Brazil and Denmark. 
 Upon completion of his MS, Derek began his PhD at the University of Kentucky 
with Drs. Roberta Dwyer and Tyler Mark.  His PhD work was focused on milk quality 
economics and milk pricing. 
 While at the University of Kentucky, Derek has served as the University of 
Kentucky Dairy Judging coach and as an assistant coach of the University of Kentucky 
Dairy Challenge Team.  At the university level, Derek is a member of Gamma Sigma 
Delta and was awarded Master’s Student of the Year in 2015.  At a national level, Derek 
served as treasurer of the American Dairy Science Association-Graduate Student 
Division and is also a member of the National Mastitis Council. 
